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Stjórnpróteinin MITF , TFEB, TFE3 og TFEC (stundum nefnd MiT-TFE 
þættirnir) tilheyra bHLHZip fjölskyldu umritunarþátta sem bindast DNA og 
stjórna tjáningu gena. MITF er mikilvægt fyrir myndun og starfsemi litfruma en 
ættingjar þess, TFEB og TFE3, stjórna myndun og starfsemi lysósóma og 
sjálfsáti. Sjálfsát er líffræðilegt ferli sem gegnir mikilvægu hlutverki í starfsemi 
fruma en getur einnig haft áhrif á myndun og meðhöndlun sjúkdóma. 
Í verkefni þessu var samstarf MITF, TFE3 og TFEB próteinanna skoðað í 
sortuæxlisfrumum og hvaða áhrif þau hafa á tjáningu hvers annars. Eins og 
MITF eru TFEB og TFE3 genin tjáð í sortuæxlisfrumum og sortuæxlum; TFEC 
er ekki tjáð í þessum frumum og var því ekki skoðað í þessu verkefni. Með 
notkun sérvirkra hindra var sýnt að boðleiðir hafa áhrif á staðsetningu 
próteinanna þriggja í sortuæxlisfrumum. Umritunarþættir þessir geta bundist 
skyldum DNA-bindisetum og haft áhrif á tjáningu gena sem eru nauðsynleg 
fyrir myndun bæði lýsósóma og melanósóma. Áhugavert er að hver 
umritunarþáttanna þriggja stjórnar tjáningu gena sem hinir hafa engin áhrif á 
en ekki er ljóst hvernig þessari takmörkun er stjórnað. Þessi þættir stjórna 
tjáningu hvers annars, bæði beint og óbeint. Með mótefnisfellingu kom í ljós 
að MITF, TFEB og TFE3 geta myndað mistvenndir í æxlisfrumum en geta ekki 
myndað mistvenndir með öðrum bHLHZip próteinum eins og MAX. Þriggja 
amínósýru-svæði, sem er til staðar í HLH-Zip svæðinu, er nauðsynlegt fyrir 
þessa sértæku tvenndarmyndun. Hlutverk þessara amínósýra var greint frekar 
og, með tilfærslu þessara þriggja amínósýra, var reynt að útbúa MITF prótein 
sem einungis geta myndað einstvenndir. Það tókst ekki en áhugaverðar 
upplýsingar fengust um hvernig tvenndarmyndun MITF fer fram.  
Niðurstaðan er að sambandið milli MITF, TFEB og TFE3 í 
sortuæxlisfrumum er flókið og felst í áhrifum á stjórnun genatjáningar, 
samstarfi próteina með myndun mistvennda og áhrifum boðleiða á 
staðsetningu í frumulíffærum. Mikilvægt er að greina og skilja þetta samband í 
sortuæxlum til að öðlast betri skilning á því hvernig unnt er að hafa áhrif á þau 
ferli sem umritunarþættir þessir stjórna. 
Lykilorð:  





The MITF, TFEB, TFE3 and TFEC (MiT-TFE) proteins belong to a larger family 
of basic helix-loop-helix leucine zipper transcription factors that are able to bind 
DNA and regulate gene expression. MITF is crucial for melanocyte 
development and has been called a lineage specific oncogene in melanoma 
whereas its relatives, TFEB and TFE3 are involved in the biogenesis and 
function of lysosomes and autophagosomes, regulating cellular clearance 
pathways. Autophagy is a biological process that plays a prominent role in 
human disease and can also have an impact on the outcome of therapeutic 
approaches. Whether MITF, TFEB and TFE3 regulate each others expression 
and whether they cooperate in the regulation of gene expression is presently 
unknown. 
I have investigated the interactions and cross-regulatory relationship of 
MITF, TFE3 and TFEB in melanoma cells. Like MITF, the TFEB and TFE3 
genes are expressed in melanoma cells and tissues. I show that these factors 
regulate each other’s expression. Also, using co-immunoprecipitation studies, 
I demonstrate that MITF, TFEB and TFE3 are able to heterodimerize in 
melanoma cells. However, they fail to interact with other members of the bHLH 
family such as MAX. Furthermore, I show that a three amino acid region 
present in the HLH-Zip region is responsible for dimerization specificity. In 
addition, several signaling pathways can post-translationally modify these 
factors, affecting their nuclear localization, activity and stability. Reporter gene 
and ChIP assays show that the three factors are able to bind and activate 
similar DNA regulatory motifs and drive the expression of genes involved in 
autophagy and pigmentation. Interestingly, some genes are exclusively 
regulated by one of the factors.  
The relationship between MITF, TFEB and TFE3 is complex and involves 
regulation of gene expression, protein-protein interactions resulting in 
complementary functions. It is important to further unravel this relationship in 
melanoma to gain a better understanding of the cross-regulatory mechanisms 
involved and how these factors regulate lysosomal function.  
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  Melanocytes  
1.1.1  Development 
Melanocytes are responsible for the production and distribution of the pigment 
melanin in vertebrates. The melanocyte precursor cells are called 
melanoblasts and are derived by lineage specification from neural crest cells 
(NCC) during embryogenesis. NCC arise from the embryonic ectoderm. These 
cells are originally multipotent and can differentiate into neurons, glial cells, 
muscle cells, fibroblasts, chondrocytes and melanocytes. They gradually 
undergo determination of their lineage fate, influenced by their anatomical 
localization along the cranial-caudal axis. Melanoblast-committed NCC 
expand and migrate to the dermis, epidermis and hair follicles. During 
development, most melanoblasts follow a dorsolateral migration trajectory from 
the neural crest (NC). However, there is evidence that a number of 
melanoblasts originate from Schwann cell precursors that have migrated 
ventrally but have not committed to the neural lineage (Adameyko et al., 2009). 
As melanoblasts travel through the dermis and proliferate, they begin to 
progressively express melanocyte-specific genes (Cichorek et al., 2013). 
Cutaneous melanocytes that are responsible for the pigmentation of skin or 
hair and have followed the dorsolateral migration pathway from the NC, are 
described as classical melanocytes. Non-classical melanocytes do not fulfill 
these three criteria, and can be found in the inner ear, retina and iris, meninges, 
adipose tissue, heart and bone. The function of non-classical melanocytes 
remains unclear (Borovanský & Riley, 2011). 
Melanocyte differentiation is dependent upon initiation of the expression of 
required transcription factors, such as paired box gene 3 (PAX3) (Potterf et al., 
2000; Tassabehji et al., 1992), sex-determining region Y (SRY)-box 10 
(SOX10) (Potterf et al., 2000; Stolt et al., 2008) and microphthalmia-associated 
transcription factor (MITF) (Adameyko et al., 2012; Opdecamp et al., 1997). 
Furthermore, the activity of signaling pathways is important, including wingless 
type (WNT) (Dunn et al., 2005), where increase of WNT3A expression and 
reduced expression of bone morphogenetic protein 4 (BMP4) induce 
melanoblast formation in avian embryo neural crest cultures (E. J. Jin et al., 
2001). The transcription factors PAX3 and SOX10 are crucial for the 
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development of melanoblasts by activating MITF transcription (Potterf et al., 
2000; Stolt et al., 2008; Tassabehji et al., 1992). Interestingly, PAX3 and 
SOX10 also contribute to initial glial cell development, suggesting that other 
factors are also involved in the differentiation pathway specific to melanocytes. 
Forkhead box D3 (FOXD3) is found in glia progenitors but not in melanocyte 
precursors. It is able to repress MITF expression in melanoma cells, even in 
the presence of PAX3 and SOX10 (Thomas & Erickson, 2009). In line with this, 
SOX2 is able to induce neural crest cells to switch to glial differentiation by 
binding to the promoter of MITF and repressing its expression (Adameyko et 
al., 2012). Mutations in PAX3 or SOX10 result in melanocytic loss in 
vertebrates, similar to mutations in MITF (Tachibana et al., 2003). Other 
pathways that are required for the development of the melanocytic lineage are 
the G-coupled endothelin B receptor (EDNRB), its ligand endothelin-3 (EDN3) 
(Stanchina et al., 2006); and the tyrosine kinase receptor KIT (Aoki et al., 2005; 
Karafiat et al., 2007). The KIT receptor has been shown to be required during 
the migration of melanocytes through the dermis and for post-natal hair 
pigmentation (Hachiya et al., 2009; Yoshida et al., 2001). 
In summary, melanocytic differentiation is based on a combination of 
silenced transcription factors, such as FOXD3 and SOX2 that are required for 
glial development from NC cells, coupled with an increase in expression of 
PAX3 and SOX10 and subsequent upregulation of MITF. 
1.1.2  Function 
Melanocytes are the cells responsible for the synthesis of melanin, by 
enzymatic oxidation and polymerization of the amino acid tyrosine.  Each skin 
melanocyte is approximately 7 μm in length and contacts 30-40 neighboring 
keratinocytes through melanocytic pseudopodia called dendrites. The 
distribution of melanocytes varies across species. In humans they constitute 
about 5-10% of the cells in the basal layer of the epidermis, whereas in rodents 
they are mostly found in the hair follicles and epidermis of hairless skin 
(Borovanský & Riley, 2011). 
Melanogenesis is the process through which melanocytes produce 
melanin. There are two major types of melanin: the dark brown/black 
eumelanin and the red/yellow pheomelanin. Melanin is produced and 
transported in specific membrane-bound organelles, called melanosomes, 
which are delivered to the adjacent keratinocytes through the melanocytic 
dendrites (Figure 1). Keratinocytes function as a barrier against pathogens 
and ultra-violet (UV) radiation, the latter being absorbed by melanin and 
thereby, minimizing cellular damage due to reactive oxygen species (ROS) 
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and DNA mutagenesis. Melanosomes are lysosome-related organelles that go 
through four different stages of maturation. Stage I premelanosomes are found 
perinuclearly and have been suggested to derive from endosomes originated 
from the trans Golgi network and go through several steps of maturation. 
Mature melanosomes produce and accumulate melanin and appear as solid 
dark pigmented vesicles (Raposo & Marks, 2007).  
The differences in skin color among the human population are not 
determined by the number of melanocytes in the individual’s skin, rather the 
size and amount of melanosomes they contain, and the quantitative and 
relative abundance of eumelanin and pheomelanin produced in the cell. 
Pheomelanin is less efficient at blocking UV radiation and has been shown to 
promote melanoma, independent of UV radiation (Mitra et al., 2012). Melanin 
biosynthesis is a process under hormonal control, arising from the cross-talk 
of melanocytes and keratinocytes. Exposure of skin to UV radiation triggers 
DNA damage and subsequent activation of TP53 which enhances the 
expression of pro-opiomelanocortin (POMC) in keratinocytes (Cui et al., 2007; 
Fields & Jang, 1990). POMC is the precursor of the alpha-melanocyte-
stimulating-hormone α-MSH, a full agonist of the melanocortin-1-receptor 
(MC1R). Binding of α-MSH to MC1R activates adenylate cyclase (AC), 
Figure 1. Classical melanocyte in the basal layer of the skin. Melanocytes produce 
melanin pigment and deliver it to neighboring keratinocytes. 
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increasing the production of the second messenger cyclic-adenosine-
monophosphate (cAMP) (Pawelek et al., 1973). Increased levels of cAMP 
activates protein kinase A (PKA), leading to phosphorylation of the 
transcription factor cAMP responsive-element binding protein (CREB) and 
CREB-mediated upregulation of MITF (Bertolotto et al., 1998; Price, 
Horstmann, et al., 1998). MITF, in turn, activates the transcription of several 
genes that are required for the melanin biosynthesis machinery. 
  Melanoma 
1.2.1  Epidemiology and molecular mechanisms 
Skin cancer is the most common of all cancers. The three main types are 
basal-cell carcinoma, cutaneous squamous-cell carcinoma and melanoma. 
Melanoma tumors account for only 2% of skin cancer diagnoses but is the most 
aggressive form of skin cancer (Figure 2). It is almost exclusively confined to 
the Caucasian population and its incidence has been rising during the past 
decades. Melanoma incidence among US and Northern Europe white 
population has increased by circa 3% annually from 1982 and 2011 (Whiteman 
et al., 2016). The melanoma incidence rate is projected to continue rising, as 
long as there are no significant improvements regarding sun-seeking and 
tanning behavior and use of protective clothing or sunscreen (Leiter et al., 
2014). It is not entirely understood whether the habit of sunbathing results from 




an aesthetic preference or it involves physiological addiction. Epidermal 
keratinocytes produce POMC and the POMC-derived β-endorphin upon UV 
exposure (Fell et al., 2014). β-endorphin is an endogenous opioid 
neuropeptide that has analgesic effects and can cause tolerance and addiction 
(Olive et al., 2001). It has also been proposed to induce sun-seeking behavior 
(Fell et al., 2014). 
Melanoma is the deadliest among skin cancers, and metastatic melanoma 
features a particularly poor prognosis. The median survival period was 6–9 
months with an overall survival (OS) of 10%–15% in 2008 (Thirlwell & Nathan, 
2008). However, great advances have been made in recent years in the 
management of metastatic melanoma. Treatment with the immune checkpoint 
inhibitor targeting programmed death-1 (PD-1) nivolumab increased the OS to 
71% at 1 year and 41% at 3 years (Hodi et al., 2010). 95% of melanomas are 
cutaneous melanomas, however, ocular, mucosal, genitourinary, meningeal 
and gastrointestinal melanomas can occur (Markovic et al., 2007). Among 
cutaneous melanomas, the sites of occurrence of melanoma tumors are sex-
dependent. The back area is the most common in males, whereas arms and 
legs are more common in females (Newell et al., 1988). 
Melanoma tumor genomes are notoriously unstable and carry the highest 
mutational burden among all cancers (Cancer Genome Atlas, 2015). Exposure 
to UV can trigger the formation of photoproducts that distort the DNA helix, 
generating C > T and CC > TT transitions, namely UV-fingerprint mutations, 
which contribute to >90% of all non-synonymous single nucleotide variants 
(nsSNVs) in melanoma (Hodis et al., 2012). The most frequent mutation found 
in cutaneous melanoma is the hot-spot BRAFV600E somatic mutation in 
approximately 50% of tumors, that results in a hyperactive BRAF-MAPK 
pathway (Forbes et al., 2008). NRAS somatic mutations is the second major 
mutation, found in 28% of cutaneous melanoma tumors. Interestingly, hot-spot 
BRAF and NRAS mutations are mutually exclusive (Cancer Genome Atlas, 
2015; Davies et al., 2002). 
In addition to the exposure to UV radiation in susceptible populations, the 
most important risk for the development of cutaneous malignant melanoma is 
the number of melanocytic nevi. Nevi are a benign clonal proliferation of 
melanocytic cells with a heterogeneous genetic background (Magana-Garcia 
& Ackerman, 1990). 20-30% of melanomas arise from preexisting nevi (Rivers, 
2004). Congenital nevi have been reported to feature a high prevalence of 
BRAF mutations (Pollock et al., 2003; Yazdi et al., 2003), while other studies 
have pointed to NRAS mutations (Bauer et al., 2007; Carr & Mackie, 1994). A 
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reason for this discrepancy is the study methodology. Nevus size and whether 
its origin is congenital or acquired after birth are factors that mark different nevi 
subpopulations that need to be taken into consideration for the analysis of 
genetic alterations. In fact, genetic characterization of large/giant congenital 
nevi shows that they feature NRAS and not BRAF mutations (Charbel et al., 
2014). A majority of nevi are acquired after birth. However, individuals with fair 
skin and a propensity to sunburn are more prone to develop nevi during their 
lifetime. In a study, 78% of all acquired nevi studied had a BRAF mutation, 
whereas NRAS was mutated in only 6% of cases (Roh et al., 2015). 
In the light of the high frequency of BRAF mutations in nevi, it is clear that 
this mutation is not sufficient to drive melanomagenesis. Nevi carrying mutated 
BRAF eventually undergo oncogene-induced senescence, involving increased 
expression of the p16 cell cycle inhibitor of kinase 4A (p16INK4A) (Michaloglou 
et al., 2005). p16INK4A and p14 alternate reading frame protein (p14ARF) are 
tumor suppressor proteins encoded by the cyclin-dependent kinase inhibitor 
2A (CDK2A) gene, crucial at controlling cell-cycle arrest. p16INK4A has been 
found to be frequently silenced epigenetically in BRAF-mutated melanomas, 
however, it was not sufficient to drive melanoma transformation in vitro, 
suggesting that other genes are involved in bypassing BRAF-induced 
senescence (Dhomen et al., 2009). Mutations occurring in other tumor 
suppressors, such as the phosphatase and tensin homolog (PTEN) and tumor 
protein 53 (TP53) have been found in advanced invasive primary melanomas 
(Shain et al., 2015).  
Another gene that has been associated to increased risk of developing 
melanoma is MC1R, which is highly polymorphic in the Caucasian population 
(Valverde et al., 1995). Several MC1R loss-of-function germline variant alleles 
have been associated to red hair, fair skin and freckling, which fail to stimulate 
cAMP production in response to α-MSH signaling to induce melanin production 
(Frandberg et al., 1998; Schioth et al., 1999). Furthermore, an increased risk 
of skin melanoma has been found for carriers of some of these variants, such 
as Val60Leu, Arg151Cys, and Arg160Trp (Palmer et al., 2000). 
1.2.2  Stages in cutaneous melanocytic tumors progression 
Due to their easy visualization, melanocytic lesions are well characterized and 
classified. The Clark scale comprises six steps of progression from a benign 
nevus to a fully transformed malignant melanoma (Clark et al., 1969): (1) the 
common acquired melanocytic nevus (CMN); (2) lentiginous melanocytic 
nevus (LMN); (3) dysplastic melanocytic nevus (DMN); (4) primary malignant 
melanoma with radial growth phase (RGP), which may be in situ or invasive 
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but is non-tumorigenic; (5) primary malignant melanoma with vertical growth 
phase (VGP), invasive and tumorigenic; and (6) metastatic melanoma.  CMN 
are fully benign local proliferations of melanocytes. DMN are intermediate 
lesions that progressively acquire genetic mutations and present signs of 
atypia such as abnormal morphology, aberrant differentiation and nuclear 
atypia. Most DMN remain stable or regress but a fraction can progress to 
malignant melanoma. A RGP melanoma is generally non-invasive (in situ) and 
expands along the surface of the epidermis showing increased signs of 
pigmentation variegation, atypia and irregular margins. RGP lesions can 
progress to the more advanced VGP stage, associated with higher metastasis 
risk. VGP lesions are nodular in morphology and can invade the dermis and 
continue proliferating, forming a dermal mass larger than the original mass 
located in the epidermis. VGP lesions undergo additional genomic progression 
to metastatic melanoma, which is responsible for the lethality of cutaneous 
malignant melanoma (Elder, 2016). 
1.2.3  MAPK/ERK pathway and melanoma 
The Ras-Raf-MEK-ERK pathway, is one of the most studied intracellular 
signaling cascades. It consists of a series of proteins that communicates an 
extracellular stimulus from a cell surface receptor to the nucleus of the cell. 
Small peptides, namely mitogens, bind to receptors in the cell membrane 
triggering phosphorylation of the cytoplasmic domain of the receptor. This 
allows the GDP-bound Ras protein to exchange its GDP by GTP. 
Subsequently, GTP-bound Ras can modify the conformation of Raf protein, 
which leads to activation of Raf. Raf is a family of serine/threonine kinases, 
found to be mutated in many types of human cancers. Ras-induced activated 
Raf forms homo- or heterodimers with other proteins like kinase suppressor of 
Ras (KSR) (Ritt et al., 2006), and then recruits downstream mitogen-activated 
protein kinase kinase (MAPKK), which is phosphorylated and, in turn, 
phosphorylates MAPK/ERK.  Phosphorylated extracellular-signal regulated 
kinase (ERK) is active and modulates the activity of transcription factors that 
are involved in cell cycle regulation or the translation of mRNA to proteins. 
MAPK activation phosphorylates 40S ribosomal protein S6 kinase (RSK), 
which in turn phosphorylates ribosomal protein S6 (RPS6) (Pende et al., 2004). 
RPS6 induces the translation of proteins involved in the regulation of glucose 
homeostasis, cell growth and proliferation (Magnuson et al., 2012). RSK can 
also directly regulate transcription factors such as c-MYC through 
phosphorylation (Zhu et al., 2008).  
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The Raf protein features a catalytic domain with kinase activity and an N-
terminal regulatory domain that contains the Ras-binding activating domain 
and a cysteine-rich domain responsible for autoinhibition of the catalytic 
domain (Chong & Guan, 2003; Cutler et al., 1998). The basis of this self-
regulatory mechanism is common to the three different members of the Raf 
family, A-Raf, B-Raf and C-Raf (Maurer et al., 2011; Tran & Frost, 2003). 
However, these proteins are differentially regulated at the level of post-
translational modifications, which has an impact on their autoinhibitory activity 
(Tran et al., 2005). Whereas B-Raf is constitutively phosphorylated at serine 
445 (Marais et al., 1997) and is more readily activated by Ras (Wellbrock et 
al., 2004), A-Raf and C-Raf need supplementary phosphorylations of activating 
residues and dephosphorylation of inhibitory residues in order to display full 
catalytic activity,  
Approximately 50% of metastatic melanomas harbor hyperactivating BRAF 
mutations. Over 90% of the BRAF mutations are at codon 600, and over 90% 
of these are the single nucleotide mutation BRAFV600E. The second most 
frequent mutation is BRAFV600K in about 5% of cases (Forbes et al., 2008). 
Hyperactive BRAF is able to continue the signaling cascade independently of 
RAS activation and is functional as a monomer (Wan et al., 2004). The 
homologous mutations of the ARAF or CRAF genes are rare events in human 
cancer, since these proteins do not share the constitutively phosphorylated 
residues occurring in B-Raf. The BRAFV600E mutation causes a higher basal 
kinase activity of this protein and makes it a key player in tumorigenesis 
(Emuss et al., 2005).  
To this date, there is no effective cure for metastatic melanoma, although 
great advances have been made with the development of immunotherapy (Syn 
et al., 2017) and targeted therapies using BRAF-MAPK inhibitors such as 
vemurafenib (Bollag et al., 2010). However, a broad interpatient heterogeneity 
and a variety of initiating events in the onset of melanoma lead to drug 
resistance and therapy failure in a majority of cases. Until recently, 
dacarbazine, a chemotherapeutic agent has been the most widely used 
treatment for metastatic melanoma, with unsatisfactory results (Gogas et al., 
2007). The knowledge of the melanoma signature BRAFV600E mutation 
(Davies et al., 2002) propelled the development of targeted therapies using 
BRAF pathway inhibitors, such as vemurafenib (Bollag et al., 2010) and 
dabrafenib (Gibney & Zager, 2013). BRAF inhibitors provided striking anti-
tumor responses and have been a breakthrough in the treatment of metastatic 
melanoma. However, the response to the treatment is short (average 7 
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months) and the tumors progress as resistance develops (Chapman et al., 
2011; Flaherty et al., 2010; Hauschild et al., 2012; Sosman et al., 2012). 
A study addressing the evolution of tumors under BRAF inhibition therapy 
identified several subsets of genes, such as G-protein coupled signaling, 
cAMP and PKA signaling and leukocyte extravasation, as the most significantly 
altered pathways in cells that have undergone BRAF inhibition treatment, 
compared to the parental untreated cell line (Kansler et al., 2017). 
Another study found that among MAPK-reactivating mechanisms, NRAS 
mutations were detected in 18% of progressive tumors, KRAS mutations in 
7%, BRAF amplification in 19% and mutant BRAF alternative splice variants in 
13% of progressive tumors (Shi et al., 2014). A subset of melanoma cells 
resistant to BRAF inhibition with vemurafenib, expressed a 61 KDa variant of 
the BRAFV600E protein. p61BRAFV600E lacks exons 4-8, which include the 
Ras-binding domain, and is able to dimerize in a Ras-independent manner 
(Poulikakos et al., 2011). A MEK1 activating mutation and CDKN2A loss were 
also detected at a lower proportion. Therefore, among all the disease 
progressive samples a reactivation of the MAPK pathway as a mechanism of 
resistance to BRAF inhibition was found at a 70% frequency. Moreover, the 
study identified that PI3K-PTEN-AKT pathway mutations, constituted a second 
core acquired resistance pathway at a 22% frequency that overlapped with the 
MAPK core pathway. This study also showed that the mutational signature of 
the progressive tumors has a reduction in C > T transitions as well as an 
attenuated dipyrimidine motif, indicating non-UV related DNA damage (Shi et 
al., 2014). 
  MITF, the master regulator of melanocytes 
The microphthalmia-associated transcription factor (MITF) was first discovered 
due to coat color mutations in mice (Hertwig, 1942). MITF belongs to the basic 
helix-loop-helix leucine zipper (bHLHZip) family of transcription factors. Mice 
that are deprived of MITF cannot produce melanocytes (Steingrimsson et al., 
2004). Mutations at the mouse Mitf locus result in pigmentation defects of the 
coat, small eyes and deafness. Moreover, mast cell defects have also been 
recognized for certain Mitf alleles (Dubreuil et al., 1991). Therefore, it is 
regarded as the master regulator of the melanocytic lineage as it is required 
for the development, growth and survival of melanocytes, where it regulates 
the expression of various differentiation and cell-cycle progression genes 
(Steingrimsson et al., 2004). MITF is an evolutionarily conserved transcription 
factor subject to differential splicing, thus, being expressed as multiple 
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isoforms that differ in their first exon and promoter usage (Hodgkinson et al., 
1993) (Figure 3). In most isoforms, the initial variable exon is spliced onto the 
exon 1B1b and then continues with exons 2–9 that include all the functionally 
important motifs necessary for protein dimerization and transactivation ability 
(Hershey & Fisher, 2005). The shortest isoform, termed MITF-M, which is the 
predominant isoform in melanocytes, contains a short exon 1M directly spliced 
onto exons 2–9 (Steingrimsson et al., 1994). 
The other isoforms of MITF have been described in a variety of cell types, 
including osteoclasts, natural killer cells, macrophages, mast cells, B cells, and 
cardiac muscle cells. MITF-MC is expressed in bone marrow-derived mast 
cells (Takemoto et al., 2002). MITF-D is mostly expressed in the human retinal 
pigment epithelium (RPE) (Takeda et al., 2002), while MITF-A, MITF-B, MITF-
E and MITF-H are more ubiquitous (Hershey & Fisher, 2005). In the RPE, A, 
D, H and M isoforms of MITF have been detected at comparable levels 
Figure 3. The nine different isoforms of MITF described in humans. Each MITF 
isoform features a variable exon 1 containing an isoform-specific promoter. Exons 2-9, 
which include the bHLHZIP and transactivation domain (TAD) are common to all 
isoforms. Figure obtained with permission from Elsevier according to permit number 
4432560184009 (Levy et al., 2006). 
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(Maruotti et al., 2012), in contrast with other studies that reported that MITF-M 
is not expressed in RPE cell lines (Shibahara et al., 2001). Whether these 
different isoforms have tissue-restricted functions is not well known. MITF-MC 
has been shown to selectively activate the promoter of the gene encoding the 
mouse mast cell protease 6 (Mmcp6) and to fail to activate the pigmentation 
related gene tyrosinase (TYR), known to be a target of MITF in melanocytes, 
as shown by gene transactivation assays (Takemoto et al., 2002). MITF-H has 
been shown to have a greater transactivation potential than MITF-M in cardiac 
cells, suggesting that the activity of MITF in the heart is isoform-specific (Tshori 
et al., 2007). Moreover, two isoforms of MITF called (+) and (-) exist, differing 
in exon 6a. The (+) isoform of MITF encodes six additional amino acids 
between Leu185 and Thr186, upstream of the DNA-binding basic domain 
(Hodgkinson et al., 1993). Both the MITF-M and MITF-H isoforms have been 
found to be expressed as (-) and (+) versions, although it is possible that this 
could be the case for all the MITF isoforms (Hallsson et al., 2000). Interestingly, 
the (+) isoform that includes the extra exon 6a exhibits a strong inhibitory effect 
on DNA synthesis (Bismuth et al., 2005). Furthermore, isoform quantification 
across melanoma samples revealed that differential expression is dependent 
on MEK1-ERK2 activation and that MITF(-) expression is enriched in a subset 
of metastatic melanomas (Primot et al., 2010). 
1.3.1   MITF mutations in humans 
In humans, mutations of MITF that lead to reduced transcription activation 
potential of MITF (Grill et al., 2013) have been linked to the relatively rare 
pigmentation disorders Waardenburg Syndrome type 2A (WS2A) (A. E. 
Hughes et al., 1994) and Tietz’s Syndrome (TS) (Read & Newton, 1997; Smith 
et al., 2000). The WS2A subtype of the Waardenburg Syndrome, originated by 
mutations in MITF is the most common subtype and is characterized by 
permanent hearing loss caused by abnormalities of the inner ear and 
heterochromia of the irises. TS is a more severe syndrome displaying complete 
deafness and a more generalized hypopigmentation. A biallelic mutation of 
MITF has been associated to COMMAD syndrome, an extremely rare disease, 
characterized by coloboma, osteopetrosis, microphthalmia, macrocephaly, 
albinism, and deafness. The severity of this phenotype indicates that MITF 
plays an important role in ocular morphogenesis and bone homeostasis in 
humans (George et al., 2016).  
Sporadic somatic mutations have been found in a 16% of a cohort of 50 
melanoma metastases (Cronin et al., 2009). A germline mutation MITFE318K 
has been linked to familial or sporadic melanoma (Yokoyama et al., 2011) 
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(Bertolotto et al., 2011). This mutation affects a small ubiquitin-like modifier 
(SUMO)-ylation site that negatively modulates the transcriptional activity of 
MITF, therefore leading to an increase in function of the MITF protein 
(Bertolotto et al., 2011; Murakami & Arnheiter, 2005). In addition, a more recent 
publication shows that the MITFE318K mutation can delay BRAFV600E-
induced senescence in human melanocytes, concomitant with decreased 
expression of p16INK4A. This role of MITFE318K in bypassing BRAF-induced 
senescence may be the underlying mechanism that favor melanomagenesis 
(Ballotti & Bertolotto, 2017). 
1.3.2  Transcriptional regulation of MITF 
MITF is subject to diverse mechanisms of transcriptional control. The CREB-
mediated regulation of the MITF-M promoter is central to the melanogenesis 
process. This is mediated by α-MSH activation of the MC1R receptor at the 
melanocyte membrane triggering cAMP signaling (Bertolotto et al., 1998; 
Price, Horstmann, et al., 1998). Despite cAMP signaling being ubiquitous, it 
specifically regulates the MITF-M promoter due to the cooperation of CREB 
with SOX10, a transcription factor exclusive to neural crest-derived cell types 
(Huber et al., 2003). Depletion of the transcriptional activator of MITF PAX3 
induces apoptosis in melanoma cells (Kubic et al., 2012). Hypoxia-inducible 
factor 1 (HIF-1) can repress MITF through the recruitment of the differentially 
expressed in chondrocytes protein 1 (DEC1) to the MITF promoter (Son et al., 
2014). Interferon γ (IFN-γ) inhibits CREB binding to the MITF promoter by 
promoting the association of CREB binding protein (CBP) with signal 
transducer and activator of transcription 1 (STAT1) (Feige et al., 2011), thus 
inhibiting the transcription of MITF. N-Oct-3 (BRN2) is a neuronal-specific 
factor expressed in melanoblasts which is lost as they undergo differentiation 
to melanocytes (Cook et al., 2003). Oncogenic BRAF induces BRN2 which, in 
turn, binds to the MITF promoter and increases MITF transcription. However, 
in non-transformed melanocytes, BRN2 is not expressed and wild-type BRAF 
cannot upregulate MITF through BRN2 (Wellbrock et al., 2008).  
β-catenin is another transcriptional activator of MITF. It can dimerize with 
the lymphoid enhancer-binding factor 1 (LEF1) and transactivate the MITF-M 
promoter (Yasumoto et al., 2002). It can also bind directly to the MITF protein 
(Schepsky et al., 2006). Interestingly, LEF-1 and MITF physically interact and 
synergistically enhance transactivation of the MITF-M promoter (Saito et al., 
2002). When the β-catenin-binding domain of LEF-1 is mutated, LEF-1 and 
MITF cannot enhance transactivation of the MITF-M promoter. Thus, MITF’s 
self-activation of the M promoter requires interaction with LEF1 and β-catenin 
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and might be an important mechanism for preserving sustained levels of 
expression of MITF during melanocyte development (Saito et al., 2003). 
1.3.3  Post-translational modifications of MITF 
A number of post-translational modifications, including phosphorylation, 
ubiquitination, SUMOylation and acetylation, are important for the regulation of 
MITF stability and function as a transcription factor. Steel factor (Sl), also 
known as stem cell factor (SCF), is a c-Kit receptor ligand essential for 
melanocyte development. It activates the BRAF-MAPK pathway, triggering the 
phosphorylation of at least two serine residues (Ser73 and Ser409) in MITF 
(Phung et al., 2011; Wu et al., 2000). Phosphorylation of Ser73 in MITF by 
extracellular-signal regulated kinase 2 (ERK2) (Hemesath et al., 1998) induces 
the association of histone acetyl transferase p300/CBP with the transactivation 
domain of MITF (Price, Ding, et al., 1998), whereas Ser409 of MITF is 
phosphorylated by p90 ribosomal s6 kinase (p90RSK) (Wu et al., 2000). The 
phosphorylation of MITF on these two residues enhances its transactivation 
ability. At the same time, phosphorylated Ser73 is required for human ubiquitin 
carrier protein 9 (hUBC9)-mediated ubiquitination of Lys201 and leads to 
subsequent proteasome-induced degradation of MITF (Price, Ding, et al., 
1998; Wu et al., 2000; Xu et al., 2000). The phosphorylation event at Ser409 
has been shown to be a priming site for further phosphorylation of three nearby 
residues at the C-terminus by glycogen synthase kinase-3β (GSK3β), a kinase 
that is known to target proteins for ubiquitination and degradation (Ploper et 
al., 2015). In this context, Wnt signaling might be able to both drive MITF 
transcriptional regulation and stabilize the protein by inhibiting GSK3β kinase 
activity and MITF degradation. In addition, GSK3β has been shown to 
phosphorylate Ser298 of MITF. The mutation of this phosphorylatable residue, 
which has been found in WS2A, impairs the transcriptional activity of MITF in 
vitro (Takeda, Takemoto, et al., 2000). In contrast, another study shows that 
mutations of Ser298 to alanine or proline did not affect the DNA-binding or 
transactivation ability of MITF (Grill et al., 2013). 
SUMOylation has been shown to affect MITF, rendering it less active 
transcriptionally. The receptor activator of NF-kappa B ligand (RANKL)/p38 
pathway phosphorylates MITF at Ser307 in osteoclasts, which allows a SUMO 
protease to deSUMOylate Lys316 of MITF (Bronisz et al., 2014). This enables 
MITF to recruit cofactors FUS (fused in sarcoma protein) and Brahma-related 
gene 1 (BRG1) to form a complex that stimulates transcription in these cells 
(Bronisz et al., 2014; Mansky et al., 2002). This finding was especially relevant 
since the MITF germline variant E318K that predisposes to familial melanoma 
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and renal carcinoma, was found to abrogate SUMOylation of K316 (Bertolotto 
et al., 2011; Yokoyama et al., 2011). PIAS3, protein inhibitor of the activated 
signal transducer and activator of transcription 3 (STAT3), is a SUMO-protein 
ligase that can covalently attach a SUMO peptide to its substrates, modulating 
their function. It was originally discovered by its ability to inhibit the 
transcriptional ability of STAT3 (Chung et al., 1997). Although PIAS3 has been 
found to modulate MITF through SUMOylation (Miller et al., 2005), PIAS3 can 
bind directly to MITF and prevent it from binding to osteoclast-specific gene 
promoters in a SUMOylation-independent manner that could be dependent on 
cell lineage context (Hikata et al., 2009; Murakami & Arnheiter, 2005). 
Phosphorylation of MITF Ser409 and STAT3 recruiting of PIAS3 dissociates it 
from MITF, enhancing MITF transcription of target genes in mast cells and 
melanocytes (Levy et al., 2003; Sonnenblick et al., 2004).  
Apart from SUMOylation, lysine residues in MITF, such as K206 and K243, 
have been shown to be acetylated, possibly regulating the activation of MITF’s 
target genes (Cheli et al., 2011). 
1.3.4  MITF and melanoma 
MITF functions as an oncogene and a focal amplification of MITF has been 
described in 20% of metastatic melanomas (Garraway et al., 2005), and has 
been found in a post-relapse tumor sample (Van Allen et al., 2014). As 
previously described, the MITF germline mutation E318K is linked to familial 
or sporadic melanoma. MITF cooperates with hyperactive mutant BRAFV600E 
in transforming human melanocytes in vitro (Garraway et al., 2005). However, 
the role of MITF in melanoma appears to be more complex and needs further 
investigation. MITF is a tightly regulated transcription factor that has been 
suggested to exert its function as a rheostat, in which different levels of 
expression of MITF dictate phenotype outcome in melanoma (Hoek & Goding, 
2010) (Figure 4). This model says that the level of MITF activity determines 
cellular function. Long-term depletion of MITF drives senescence in melanoma 
cells (Giuliano et al., 2010), impairing DNA replication, mitosis and genomic 
stability (Strub et al., 2011). Low expression has been associated with an 
invasive phenotype whereas intermediate levels promote proliferation and high 
expression of MITF activates a differentiation-associated cell cycle arrest via 
increase in cyclin-dependent kinase inhibitors, leading to a non-proliferating 




High expression of MITF has been shown to display anti-proliferative 
effects. On the other hand, MITFhigh melanomas display greater resistance to 
BRAF/MEK-inhibition targeted therapy by overcoming the cytotoxic effects of 
the inhibitors (Wellbrock & Arozarena, 2015). Overexpression of MITF in vitro 
increases the expression of anti-apoptotic and pro-survival genes when 
compared to control cells (Van Allen et al., 2014), whereas hyperactive BRAF 
lowers the expression of MITF to basal levels, that might be required for the 
survival of melanoma cells (Wellbrock & Marais, 2005). Even though these two 
studies may seem to be contrasting, it could be hypothesized that a genomic 
amplification of MITF counteracts the BRAF-induced reduction of MITF which 
is required for sustaining melanoma survival, without impairing proliferation 
and clonal expansion. Overexpression of MITF halts the proliferative 
phenotype, indicating that MITF-positive melanoma cells present a finely-tuned 
control of the expression of MITF.  
Another study shows that BRN2 represses MITF expression, marking two 
distinct subpopulations of melanoma cells, those with MITF or BRN2 
expression (Goodall et al., 2008), which highlights melanoma tumors 
heterogeneity and their possible different phenotypes regarding their 
invasiveness or migratory ability during melanoma progression. As the master 
regulator of the melanocytic lineage and an oncogene important for melanoma 
survival, motility, oxidative stress and DNA repair (Liu et al., 2009); modulating 
MITF is likely to be crucial in controlling tumor proliferation and a relevant target 
of future research in melanomagenesis. 
Figure 4. MITF rheostat model. MITF has been hypothesized to control the 
phenotypic switch of melanocytes and melanoma cells according to its expression 
level. Figure obtained with permission from Springer Nature according to permit 
number 4403750847962 (Goding, 2011). 
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  The MiT-TFE subfamily of transcription factors 
MITF belongs to the basic helix-loop-helix leucine zipper (bHLHZip) family of 
transcription factors, a large family first described by Murre et al. (Murre et al., 
1989). It includes other members such as C-MYC, a well-known oncogene in 
several types of tumors (Baudino & Cleveland, 2001; Dang, 2012). The 
members of this family are characterized by evolutionarily conserved domains, 
including a basic region at the N-terminus required for binding of the 
transcription factor to DNA. The DNA binding domain generally interacts with 
the consensus sequence CANNTG, called E-box (Ephrussi boxes), or to 
variations thereof by one or two nucleotides (Aksan & Goding, 1998). Following 
the basic domain, other two structural domains of the protein mediate 
dimerization with other proteins, forming homo- or hetero-dimeric complexes. 
These are the helix-loop-helix domain (HLH) that presents two α-helices 
connected by a loop, and a leucine-zipper domain (Zip) which forms a helix 
that is contiguous to the second helix of the bHLH domain. The leucine zipper 
consists of heptad repeats of leucine in a pattern of hydrophobic residues 
followed by polar residues with an amphipathic nature (Jones, 2004). In 
addition to MITF, TFEB (transcription factor EB), TFE3 (transcription factor 3), 
and TFEC (transcription factor EC) (Hodgkinson et al., 1993; M. J. Hughes et 
al., 1993) are bHLHZip factors that constitute a subfamily within the larger 
family of bHLHZip proteins, namely microphthalmia subfamily of bHLHZip 
transcription factors (MiT-TFE) (Hemesath et al., 1994). 
1.4.1  Dimerization properties of the MiT-TFE transcription factors 
The members of the bHLHZip family of transcription factors need to form 
dimers in order to be transcriptionally active. C-Myc participates in the 
formation of heterodimers with other members of the family, such as Max, Mad 
and Mnt, and depending on which dimer is formed, these factors will positively 
or negatively function to regulate cell growth, proliferation, differentiation, and 
apoptosis (Amati & Land, 1994). An example of this kind of transcription 
molecular switch is that c-Myc/MAX heterodimers operate as a transcriptional 
activator to promote cell differentiation, whereas MAD/MAX heterodimers 
bound to the same DNA regulatory element are transcriptional repressors 
(Luscher, 2012). Modulating the dimerization properties of these transcription 
factors is an attractive approach that could provide the basis for new cancer 
cures (Dang, 2012). Transcription factors of the MiT-TFE family need to form 
dimers in order to bind DNA and exert their function. They have been shown 
to form homo- or hetero-dimers through their bHLHZip motif with members 
within the subfamily. These proteins display nearly identical basic regions and 
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very similar HLH and Zip domains (Hodgkinson et al., 1993). However, they 
fail to dimerize with other related bHLHZip proteins such as c-Myc, MAX or 
USF (Hemesath et al., 1994). Upon dimerization, the MiT-TFE factors are able 
to bind DNA regulatory elements of their target genes, such as the E-box 
(CACGTG) and M-box (CATGTG) through their basic domain (Figure 5A). 
They regulate the transcription of genes involved in a wide range of different 
cellular processes, ranging from cellular homeostasis (Settembre & Ballabio, 
2014) and pluripotency (Betschinger et al., 2013), to lineage-specific 
differentiation, reviewed in (Steingrimsson et al., 2004).  
Recently, a three-dimensional structure of MITF in the absence of DNA 
revealed that the homodimeric assembly of MITF is asymmetric. One of the 
A 
B 
Figure 5. Dimerization and DNA binding properties of MITF. (A) Structural 
characterization of the MITF DNA-binding and assembly region. (B) Multiple 
sequence alignment of the MiT-TFE transcription factors (top) and canonical bHLHZip 




two alpha-helices of the leucine zipper forms a kink due to an interruption of 
the coiled coil register consisting of an insertion of three residues at the junction 
of the two first heptad repeats (Pogenberg et al., 2012) (Figure 5B). This 
particular break in the heptad pattern is termed stammer. Skip, stammer and 
stutter motifs, corresponding to the insertion of one, three or four residues, 
respectively, introduce some structural flexibility into long coiled coils, with the  
coiled-coil  heptad  continuity (J. H. Brown et al., 1996; Lupas & Gruber, 2005). 
Stammers within leucine zippers are uncommon and possibly driven by the 
protein’s functional requirements. All the MiT-TFE transcription factor family 
members contain the same three-residue insert in the N-terminal part of the 
leucine zipper, forming an essential structural element for the proper 
recognition of the homotypic dimerization partner in the MITF/TFE subfamily 
of bHLHZip transcription factors and the key determinant for 
heterodimerization selectivity (Pogenberg et al., 2012). 
1.4.2  TFEB 
TFEB has been described as the master regulator of cellular clearance 
pathways by transcriptionally upregulating genes involved in lysosome and 
autophagosome biogenesis and function, lysosomal exocytosis and lipid 
metabolism (Palmieri et al., 2011; Settembre et al., 2013; Settembre et al., 
2011). It acts as a link between nutrient and signal-sensing mammalian target 
of rapamycin complex 1 (mTORC1) and the transcriptional regulation of the 
machinery that responds to nutritional stress (Roczniak-Ferguson et al., 2012; 
Settembre et al., 2012). TFEB activates the transcription of target genes 
through direct binding to the Coordinated Lysosomal Expression and 
Regulation (CLEAR) consensus sequences (TCACGTGA), which are enriched 
in a great number of loci nearby transcription start sites (TSS) of promoters 
associated to lysosomal genes (Martina, Diab, Lishu, et al., 2014; Palmieri et 
al., 2011). 
TFEB controls lipid catabolism in the liver, regulating the peroxisome 
proliferator-activated receptor-γ coactivator 1α (Pgc1α) (J. Lin et al., 2005), a 
transcriptional coactivator involved in energy metabolism and master regulator 
of mitochondrial biogenesis (Valero, 2014). However, increasing focus on 
TFEB has revealed diverse tissue-specific functions. Loss of TFEB results in 
defective development of the endoderm (Young et al., 2016), and TFEB-
deficient mice showed abnormal vascularization of the placenta with lethality 
effects during embryonic development (Steingrimsson et al., 1998). 
Furthermore, TFEB regulates post-ischemic angiogenesis, inducing 
adenosine monophosphate (AMP)-kinase (AMPK) and autophagy (Fan et al., 
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2018). TFEB-induced lysosomal activity is also essential for bone resorption 
by osteoclasts (Ferron et al., 2013) and, interestingly, it has been reported to 
be activated, together with TFE3, in macrophages exposed to pathogens, 
triggering the increased expression of cytokines and chemokines (Pastore et 
al., 2016). Presentation of intracellular antigens such as viral antigens is 
generally achieved by degradation of cytosolic proteins by the proteasome 
followed by transport into the endoplasmic reticulum where the processed 
antigen is loaded onto the major histocompatibility complex (MHC) class I. 
Presentation of exogenous antigens at macrophages and other antigen-
presenting cells involves a certain degree of lysosomal degradation of the 
antigens that is controlled by TFEB through regulation of lysosomal activity 
(Samie & Cresswell, 2015). 
More recent studies point to an increasing interest on TFEB’s role in 
neurodegeneration and lysosomal storage disorders. TFEB has been shown 
to enhance neurotrophy and prevent loss of dopaminergic neurons through 
activation of the MAPK and AKT pathways, inducing phosphorylation of the 
eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1) and 
ribosomal protein S6 kinase beta-1 (S6K1), which leads to an increase in 
protein synthesis (Torra et al., 2018). Therefore, TFEB as a therapeutic target 
transcends beyond lysosomal regulation. 
1.4.3  TFE3 
Similar to TFEB, Transcription Factor E3 (TFE3) participates in the biogenesis 
of lysosomes and autophagosomes and the clearance of cellular debris upon 
starvation or lysosomal stress, through the activation of the CLEAR network of 
target genes (Martina, Diab, Li, et al., 2014; Martina, Diab, Lishu, et al., 2014). 
Depletion of TFE3 abolishes the increase in starvation-induced lysosomal 
function. This is regulated, by the mTOR complex and the nutritional status 
that dictates subcellular localization of TFE3. TFE3 is a key regulator of cell 
metabolism; it activates the insulin signaling cascade in hepatocytes, 
stimulates glycogen synthesis in skeletal muscle and liver through the 
activation of GSK3β, and its absence may induce the onset of insulin 
resistance (Iwasaki et al., 2012; Nakagawa et al., 2006). Moreover, recent 
evidence points to a role of TFE3 in thermogenesis and lipid metabolism in 
adipose tissue (Fujimoto et al., 2013).  
Other functions of TFE3 have been described that are linked to lysosomal 
biogenesis, suggesting that the relevance of this cellular process spans over 
many different tissues, such as the regulation of thymus-dependent humoral 
immunity together with TFEB (Huan et al., 2006), and bone resorption in 
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osteoclasts (Hershey & Fisher, 2004; Steingrimsson et al., 2002). Interestingly, 
TFE3 has a role in the maintenance of cellular pluripotency, where embryonic 
stem cells (ESC) require cytoplasmic localization of TFE3 in order to start 
differentiation by exiting their naïve pluripotent state (Betschinger et al., 2013). 
1.4.4  TFEC 
TFEC is the least studied among the members of this family of transcription 
factors. In mice and rats it is not ubiquitously expressed and it lacks the acidic 
transcriptional activating domain, but is able to form heterodimers with TFE3 
that inhibit TFE3-dependent transactivation (Zhao et al., 1993). However, the 
human homolog of TFEC contains this acidic domain and can activate or inhibit 
CANNTG motifs associated to TYR or the heme oxygenase-1 gene promoter 
(Yasumoto & Shibahara, 1997). In contrast to MITF and TFE3 mutant mice, 
mutations in TFEC do not induce abnormalities in osteoclast development 
(Steingrimsson et al., 2002).   
1.4.5  The MiT-TFE factors and cancer 
In addition to the prominent role of MITF in melanoma survival and 
progression, MITFE318K has been linked to renal clear cell carcinoma 
(Bertolotto et al., 2011). Interestingly, the related TFEB and TFE3 proteins 
have also been reported to be dysregulated in pediatric renal cell carcinomas 
(Kuiper et al., 2003) (Ramphal et al., 2006), 
MITF, TFEB and TFE3 have been identified as regulators of metabolic 
reprogramming in pancreatic ductal adenocarcinoma (PDA) cells. These 
factors appear to escape cytoplasmic retention under normal fully-fed 
conditions in PDA cells in contrast with non-transformed human pancreatic 
ductal epithelial cells. In PDA cells, they localize to the nucleus and maintain 
high levels of autophagy and amino acid supply required for stimulation of 
anabolic pathways and proliferation. In this context, the MiT-TFE factors 
constitute a marker of pancreatic adenocarcinoma aggressiveness (Perera et 
al., 2015). 
Many carcinogenesis events originate from aberrant transcription factor 
activity or can indirectly modulate transcription factor activity 
(Konstantinopoulos & Papavassiliou, 2011). The MiT-TFE family members are 
no exception and have been reported to be dysregulated in many forms of 
cancer (Haq & Fisher, 2011). Ongoing efforts on targeting oncogenic 
transcription factors may lead to selective death of tumor cells that depend on 
these pathways, in contrast to normal cells that can find redundancies in 
normal signaling pathways (Yeh et al., 2013). 
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  The mTORC1/2 complexes 
The mammalian target of rapamycin complex, also known as mechanistic 
target of rapamycin complex, consists of the mTOR phosphatidylinositol 3-
kinase-related kinase (PIKK) forming the core of two distinct complexes, 
mTORC1 and mTORC2 (Heitman et al., 1991), that associate with different 
proteins and localize to different subcellular compartments. Dishevelled, Egl-
10 and Pleckstrin (DEP) domain-containing mTOR-interacting protein 
(DEPTOR) is a negative regulator of the mTOR catalytic activity, common to 
both complexes (Peterson et al., 2009). Specific to the mTORC1 are the 
regulatory-associated protein of mTOR (RAPTOR) (Hara et al., 2002) and the 
40-kDa proline-rich Akt substrate (PRAS40) (Sancak et al., 2007). In turn, 
rapamycin-insensitive companion of mTOR, (RICTOR) and the mammalian 
stress-activated MAP kinase-interacting protein 1 (mSIN1) form part of the 
mTORC2 (Zoncu et al., 2011). The mTORC1/2 complexes control protein 
synthesis necessary for cell growth and proliferation. This complex is capable 
of sensing various signaling pathways, growth factors, hormones, redox status 
and certain amino acids and derivatives, ensuring the availability of the 
adequate resources for protein synthesis (Bartolome & Guillen, 2014; Hay & 
Sonenberg, 2004). 
The FK506-binding protein 12 (FKBP12) binds to the macrolide rapamycin 
forming a complex that directly inhibits the mTORC1 (E. J. Brown et al., 1994). 
On the other hand, the mTORC2 is insensitive to rapamycin (Jacinto et al., 
2004). Active mTORC2 can induce phosphorylation of AKT at Ser473, a step 
needed for full activation of AKT (Sarbassov et al., 2005). 
1.5.1  The mTORC1 pathway 
Active mTORC1 phosphorylates S6K1 and 4E-BP1 facilitating mRNA 
translation. The tuberous sclerosis complex (TSC) is the main upstream 
regulator of mTORC1. It stimulates the GTPase activity of the Rheb protein 
that hydrolyzes Rheb-GTP to Rheb-GDP. TSC can be inhibited by AKT, MAPK 
and Wnt pathways, but it is also controlled by the cellular energy status through 
an activating phosphorylation by AMPK, a kinase that is active when the ATP 
to AMP ratio is low. Another feature of this complex that connects the cell 
environmental status to cellular metabolism is that amino acid deprivation can 
inhibit mTORC1 activity. Of note, the particular circulating amino acids 
responsible for the activation of the complex remain elusive. Arginine and 
leucine have been shown to be required for mTORC1 activation, however they 
were not sufficient (Hara et al., 1998). More recent studies support a two-step 
mechanism for the activation of mTORC1 by two distinct groups of amino 
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acids, namely priming and activating amino acids (Dyachok et al., 2016). 
Additionally, mTORC1 plays a pivotal role in the regulation of autophagy in a 
transcription-independent manner. Under sufficient supply of nutrients, growth 
factors and cellular signaling stimuli, mTORC1 is activated at the lysosomal 
surface and, through phosphorylation, inhibits proteins that are important for 
autophagy and lysosomogenesis. These include TFEB (Martina et al., 2012; 
Roczniak-Ferguson et al., 2012) and TFE3 (Martina, Diab, Lishu, et al., 2014), 
two important transcriptional regulators of these cellular processes, and ULK1 
and ATG13 (Hosokawa et al., 2009), proteins that are directly involved in the 
formation of autophagosomes. 
When amino acids are abundant, this induces a conformational change in 
Rag-GTPase heterodimers. These heterodimers interact with the regulatory-
associated protein of mTOR (Raptor), a member of the mTORC1 complex, 
which in turn localizes the complex to the surface of late endosomes and 
lysosomes where it is activated by Rheb-GTP (Sancak et al., 2008) (Martina & 
Puertollano, 2013). This highlights the notion of the endosome-lysosomal 
network being a central hub for intracellular signaling and not just mere 
degradation stations (Perera & Zoncu, 2016). 
TFEB, contains a number of amino acids that are likely to be modified by a 
panel of different kinases by means of phosphorylation. Serine 142 of TFEB 
has been shown to be phosphorylated by ERK and mTORC1, which also 
targets serine 211 of TFEB. This takes place at the outer lysosomal membrane 
and affects the subcellular localization of the protein. Phosphorylated TFEB at 
the lysosomal membrane is bound by 14-3-3 proteins that mask a nuclear 
localization signal (NLS) in the vicinity, thereby retaining TFEB in the 
cytoplasm (Pena-Llopis et al., 2011; Settembre et al., 2012). Similarly, 
mTORC1 phosphorylates TFE3 and MITF, and regulates their activity through 
the same mechanism of cytoplasmic retention (Martina, Diab, Lishu, et al., 
2014; Martina & Puertollano, 2013). Inactivation of the complex due to the lack 
of nutrients or mitogens switches off the mTORC1 and MAPK/ERK pathways, 
leading to nuclear translocation of these factors and upregulation of target 
genes. Unphosphorylated TFEB and TFE3 shuttle to the nucleus, where they 
bind to CLEAR consensus sequences (further described in Page 120), 
whereas nuclear MITF has been shown to activate genes involved in 
melanogenesis in MNT-1 melanoma cells (Bentley et al., 1994; Hah et al., 
2012). mTORC1-induced shuttling of the MiT/TFE proteins to the nucleus 
establishes a negative feedback loop, turning on the expression of genes 
required for mTORC1 activity such as FNIP2, RagC/D, and vATPase and 
promoting lysosomogenesis and autophagy that increase amino acid pools 
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(Palmieri et al., 2011; Zhang et al., 2015). Interestingly, mTORC1 can be 
positively regulated through the MAPK/ERK axis by two different routes, 
pointing to a crosstalk between these two distinct pathways in the regulation of 
the CLEAR network. First, ERK can phosphorylate and inhibit the TSC, and 
this, in turn, activates mTORC1 (Xue et al., 2017). Second, MAPK signaling 
leads to phosphorylation of raptor on proline sites prior to raptor-mediated 
scaffolding and recruitment to the lysosomes of active mTORC1 (Carriere et 
al., 2011). 
1.5.2  mTORC1 and melanoma 
The mTORC1 protein complex can sense the cellular nutritional status and 
regulate the synthesis of mRNA, controlling cellular growth and proliferation. 
Hyperactive BRAF-MAPK signaling is known to be a hallmark of melanoma 
tumors. ERK1/2 downstream of the BRAF/MAPK pathway can phosphorylate 
RSK which, in turn, activates mTORC1 in melanoma cells and its downstream 
targets, promoting increased protein translation, growth and proliferation 
(Romeo et al., 2013). A role of mTORC1/2 in bypassing oncogene-induced 
senescence has been described (Dankort et al., 2009). In another study, 
BRAFV600E mutation and CDKN2A loss were not sufficient to drive 
melanomagenesis in a mouse model, as this leads to repression of the PI3K-
AKT axis, oncogene-induced senescence (OIS) and growth arrest. However, 
the melanocytes that underwent transformation exhibited increased mTORC1 
and AKT-mTORC2 signaling, suggesting that mTORC1/2 activation is a 
mechanism used by tumor cells to bypass BRAF-induced senescence and 
trigger progression (Damsky et al., 2015). Dysregulation of mTORC1 has an 
impact on the signaling mechanisms affecting tumor progression, which 
defines the complex as an oncogene that may be relevant in several types of 
cancer. 
  Subcellular localization of the MiT-TFE transcription 
factors 
As previously described, MITF is expressed as different tissue-specific 
isoforms that differ in their N-termini. Furthermore, the subcellular localization 
of MITF has been reported to vary across tissues or cell lines examined. The 
MITF-M isoform which is predominantly expressed in melanocytes, is 
constitutively nuclear (Takebayashi et al., 1996). This is in contrast with TFEB, 
TFE3, and other MITF isoforms, which have been shown to be located in the 
cytoplasm under normal conditions. In monocytes, MITF-A is cytoplasmic and 
shuttles to the nucleus upon RANKL signaling and, interestingly, deletion of 
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the 1B1b N-terminal region of MITF-A that is absent in melanocyte-specific 
MITF-M, promotes constitutively nuclear localization of the protein and may 
contribute to increased transcriptional activity (Lu et al., 2010). Independently, 
nuclear localization signals (NLS) spanning amino acids 197-206 and 214-217 
within the DNA-binding region of MITF-M have been described, which are 
required for shuttling of the protein into the nucleus. Disruption of this NLS 
results in cytoplasmic retention of MITF (Fock et al., 2018; M. Sato et al., 1999; 
Takebayashi et al., 1996). A third NLS between residues 255 and 265 has 
been identified. This in line with another study showing that two C-terminal 
truncations found in WS2A and TS, R214X and R259X cause the mutated 
MITF protein to have increased presence in the cytoplasm (Grill et al., 2013). 
Additionally, a hydrophobic nuclear export signal (NES) has been described 
between amino acids 75 and 80 of MITF-M. Stimulation of ERK activity with 
12-O-Tetradecanoylphorbol-13-acetate (TPA) treatment in melanoma cells, 
triggered phosphorylation of Ser73 which primed subsequent phosphorylation 
of Ser69 by GSK3β, leading to activation of the NES and cytoplasmic 
accumulation of MITF-M (Ngeow et al., 2018). 
The predominant nuclear localization of MITF-M under normal fully-fed 
conditions has been explained by the absence of an N-terminal domain 
important for cytoplasmic retention (Martina & Puertollano, 2013; Roczniak-
Ferguson et al., 2012). This N-terminal region of 30 amino acids present in 
some isoforms of MITF such as MITF-A, is conserved in the N-terminus of 
TFEB and between amino acids 110-140 of TFE3 (Martina, Diab, Lishu, et al., 
2014; Martina & Puertollano, 2013) (Figure 6). It contains a Rag-binding 
domain that allows the interaction of these factors with active Rag-GTPase 
heterodimers, which is required for the localization of these factors to the 
lysosome and subsequent phosphorylation by different kinases that regulate 
their subcellular localization. Phosphorylation of TFEB and TFE3 by mTORC1 
allows the interaction with 14-3-3 proteins that retain them in the cytoplasm 
(Roczniak-Ferguson et al., 2012; Settembre et al., 2012) (Figure 6). In a 
similar mechanism, ERK2 phosphorylates TFEB and promotes its cytoplasmic 
retention (Settembre et al., 2011). Moreover, AKT inhibition has been shown 
to block AKT-mediated phosphorylation of TFEB at Ser467. Unphosphorylated 
TFEB at this residue resulted in translocation of TFEB to the nucleus and 
subsequent enhancement of its transcriptional activity leading to induction of 
autophagy and clearance of intralysosomal aggregates in a model of 
neurological Batten disease (Palmieri et al., 2017). 
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These studies suggest that kinases regulate the subcellular localization of 
the MiT-TFE transcription factors, and that this has a profound effect on 
expression of their target genes, which are involved in several crucial cellular 
processes, from metabolism, to the regulation of growth and proliferation. 
However, it is important to note that when assaying the phosphorylation status 
of these proteins, ectopically overexpressed factors present in non-physiologic 
concentrations could saturate the ability of the relevant kinases to 
phosphorylate them, and therefore escape the normal regulation of its 
cytoplasmic retention. As an example, when overexpressing TFEB, a 
significant fraction can be found in the nucleus of normally fed cells 
(Puertollano et al., 2018).  
 The endosomal system 
Endosomes are membrane-bound compartments contained within eukaryotic 
cells. These vesicles originate from the trans Golgi and can be categorized as 
early endosomes, recycling endosomes, late endosomes and fully mature 
lysosomes. Endosomes store and sort intracellular material that will be 
recycled back to the plasma membrane or to the Golgi system, whereas 
acidified late endosomes mature to lysosomes. Fully mature acidic lysosomes 
are capable of fusing with autophagosomes, targeting their content for protein 
degradation in a process known as autophagy, which is vital for intracellular 
recycling and clearance of unwanted debris. 
Figure 6. Multisequence alignment of the Rag-binding domain and mTOR 
phosphorylation sites in TFEB, TFE3, MITF-A and MITF-M. The residues marked in 
green have previously been identified as required for the interaction between Rag 
proteins and TFEB (Martina & Puertollano, 2013). MITF-M lacks this Rag-binding 
domain. Serine residues marked in red are the mTOR phosphorylation sites in TFEB 
which are conserved in TFE3 and MITF. 
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The endosomal and lysosomal network has traditionally been considered 
as a mere mechanism of intracellular sorting and delivery, degradation and 
recycling. However, recent studies point to a very complex role as a major 
signaling hub that links environmental cues such as sensing amino acid 
availability through the mTORC1 pathway to gene regulation involved in 
cellular metabolism (Dibble & Manning, 2013). For example, lysosome-
mediated degradation of epidermal growth factor receptor (EGFR) and other 
receptor tyrosine kinases (RTKs) which downregulate mitogenic signals (Burke 
et al., 2001), and processing of 5' adenosine monophosphate-activated protein 
kinase (AMPK) signaling that leads to upregulation of mitophagy (Laker et al., 
2017). 
1.7.1  The melanosome 
Melanosomes are rather large organelles (∼500 nm in diameter) closely 
related to lysosomes. They are thought to originate from the ER or the trans 
Golgi as stage I premelanosomes. The notion that endosomes originate from 
the trans Golgi network is supported by the accumulation of mature 
premelanome protein (PMEL) in endosomal vesicles before the formation of 
non-pigmented stage I premelanosomes (Raposo et al., 2001). It is suggested 
that the endosomes destined to form melanosomes favor the accumulation of 
melanosome-related proteins while they discard proteins directed to the 
cellular membrane or to the formation of lysosomes (Raposo & Marks, 2002). 
Stage II melanosomes develop characteristic internal striations formed by 
proteolitically cleaved PMEL. In the next steps of development, stage III 
melanosomes become elongated and progressively acquire melanosome-
specific enzymes like TYR and tyrosinase-related protein-1 (TYRP1). These 
melanogenic enzymes have been shown to be transported through the Golgi 
system to the nascent melanosome, indicating an overlap with lysosomal 
biogenesis (Kushimoto et al., 2003). Stage III melanosomes begin to 
synthesize melanin and to deposit it onto the luminal fibrillar matrix until they 
become fully melanized mature stage IV melanosomes. 
1.7.2  The lysosome 
The lysosome is a type of endosomal vesicle with the characteristic of a highly 
acidic lumen that contains about 60 different hydrolases, among them 
nucleases, proteases, glycosidases, lipases, phosphatases, sulfatases and 
phospholipases, which require an optimum pH of 4.5-5.0. Lysosomal 
acidification is carried out by a highly conserved multimeric enzyme complex, 
the vacuolar-type (V-type) ATPases located at the lysosomal membrane. Their 
function is to utilize energy from ATP to pump protons into the lysosomal 
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lumen. Besides vATPases, the lysosomal membrane contains a wide array of 
different proteins. These include highly conserved ion and channel 
transporters, which regulate the content of the lysosomes and the export of 
degradation products. An example of a channel protein crucial for lysosomal 
function is the transient receptor potential cation channel mucolipin (TRPML), 
which regulates the release of Ca2+ from the lysosome via calmodulin-
mediated lysosomal fission and recovery (Peters & Mayer, 1998). In addition, 
lysosome-associated membrane proteins (LAMPs) are highly-glycosylated 
proteins that protect the lysosomal membrane against digestion by lysosomal 
hydrolases. SNARE (soluble NSF (N-ethylmaleimide-sensitive factor) 
attachment protein receptor) proteins mediate the fusion of lysosomes with 
their target intracellular compartments (Pu et al., 2016). Mature lysosomes can 
fuse with vesicles that engulf extracellular material that has been taken up 
through the process of endocytosis for further digestion. Lysosomes can also 
fuse with autophagosomes that contain misfolded aggregates, oxidized lipids, 
pathogens and damaged or unneeded intracellular components, in a process 
called autophagy. The products from endocytic vesicles or autophagic 
degradation are used to meet the nutritional needs of the cell for energy 
production or availability of building blocks for the biosynthesis of new cellular 
components.  
A small fraction of all the cellular lysosomes are secretory lysosomes, also 
called lysosome-related organelles. Secretory lysosomes localize closer to the 
plasma membrane. The process of exocytosis is calcium-dependent and 
regulated by TFEB, which controls the transcription of genes involved in 
translocation to the plasma membrane and unloading of cellular metabolites 
(Medina et al., 2011). Lysosomal exocytosis is very active in some cell 
lineages. Melanocytes secrete melanosomes with the pigment melanin 
(Raposo & Marks, 2002). Osteoclasts resorb bone material by endocytosis and 
transport the vesicles through the cytoplasm to the opposite pole at the basal 
plasma membrane, releasing their content into the extracellular space (Salo et 
al., 1997). Spermatozoa secrete hydrolases during fertilization (Tulsiani et al., 
1998). Lysosomal exocytosis is important for the immune function through the 
secretion of antigen-loaded MHC-II complex by dendritic cells, and cytotoxic T 
cells secretory degranulation (Pu et al., 2016). In addition, lysosomes migrate 
to the plasma membrane to promote repair, a process dysregulated in 
muscular dystrophy (Han et al., 2007). 
  Autophagy 
Autophagy, or “self-eating”, is a catabolic pathway involving the delivery of 
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intracellular material to acidic lysosomes that mediate degradation and 
recycling. Autophagy can be divided into three different subtypes. 
Microautophagy directly delivers cytosolic components to the lysosome 
through small invaginations in the lysosomal membrane. During chaperone-
mediated autophagy (CMA), a substrate is targeted for degradation by forming 
a complex with heat shock cognate 71 kDa (hsc70) proteins, which are 
recognized by chaperones. The complex is transported to the lysosomal 
membrane where it binds a CMA receptor for internalization. Finally, 
Figure 7. Three major types of the autophagy process. Figure obtained with 
permission from Elsevier according to permit number 4375950128309 (Mizushima 
& Komatsu, 2011). 
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macroautophagy, which is the most studied type, involves the fusion of the 
autophagosome, an endosomal membrane-bound organelle that engulfs 
intracellular material, with an acidic lysosome, forming an autolysosome 
(Figure 7). In turn, macroautophagy can be divided into bulk autophagy or 
selective autophagy, the latter referring to the degradation of specific 
subcellular structures, such as mitophagy of mitochondria, lipophagy of lipid 
droplets, or chlorophagy of chloroplasts. There are 35 autophagy-related 
genes (ATGs) identified so far, with a subset (the “core” ATGs) being 
conserved across eukaryotic organisms from yeast to mammals (Bento et al., 
2016; Mizushima & Komatsu, 2011), governing autophagosome induction and 
formation, expansion, closure and fusion with lysosomes.  
1.8.1  Initiation of autophagy 
Autophagy initiation is controlled by mTORC1 and is triggered by starvation 
and other stresses that release mTORC1 from the lysosome. Inactive 
mTORC1 impairs the phosphorylation of autophagy-initiating UNC51-like 
kinase 1 (ULK1) and TFEB. Unphosphorylated TFEB shuttles to the nucleus 
and activates the transcription of genes involved in the regulation of 
downstream autophagy (Palmieri et al., 2011; Sardiello et al., 2009; Settembre 
et al., 2011). Unphosphorylated ULK1 is active and, promotes phosphorylation 
and activation of beclin-1 (BECN1), and thus initiates phagophore formation, 
the autophagosome precursor, nearby the endoplasmic reticulum (ER) (Itakura 
& Mizushima, 2010; Russell et al., 2013). It remains unclear whether the ER 
membrane forms part of a newly synthesized phagophore, and whether other 
structures of the endomembrane system (Golgi, mitochondria) also contribute 
to the complex process of autophagosome biogenesis (Bento et al., 2016; 
Hailey et al., 2010; Mizushima et al., 2011). Next, the ATG14-containing class 
III phosphatidylinositol 3-kinase (PI3K) complex is recruited to the nascent 
autophagosome where it interacts with BECN1. 
1.8.2  Expansion of the autophagosome 
In both yeast and mammals, ubiquitin-like proteins contribute to the expansion 
of the lysosome. The mammalian ATG5, ATG12 and ATG16L protein complex 
associates with the phagophore until dissociation following vesicle maturation 
(Mizushima et al., 2003; Mizushima et al., 2001), a process regulated by the 
Golgi protein RAB33A which binds and inhibits ATG16L1 (Itoh et al., 2008). 
A second mechanism involving ubiquitin-like proteins that promote 
autophagosomal expansion, includes the protein ATG8, also known as 
microtubule-associated protein light chain 3 (LC3). The cysteine protease 
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ATG4, with four isoforms in mammals, exposes a glycine in the C-terminus of 
LC3 (Kirisako et al., 2000), which is then named LC3-I, and subsequently is 
covalently conjugated to phosphatidylethanolamine (PE) to constitute the 
lipidated form LC3-II (Geng & Klionsky, 2008), a process that determines 
autophagosomal size (Z. Xie et al., 2008). Nutrient starvation and stress can 
induce lipidation of LC3 (Kabeya et al., 2000). Eventually LC3-II will undergo 
deconjugation. Deficiencies in the deconjugation step have been associated to 
impaired macroautophagy, although the mechanism is not entirely understood 
(Nair et al., 2012). LC3 constitutes one of the most prominent markers in 
experimental research for the assessment of the autophagy function in 
mammals. 
1.8.3  Autophagosome completion and fusion 
The last step in autophagosome formation involves its maturation and fusion 
with a lysosome or late endosome in order to conform a fully mature 
autolysosome that can undergo degradation of the cargo. Microtubules play an 
important role in phagosome trafficking (Monastyrska et al., 2009). UV 
radiation resistance-associated gene protein (UVRAG) can interact with the 
PI3K complex at the autophagosome and activate Rab7, a GTPase that 
promotes fusion with lysosomes (C. Y. Liang et al., 2008), in collaboration with 
other proteins from the SNARE family (Pu et al., 2016). The soluble hydrolases 
in the lysosome are active in the lysosomal low pH and can degrade the 
substrates provided by the autophagosome in the final step of the autophagy 
process. 
1.8.4  Autophagy in human disease 
Defective lysosomal function is the cause of a group of more than 50 rare 
inherited metabolic disorders denominated lysosomal storage diseases 
(LSDs). These disorders are characterized by mutations that usually result in 
deficiency of a single enzyme required for the metabolism of substrates, 
leading to enlarged lysosomal vacuoles filled with undegraded material, often 
localized adjacent to the nucleus. They are further classified, depending on the 
substrate that accumulates, into lipid storage disorders, 
mucopolysaccharidoses, or glycoprotein storage disorders. Pompe disease is 
another LSD characterized by an accumulation of glycogen in the lysosomes 
of muscle cells, nervous system and liver. To this date there is no cure for 
LSDs, and treatment is mostly symptomatic. 
Recently, increasing attention has been drawn to a link between abnormal 
lysosomal function and neurodegeneration, and the induction of autophagy as 
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a potential therapeutic target for conditions such as Huntington’s, Parkinson’s 
and Alzheimer disease (AD), where pathogenic protein aggregation is a 
hallmark. These conditions involve changes in mTORC1, dynein and Rab7 
activity (Caviston et al., 2011; Erie et al., 2015; Wen et al., 2017), preventing 
degradation of protein deposits by the autolysosomal pathway, through a 
mechanism not yet fully elucidated. Accumulation of lysosomes that disturb the 
normal morphology of neuronal axons, due to blockade of lysosomal 
proteolysis and vesicle transport, has been described in AD (Lee et al., 2011). 
Understanding the role of the autophagy response in cancer biology is 
crucial in the search for novel effective therapies. Many anticancer agents 
activate autophagy, as it can serve as a mean for promoting survival through 
efficient use of available nutrients, handling of oxidative stress and limiting 
DNA damage. Activated autophagy can be detected at the most hypoxic 
regions of the tumor where there is considerable metabolic stress, conferring 
a survival advantage. 
Autophagy inhibition improves the performance of anticancer drugs, 
including the response to chemotherapy, in several tumor samples and 
preclinical models. It has been shown to enhance the cytotoxic activity of 
effector T lymphocytes and natural killer (NK) cells against tumoral cells 
(Amaravadi et al., 2011). Human pancreatic tumors and pancreatic cancer cell 
lines are dependent on elevated basal levels of autophagy compared to normal 
pancreatic cells (Yang et al., 2011). Consistent with that, autophagy inhibition 
was shown to induce apoptosis and to halt tumor growth (Marchand et al., 
2015). During oncogenic transformation, lysosomes undergo changes in pH, 
subcellular localization or composition. Reduction of RAB7 expression 
promotes lysosomal relocation to the cell periphery, which has been 
documented in prostate cancer and is associated with increased tumor 
invasiveness (Steffan et al., 2014). It has been proposed that the mechanism 
behind this involves the unloading of proteolytic enzymes into the extracellular 
space that then digest extracellular matrix (Steffan et al., 2014). In addition, 
the endosomal network can incorporate proteins such as the transmembrane 
type 1 matrix metalloproteinase into the plasma membrane invadopodia, 
facilitating tumor migration, invasion and metastasis (Macpherson et al., 2014; 
Monteiro et al., 2013). Peripheral lysosomal relocation has also been 
associated with increased expression of integrins in the plasma membrane, 
enhancing migration and cell adhesion necessary for the establishment of new 
tumor populations (Dozynkiewicz et al., 2012). Importantly, tumor cells that 
undergo the process of autophagy cease cell division and motility and enter a 
dormant state, while maintaining the capacity to regenerate and resume 
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proliferation when proper growth conditions are restored. Tumor regeneration 
and re-emergence form latency is a key issue in cancer management (White 
& DiPaola, 2009). 
Paradoxically, a tumor-suppressive role of autophagy in line with its basic 
role at clearing damaged organelles and cellular components has been 
documented. This role is particularly prominent in hepatocellular carcinoma. 
Mice carrying deletions of Atg5 or Atg7 display inactivated autophagy and pile-
up cellular waste. Defective autophagy leads to increased DNA-damaging 
ROS production, genomic instability and generalized inflammation, which may 
promote tumor initiation (Komatsu et al., 2007; Takamura et al., 2011). 
Monoallelic loss of Beclin 1, a gene required for autophagy induction, has been 
reported in ovarian and breast cancer (X. H. Liang et al., 1999). Beclin 1 
deletions induce chromosome instability and tumor initiation (Mathew et al., 
2007). A very common mutagenesis event in a wide fraction of human cancers 
involve mutations that lead to abnormal activity of the PI3K and mTOR 
pathways. Hyperactive PI3K inhibits autophagy and simultaneously stimulates 
uncontrolled cell growth and proliferation, regardless of nutrient and growth 
signals availability, which eventually leads to extreme metabolic stress and cell 
death (S. Jin et al., 2007), perhaps in a delicate balance that is still 
advantageous to the tumor. Therefore, autophagy has been referred to as a 
double-edged sword regarding whether it contributes to the suppression or 
promotion of tumorigenesis (White & DiPaola, 2009). Current efforts are 
directed to understand how pharmacological modulation of autophagy in 
cancer could lead to the development of novel, effective therapies, depending 
on the particular autophagy context, whether it is activated or suppressed.  
On another note, current research on therapies that aim to prolong lifespan 
show that the autophagy pathway is one of those implicated in the aging 
process. Age-related impaired autophagy has been reported in rat liver and 
studies with Saccharomyces cerevisiae, Caenorhabditis elegans and 
Drosophila melanogaster revealed that specimens deficient in key autophagy 
genes Atgs showed a reduced lifespan (Martinez-Lopez et al., 2015). The 
effects of pharmacological approaches directed to promote longevity like 
caloric restriction, sirtuin-1 activation, mTOR or insulin growth factor inhibition 
require autophagy activation (Rubinsztein et al., 2011). However, there are 
other documented effects that are autophagy-independent. Thus, autophagy 
is one of the players to be considered before the challenge of understanding 
the complex biological process of aging, with the goal of boosting cellular 
rejuvenation and lifespan extension.  
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1.8.5  Autophagy and melanoma 
A number of autophagy-related genes have been found to be overexpressed 
across melanoma tumors compared to other cancer types. Specifically, 
expression of Rab7 is increased from early stages of melanoma, resulting in 
enhanced lysosomal trafficking. Rab7-induced autophagy promotes tumor 
fitness, proliferation and remodeling of extracellular matrix, migration and 
invasion (Alonso-Curbelo et al., 2015). A genetically engineered mouse model 
tested depletion of Atg7 in a BrafV600E and Pten-deficient context, showed that 
Atg7-impaired melanomas have growth defects, increased senescence and 
oxidative stress. Moreover, the antiproliferative effects induced by BRAF 
inhibition were more pronounced in the Atg7-deficient tumors (X. Xie et al., 
2015). Partial loss of ATG5, has been identified as the only autophagy-related 
marker of advanced stage and poor prognosis in melanoma tumors. This was 
confirmed in mice carrying a melanocyte-specific heterozygous deletion of 
ATG5 that presented melanoma tumors with increased metastatic potential 
and resistance to BRAF inhibition with dabrafenib (Garcia-Fernandez et al., 
2016). BRAF inhibition therapy in metastatic melanoma has been shown to 
increase cytoprotective autophagy triggered by the ER-stress response 
through binding of BRAF to the chaperone GRP78 that induces ER expansion 
(Ma et al., 2014). In contrast, ATG5 depletion in melanoma cell lines reduced 
their proliferation rate, invasion and metastatic potential, pointing to the 
requirement of a basal level of autophagy for melanoma tumors to endure 
acidic conditions and metabolic stress (Marino et al., 2012). It further highlights 
the importance of taking into account whether therapies designed to treat 
metastatic melanoma partially or completely abolish the autophagy function, 
as this may worsen patient survival. 
Malignant melanomas often present areas significantly more melanized 
than adjacent healthy skin. Microscopy analysis of those hyperpigmented 
regions shows the presence of “coarse melanin”, characterized by a large 
number of melanosome-engulfing autophagosomes (Lazova & Pawelek, 
2009). Despite the fact that autophagy degradation of defective melanosomes 
prevents leakage of melanogenesis by-products that are toxic for the cell, 
increased autophagy and coarse melanin in melanoma tumors are defined as 





MITF is a bHLHZip transcription factor that regulates differentiation, growth 
and survival of melanocytes and is found to be amplified in a fraction of 
melanoma tumors. The close relatives of MITF, TFEB and TFE3, have recently 
been shown to be key regulators of lysosome and autophagosome biogenesis. 
Both have been shown to be regulated in a similar fashion by post-translational 
modifications resulting in effects on their subcellular localization and activity. 
This work focuses on characterizing the interactions and functional interplay 
between MITF and its relatives TFEB and TFE3 in melanoma. Three major 
aims have been addressed: 
 
• Aim 1: Determining the expression of the MiT-TFE transcription 
factors in melanoma and analyzing the effects of signaling 
pathways on their subcellular localization. 
 
• Aim 2: Assessing the interactions among the MiT-TFE transcription 
factors with regard to dimerization properties and transcriptional 
cross-regulation. 
 
• Aim 3: Characterizing the overlap in target gene selection of the 





2 Materials and methods 
  Plasmid constructs 
Site-directed mutagenesis (Braman et al., 1996) was used to generate FLAG-
tagged mouse MITF-M constructs carrying the Ser73Ala and Ser409Ala 
mutations, GFP-tagged human MITF-A constructs carrying the Ser180Ala and 
Ser504/508/512Ala mutations and the pEGF-N1-MITF-M (+) construct, the 
FLAG-tagged and GFP-tagged MITF(Δ259-261), MITF(Δ259-
261)_N269_R270insEQQ and N269_R270insEQQ constructs. MLANA-intron-
2, TFEB-intron-1 and MITF-enhancer luciferase reporter constructs were 
generated by amplifying human genomic DNA from Skmel28 cells and 
restriction digestion and ligation in the appropriate luciferase reporter 
constructs. Site-directed mutagenesis was also used to mutate the regulatory 
element in both the TFEB-intron-1 and the MITF-enhancer luciferase reporter 
constructs to scrambled versions. Gibson assembly cloning method (Gibson 
et al., 2009) was used to generate the FLAG-HA-tagged human TFE3 
construct and the FLAG-tagged human MAX construct. All the constructs used 
for the generation of the stable inducible cell lines were generated by restriction 
enzyme digestion followed by ligation to a pBac recipient plasmid. Further 
details on the generation of each of these constructs are explained below in 
separate sections. 
2.1.1  Site-directed mutagenesis and cloning 
I performed in vitro site-directed mutagenesis PCR (Braman et al., 1996) in 
order to mutate the plasmid constructs used in these experiments and to 
amplify genomic DNA for the generation of the luciferase reporter constructs 
used in transcription activation assays. I used 0.02 units/µl Q5® Hot Start High-
Fidelity DNA polymerase (#M0493S, NEB), 1X Q5® reaction buffer, 0.5 μM of 
primers, 200 μM dNTPs, and 1 ng of template plasmid in a total volume of 20 
μl adjusted with DEPC water. The plasmid mutagenesis PCR reaction was 
carried out at the conditions shown in Table 1. PCR conditions for amplification 
of genomic DNA are shown in Table 2. A quarter of the PCR product (5 μl) 
was loaded on an agarose gel to confirm that the PCR was successful and the 
amplified fragment showed the correct size. Subsequently, 20 units of DpnI 
(#R0176S, NEB) were added to the PCR product and incubated at 37°C for 
one hour in order to digest the parental plasmid template. 1 μl of the DpnI-
treated PCR product was mixed with 5 units of T4 polynucleotide kinase (PNK) 
(#M0201S, NEB) and 0.5 μL of 10x T4 DNA ligase buffer in a total volume of 
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5 μl, and incubated at 37°C for 30 minutes in order to phosphorylate the 5‘-
ends of the amplified DNA fragments. Next, the phosphorylated mutated DNA 
fragments were recircularized by DNA ligation using 400 units of T4 DNA ligase 
(#M0202S, NEB). For transformation, 2.5 μl of the ligation product were added 
to 25 μl of NEB® 5-alpha Competent E. coli cells (High Efficiency) (#C2987, 
NEB), which were incubated for 30 min on ice, then heat-shocked at 42°C for 
30 seconds and re-incubated on ice for 5 minutes. Transformed bacteria were 
allowed to grow in 475 μl of SOC outgrowth medium (#B9020S, NEB) for one 
hour at 37°C prior to plating onto LB agar plates containing the appropriate 
antibiotic matching the resistance gene contained in the plasmid. Plates were 
incubated at 37°C overnight and then a number of colonies was isolated and 
inoculated overnight at 37°C in LB medium liquid cultures with the appropriate 
selection antibiotic. Plasmid DNA was isolated using Monarch® Plasmid 
Miniprep Kit (#T1010S, NEB) and sent out to GENEWIZ Beckman Coulter 
genomics for Sanger sequencing using universal primers aligning to the 
plasmid backbone.  
 
  
Table 2. PCR cycling conditions for genomic DNA amplification 
Temperature (oC) Time (sec) Number of cycles
Initial denaturation 98 30 1
Denaturation 98 10
Annealing 50-72* 20
Extension 72 20 sec/kb
Final extension 72 120 1
35
* According to primer pair melting temperature
Table 1. PCR cycling conditions for mutagenesis PCR of plasmid 
constructs 
Temperature (oC) Time (sec) Number of cycles
Initial denaturation 98 30 1
Denaturation 98 10
Annealing 50-72* 20
Extension 72 20 sec/kb
Final extension 72 120 1
35
* According to primer pair melting temperature
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2.1.2  MITF constructs 
FLAG-tagged MITF-M constructs carrying the Ser73Ala and Ser409Ala 
mutations were generated from a p3XFLAG-CMVTM-14 construct expressing a 
FLAG-tagged version of mouse MITF-M (MITF-M-FLAG), kindly provided by 
Colin Goding. The GFP-tagged MITF-A plasmid (Addgene plasmid #38132) 
was provided by Shawn Ferguson (Roczniak-Ferguson et al., 2012) and was 
used to generate by site-directed mutagenesis a GFP-tagged version of 
human MITF-A carrying the Ser180Ala and Ser504/508/512Ala mutations. The 
pEGFP-N1-MITF-M (+) construct was generated by in vitro mutagenesis from 
the pEGFP-N1-MITF-M (-) (Addgene plasmid # 38131) kindly provided by 
Shawn Ferguson (Roczniak-Ferguson et al., 2012). The primers used for the 
in vitro mutagenesis are listed in Table 3. 
A FLAG-tagged deletion construct MITF(Δ259-261) construct was 
generated from the MITF-M-FLAG construct described above. A GFP-tagged 
MITF(Δ259-261) was generated from a wild type mouse MITF-M construct 
(pEGFP-N1-MITF-M), kindly provided by Valerie Fock (Fock et al., 2018). A 
FLAG-tagged MITF(Δ259-261)_N269_R270insEQQ MITF construct was 
generated from the FLAG-tagged MITF(Δ259-261) construct by site-directed 
mutagenesis, whereas GFP-tagged MITF(Δ259-261)_N269_R270insEQQ 
was generated from the GFP-tagged MITF(Δ259-261) construct. FLAG-tagged 
N269_R270insEQQ construct was generated from MITF-M-FLAG and GFP-
tagged N269_R270insEQQ was mutated from pEGFP-N1-MITF-M by site-
directed mutagenesis. All the primers used for the in vitro mutagenesis are 
listed in Table 3. 
2.1.3  TFEB and TFE3 constructs 
The human GFP-tagged pEGFP-N1-TFEB (Addgene plasmid # 38119), and 
pEGFP-N1-TFE3 (Addgene plasmid # 38120) were kindly provided by Shawn 
Ferguson (Roczniak-Ferguson et al., 2012). 
A TFE3-FLAG-HA construct was generated by amplifying TFE3 from the 
pEGFP-N1-TFE3 vector and cloning into a pBac FLAG-HA vector downstream 
of a tetracycline response element (TRE), using Gibson assembly (Gibson et 
al., 2009). 50 ng of amplified FLAG-HA backbone were mixed with 3-fold molar 
excess of amplified TFE3 PCR product, together with 15 μl of DEPC water for 
a total volume of 25 μl. 25 μl of 2X Gibson Assembly Master Mix (E2611S, 
NEB) were added to the mix and incubated 15 minutes at 50°C. Subsequently, 
high-competent E. coli were transformed with the ligation mixture. Cloning 
primers are listed in Table 3. 
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2.1.4  MAX-FLAG construct 
A construct expressing a MAX-FLAG fusion protein was generated by 
digesting the pVZ1-MAX vector (kindly provided by R. N. Eisenman (Ayer et 
al., 1993), containing the human MAX gene, by digesting it with the BamHI and 
NotI restriction enzymes  followed by ligation into a pcDNA3.1(+) vector. 
Subsequently, FLAG was amplified from the MITF-M-FLAG construct with the 
primers listed in Table 3, and cloned into the pcDNA3.1(+)-MAX construct with 
Gibson assembly. 50 ng of the pcDNA3.1(+)-MAX fragment amplified with the 
primers listed in Table 3 were mixed with 3-fold molar excess of the PCR 
product containing FLAG. 15 μl of DEPC water for a total volume of 25 μl were 
added in addition to 25 μl of 2X Gibson Assembly Master Mix (E2611S, NEB). 
The ligation mix was incubated 15 minutes at 50°C. Subsequently, high-
competent E. coli were transformed with the ligation mixture. 
2.1.5  Constructs for transcription activation assays 
The TYR promoter reporter construct contains a 380 bp region at the promoter 
of the human TYR gene between bases -382 and -3 upstream of the TSS at 
location +1. This sequence was then cloned into a pGL3-Basic vector 
upstream of the luciferase reporter gene and verified by Sanger sequencing. 
The regions within MLANA intron 2 enhancer (MLANA-intron-2), TFEB intron 
1 enhancer (TFEB-int1) and MITF intron 1 enhancer (MITF-enh) containing 
putative regulatory elements were amplified from human genomic DNA (see 
Site-directed mutagenesis and cloning, Table 2). The 731 bp PCR product 
of MLANA-intron-2 was digested using NheI and XhoI and ligated into the NheI 
and XhoI sites at the multiple cloning site upstream of the 5´ end of the 
luciferase gene in a pGL3-Basic vector. To generate the TFEB-int1 reporter 
vector, an 853 bp fragment containing a CAGCTGA regulatory element within 
intron 1 of the TFEB gene was blunt-ligated into the NheI site of the pGL3-
Promoter vector. The scrambled TFEB intron 1 (TFEB-int1-scrbl) was 
generated by mutating the TFEB-int1 luciferase reporter plasmid by changing 
the CAGCTGA regulatory element to CCCTTTA. To generate the MITF-enh 
reporter vector, a 670 bp fragment containing a CACGTG regulatory element 
within intron 1 of the MITF gene was blunt-ligated into the NheI site of the Pgl3-
Promoter vector. The scrambled MITF intron 1 enhancer (MITF-enh-scrbl) was 
generated by mutating the MITF-enh reporter plasmid by changing the 
CACGTG regulatory element to CCCTTTA. All the constructs were confirmed 




The pGL3-Basic vector (#E1751, Promega) was used as a control for 
tyrosinase (pTYR) transactivation, whereas pGL3-Promoter vector (#E1761, 
Promega) was used as a control for MLANA intron 2 enhancer (MLANA-intron-
2), TFEB intron 1 enhancer (TFEB-intron-1) and TFEB intron 1 scrambled 
(TFEB-int1-scrbl) promoter constructs. 
 Cell culture 
Four human melanoma cell lines were used in this study, namely 501Mel cells 
(generously donated by Ruth Halaban (Halaban et al., 2002)), SkMel28 cells 
(#HTB-72) obtained from the ATCC, SkMel31 cells (#HTB-73) obtained from 



































the ATCC and A375P cells (#CRL-3224) also obtained from the ATCC. 
HEK293T human embryonic kidney cells (#CRL-3216, ATCC) were used for 
luciferase assays since they do not express the MiT/TFE transcription factors 
endogenously. All the cells were grown in Dulbecco’s Modified Eagle (DMEM) 
medium (#10569-010, GIBCO) supplemented with 10% fetal bovine serum 
(FBS #10270-106, GIBCO). The cells were grown at 37°C in 5% CO2 and split 
with fresh medium two to three times per week.   
  Inducible cell lines 
2.3.1  GFP-tagged MITF, TFEB and TFE3 
In order to be able to induce expression of the different transcription factors at 
will, I used an inducible piggybac (pBac) system. We generated inducible 
501mel cells by transfecting the cells with three piggybac (pBac) vectors, one 
generating either GFP-tagged human MITF (pBac-pEGFP-N1-MITF), TFEB 
(pBac-pEGFP-N1-TFEB), TFE3 proteins (pBac-pEGFP-N1-TFE3) or GFP 
alone (pBac-pEGFP-N1), one containing a reverse-tetracyclin transcription 
activator, and one containing transposase. The pBac vectors were a gift from 
Dr. Kazuhiro Murakami (Hokkaido University) (Magnusdottir et al., 2013). The 
GFP-tagged MITF-M, TFEB and TFE3 cDNAs were amplified from the 
plasmids pEGFP-N1-MITF-M (Addgene plasmid # 38131), pEGFP-N1-TFEB 
(Addgene plasmid # 38119), and pEGFP-N1-TFE3 (Addgene plasmid # 
38120), kindly provided by Shawn Ferguson (Roczniak-Ferguson et al., 2012), 
using the primers listed in Table 3 (pBac-pEGFP), and then introduced into the 
pBac vector by digestion of the PCR product and the pBac recipient vector 
using the MluI and NotI restriction sites. DNA ligation was performed at the 3:1 
insert to backbone ratio using Instant Sticky-end Ligase Master Mix (M0370S, 
NEB). The ligation products were transformed into high-competent cells. 
Bacterial plasmid DNA was isolated from individual colonies and sequenced 
as described above in Site-directed mutagenesis and cloning. Cells 
transfected with the pBac plasmids were cultured in DMEM medium 
supplemented with 10% FBS and kept under G418 selection (#10131-035, 
GIBCO) for 8 days to obtain stable cell lines. Expression of the constructs was 
induced by addition of 0.2 µg/mL doxycycline to the culture medium. 
2.3.2  MITF knockdown cell lines 
In order to be able to induce knockdowns of MITF at will, we generated two 
piggybac constructs containing miRNAs under the regulation of an inducible 
promoter. 501 Mel MITF inducible knockdown cell lines were generated using 
a piggybac transposable vector pPBhCMV_1-miR(BsgI)-pA-3 obtained from 
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Dr. Kazuhiro Murakami (Hokkaido University) (Magnusdottir et al., 2013). 
MicroRNAs target sequences were selected using the BLOCK-iT RNAi 
Designer, targeting both MITF-M exon 2 (miR(MITF-X2) and 8 (miR(MITF-X8). 
A non-targeting control (miR(NTC) was used as a negative control. The 
BLOCK-iT RNAi Designer was also used to design primers for inserting the 
pre-miRNA (including a mature miRNAi sequence, terminal loop and 
incomplete sense targeting sequence required for the formation of the stem-
loop structure) RNAi into the murine miR-155 cassette in the piggybac vector 
pPBhCMV_1-miR(BsgI)-pA-3 containing the reverse tetracycline transcription 
activator. Sequences of the mature miRNAs and the primers used for the 
generation of the pre-miRNAs are listed in Table 4. Primers were annealed by 
initial denaturation at 95°C followed by slow cooling in water bath forming a 
short double stranded DNA with overhangs matching a BsgI overhang. The 
backbone vector was digested with BsgI (#R05559S, NEB) and the vector 
DNA purified after running the DNA on an agarose gel. The backbone vector 
and the annealed primers were ligated at 15:1 insert to backbone molar ratio 
using Instant Sticky-end Ligase Master Mix (M0370S, NEB). The ligation 
products were transformed into high-competent cells and the plasmid DNA 
isolated from the individual clones were screened as described above in 
Mutagenesis and cloning. For generation of miR-MITF cell lines, 501Mel cells 
were transfected with the transposase-containing plasmid pA-CAG-pBase, the 
plasmids pPBhCMV_1-miR(MITF_X2)-pA and pPBhCMV_1-miR(MITF_X8)-
pA encoding miRNA targeting two different exons of MITF and the plasmid 
pPB-CAG-rtTA-IRES-Neo (10:5:5:1) that confers resistance to neomycin. For 
miR-Ctrl cell lines, 501Mel cells were transfected with pA-CAG-pBase, 
pPBhCMV_1-miR(NTC)-pA encoding a non-targeting miRNA and pPB-CAG-


















rtTA-IRES-Neo (10:10:1). After 48 hours of transfection, miR-MITF, miR-empty 
vector and non-transfected cells were selected with 0.5mg/ml G418 (#10131-
035, GIBCO) for 2 weeks and 1ug/ml of doxycycline was used for induction. 
  Transfection of plasmids 
Cells were cultured in 6 or 12-well plates one day prior to transfection. Then 
they were transfected with 2 μg of plasmid DNA using 6 μl FuGENE HD 
transfection reagent (#E2311, Promega) and diluted up to a 100 μL of serum-
free medium per mL of cell culture medium. The cell culture medium containing 
the transfection complexes was removed after 24 hours and replaced with 
fresh culture medium. The cells were harvested 48 hours after transfection 
cells for RNA or protein extraction. Expression of the constructs was verified 
by Western blotting. 
  RNAi treatment 
Cells were cultured in 6 or 12-wells plates one day prior to transfection. Cells 
were transfected with 10 μM of the respective siRNA and 1 μL Lipofectamine™ 
RNAiMAX transfection reagent (#13778075, Invitrogen) in 100 μL of Optimem 
Pro (#31985-062, GIBCO) transfection medium per mL of cell culture medium. 
Cells were harvested for RNA or protein extraction 2 days after transfection. 
The siRNAs used for the procedure were the following: siRNA for human MITF 
(#4390824, Ambion), siRNA for human TFEB (#M-009798-02, Dharmacon), 
siRNA for human TFE3 (#M-009363-03, Dharmacon) and a control siRNA 
(#4390843, Ambion).  
  Gene expression analysis from melanoma and 
melanocyte cell lines 
The expression of MITF, TFEB, TFE3 and TFEC mRNA transcripts was 
obtained from 23 different melanoma cell lines and a human melanocyte cell 
line using microarray analysis performed in the laboratory of Dr. Lionel Larue 
(Institut Curie. Paris, France) (Rambow et al., 2015) and kindly shared with the 
Steingrimsson laboratory. 
  Immunostaining and confocal imaging 
501mel and Skmel28 cells (3x104 per well) were cultured for 48 hours in 8-well 
chamber slides (#354108 from Falcon). In order to induce MITF expression in 
the inducible 501mel cell lines, 0.2 µg/mL of doxycycline were added to the cell 
culture medium. At day 2, cells were fixed for 2 min with 2% paraformaldehyde 
(PFA) (#P6148, Sigma Aldrich) in cell culture medium and then for 15 min with 
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4% PFA in PBS (Appendix I). For imaging of the overexpressed GFP-tagged 
factors, cells were washed 3 times with PBS, followed by DAPI staining (#D-
1306, Life Technologies) and two additional washes with PBS. The chambers 
were then removed and the samples allowed to dry prior to adding a drop of 
Fluoromount-G™ (#00-4958-02, Invitrogen) onto each well and then topping 
with a cover slide. For immunostaining of the endogenous MiT/TFE factors, 
following the treatment with Torin1 (#4247, Tocris) or PLX4032 (#S1267, 
Selleck Chemicals) inhibitors, cells were washed once with PBS after fixation, 
then permeabilized for 8 min with 0.1% Triton X-100 in PBS, followed by 3 
washes with PBS. They were then blocked with blocking buffer (5% normal 
goat serum, 0.05% Triton X-100 and 0.25% BSA in PBS) for 1 hour at room 
temperature, and stained overnight at 4°C with 0.25% BSA in PBS antibody 
buffer containing the primary antibodies: MITF (MS771-PABX, Thermo 
Scientific), TFEB (#4240, CST) (#2775, CST), and TFE3 (#14779, CST) 
(Table 5). Cells were then washed 3 times with PBT (0.1% Tween-20 in PBS) 
and stained for 1 hour at room temperature with the Alexa Fluor 546 goat anti-
mouse IgG(H+L) (#A11003, Invitrogen) or the Alexa Fluor 488 goat anti-rabbit 
IgG(H+L) (#A11070, Invitrogen) (Table 6) fluorescent secondary antibodies 
diluted in PBT. Subsequently, the cells were washed twice with PBT and once 
with PBS and finally stained with DAPI and prepared for imaging as previously 
described. Imaging was performed using a FluoView FV1200 laser scanning 
confocal microscope (Olympus) equipped with a PlanApo N 60X/1.40 ∞/0.17 
Oil Microscope Objective. The environmental temperature was set to 17°C. 
Images were digitally zoomed (1.5X) using FluoView 4.2 acquisition software. 
Name Clonality Product # Company Dilution used
MITF Mouse monoclonal MS771-PABX Thermo Scientific 1:2000
TFEB Rabbit polyclonal 4240 CST 1:2000
TFE3 Rabbit polyclonal 2775 CST 1:2000
GFP Rabbit polyclonal ab290 Abcam 1:5000
FLAG Mouse monoclonal F3165 Sigma Aldrich 1:5000
Actin Mouse monoclonal MAB1501 Millipore 1:10000
Actin Rabbit monoclonal 4970 CST 1:4000
Primary antibodies




  Western blotting 
2.8.1  Protein extraction from cell cultures 
For total protein extraction, cells were cultured in 6 or 12-wells plates. The day 
of harvest, cells were washed with PBS, lysed in a variable amount (depending 
on culture plate size and concentration of the protein to be analyzed) of 1x 
Laemmli sample buffer containing 63 mM Tris-HCl (pH 6.8) (#RES3098T-B7, 
Sigma Aldrich), 0.1% 2-Mercaptoethanol (#M3148, Sigma Aldrich), 0.0005% 
Bromophenol blue (#114391, Sigma Aldrich), 10% glycerol (#G5516, Sigma 
Aldrich) and 2% SDS (#L3771, Sigma Aldrich), boiled at 95°C for 5 minutes 
and the samples were stored at -20°C until further use.  
2.8.2  Gel electrophoresis, transfer and western blot 
Samples were then run on 8% or 10% gels. To make 8% resolving gels, 2.1 
mL of 40% acrylamide (#1610140, Bio-Rad), 2.5 mL of resolving gel (lower) 
Tris Buffer (Appendix I), 100 μl of 10% ammonium persulfate (APS) (#A3678, 
Sigma Aldrich), 10 μl of N,N,N′,N′-Tetramethylethylenediamine (TEMED) 
(#T9281, Sigma Aldrich) and 530 mL of distilled water were mixed and poured 
between two glass plates, topped with 100% isopropanol to avoid contact of 
the gel with air which prevents polymerization. Upon polymerization of the 
resolving gel, a 5% stacking gel was prepared by mixing 375 μl of 40% 
acrylamide, 750 μl of stacking gel (upper) Tris Buffer (Appendix I), 30 μl of 
10% APS, 3 μl of TEMED and 2.17 mL of distilled water. The stacking gel 
solution was added on top of the resolving gel between the glass plates after 
removal of the isopropanol, and a comb was inserted for loading well formation. 
Enough incubation time was allowed for the gel to harden and use. The gel 
was placed in electrophoresis cassettes and covered with 1x running buffer 
(Appendix I). One lane of the gel was loaded with 5 μl of PageRuler™ 
Prestained Protein Ladder (#26616, Thermo Scientific), and different amounts 
Name Channel Isotype Product # Company Dilution used
Alexa Fluor goat anti-mouse 546 IgG(H+L) A11003 Invitrogen 1:1000
Alexa Fluor goat anti-rabbit 488 IgG(H+L) A11070 Invitrogen 1:1000
Secondary antibodies
Table 6. Secondary antibodies used for immunostaining 
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of protein samples extracted from cell cultures were loaded in the remaining 
wells, ranging from 15 μl to 40 μl of protein sample. Samples were run at 100V 
for 20 min and subsequently at 130V until the front dye would diffuse out of the 
gel. Gels were removed from the glass plates and washed in 1X transfer buffer 
(Appendix I). A 0.2 μm PVDF membrane (#88520, Thermo Scientific) was 
activated for 10 seconds in methanol and then washed in 1x transfer buffer. 
Gel and membrane were assembled in a wet transfer cassette covered in 1x 
transfer buffer and the gel proteins were blotted onto the PVDF membrane at 
90V for 100 min at 4°C. The membranes were blocked with 5% BSA in TBS-T 
(0.1% Tween 20 in TBS (Appendix I) for 1 hour at room temperature, and 
stained overnight at 4°C with 3% BSA in TBS-T and one of the appropriate 
primary antibody (Table 5) in 5% BSA TBS-T blocking buffer. Membranes were 
washed 3x with TBS-T and stained for 1 hour at room temperature with the 
anti-mouse IgG(H+L) DyLight 800 conjugate (#5257, CST) or the anti-rabbit 
IgG(H+L) DyLight 680 conjugate (#5366, CST) (Table 7) fluorescent 
secondary antibodies. The membranes were again washed 3x with TBS-T and 
visualized using CLx Imager (LI-COR Biosciences).  
2.8.3 Quantification 
Images obtained from scanning of Western blotting membranes with the CLx 
Imager (LI-COR Biosciences) were quantified using ImageJ software. The 
intensity of the bands of each immunoblotted protein was normalized with the 




For coimmunoprecipitation experiments, cells were cultured in 6-well plates or 
in individual 10-cm plates and then lysed with a lysis buffer containing 50mM 
Name Channel Isotype Product # Company Dilution used
Anti-mouse 800 nm IgG(H+L) 5257P CST 1:10000
Anti-rabbit 680 nm IgG(H+L) 5366S CST 1:10000
Secondary antibodies
Table 7. Secondary antibodies used for Western blotting 
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TrisHCL pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-100 and 
supplemented with 1:100 protease inhibitor cocktail (#P8340, Thermo 
Scientific) and 1:100 PMSF (100 mM) for 15 min on a shaker at 4°C. The 
lysates were scraped and collected in microcentrifuge tubes, homogenized by 
pipetting several times and then allowed to rotate in a rotating platform at 4°C 
for 10 min. The lysates were centrifuged in order to remove cell debris at 14000 
g for 10 min at 4°C. 10% of the supernatant was collected as the input fraction 
and the rest of the supernatant was used for immunoprecipitation. For the 
immunoprecipitation of GFP-tagged proteins, samples were rotated for 2 hours 
with 1 μl per million cells of antibodies against GFP (#ab290, Abcam). 
Subsequently, immunocomplexes were formed by adding 20 μl of protein A/G 
plus-agarose beads (#sc-2003, Santa Cruz Biotechnology) for 1 hour at 4 °C 
on a rotating platform. Samples were centrifuged (2,500 rpm for 5 min) to 
collect the beads and then washed with TBS buffer and centrifuged 3 times. 
The samples were eluted with 25μl of 2x Laemmli buffer. For the 
immunoprecipitation of FLAG-tagged proteins, samples were rotated for 3 
hours with the ANTI-FLAG M2 Affinity Gel (#A2220, Sigma-Aldrich) as 
described by the manufacturer’s instructions, followed by centrifugation of the 
immunocomplexes at 8200 g for 30 seconds at 4°C, and 3 cycles of washes 
and centrifugations with TBS. The immunoprecipitated FLAG-tagged proteins 
and coimmunoprecipitated proteins were eluted by competition with 150 ng/μl 
3X FLAG peptide in TBS shaking at 4°C for 30 min, followed by centrifugation 
at 8200 g for 30 seconds at 4°C. Eluted immunoprecipitated samples and 
previously collected supernatant were boiled with 2x Laemmli buffer for 5 min. 
 Transcription activation assays 
HEK293T cells (1.5x104 per well) were seeded in white 96-well plates 
(#781965, BRAND) and cultured for 24h prior to transfection (FuGENE, 
Promega) with 33 ng of a construct carrying the relevant regulatory region 
(TYR, MLANA, TFEB-int1 or TFEB-Int1-scrb) coupled to the luciferase gene, 
33 ng of an MITF-M construct and 33 ng of a pRL Renilla control reporter 
vector. Cells were assayed 24 hours after transfection using the Luciferase 
DualGlo kit (E2940, Promega) as described by the manufacturer. The 
luminescence activity was measured in a multimode microplate reader 
(GloMax, Promega) with a 300-millisecond reading per well. The luciferase 
signal of each sample was normalized to the renilla signal for transfection 
efficiency and cell viability. The pGL3-Basic (#E1751, Promega) or pGL3-
Promoter (#E1761, Promega) vectors were used in order to calculate the fold 
induction of each regulatory element activity, respectively. Three technical 
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replicates per sample were included in each assay and the assays were 
repeated for at least three biological replicates. Error bars indicate standard 
error of the mean (SEM) and statistical significance was assessed with 
student’s t-tests. 
 Quantitative PCR for gene expression analysis 
 






MITF (+/-) FW 5’-CGACAGAAGAAACTGGAGCAC-3‘
REV 5’-AAATCTGGAGAGCAGAGACCC-3‘
MITF (+) FW 5’-ATGGAAACCAAGGTCTGCCC-3‘
REV 5’-GGGAAAAATACACGCTGTGAGC-3‘





















TRIzol reagent (#15596-026, Ambion) was used for total RNA extraction, 
followed by isopropanol precipitation of the RNA. The cDNA was generated 
according to the manufacturer’s instructions with High-Capacity cDNA Reverse 
Transcription Kit (#4368814, Applied Biosystems). Exon-spanning human 
gene-specific primers for q-PCR were designed using NCBI Primer BLAST 
(Table 8), and qPCR performed with the SensiFAST SYBR Lo-ROX Kit (#BIO-
94020, Bioline) using a CFX384 Touch Real-Time PCR Detection System (Bio-
Rad). The qRT-PCR reactions were performed in technical triplicates, using 1 
ng/μl cDNA, 0.3 μM of primer mix and 2.5 μl of SensiFAST SYBR Lo-ROX per 
reaction, adjusted to 5 μl with DEPC treated water. Cycling conditions are 
described in Table 9. The fold change in gene expression was calculated with 
the 2^(-Delta Delta C(T)) method (Livak & Schmittgen, 2001), normalized to 
the geometrical mean of β-Actin and human ribosomal protein lateral stalk 
subunit P0 (RPLP0) expression. Standard curves for primer efficiency were 
calculated using the formula E=10^(-1/slope) for each primer pair. 
 Proliferation assay  
1x105 cells were seeded per well onto a 12-wells plate. After 24 hours, cells 
were transfected for the overexpression of GFP-tagged TFEB (pEGFP-N1-
TFEB), TFE3 (pEGFP-N1-TFE3) or GFP alone (pEGFP-N1). On day three, 
cells were trypsinized and seeded onto 96-well plates at a density of 2x103 
cells per well in triplicates. Images were recorded with Incucyte Zoom system 
(Essen BioScience) every 2 hours for at least 7 days. Collected images were 
then analyzed using Incucyte software by measuring cell confluency to graph 
the growth curves. The doubling time was calculated with the formula: Duration 
x log(2)/log(FinalConfluency)-log(InitialConfluency). 
 
Temperature (oC) Time (sec) Number of cycles









 Bioinformatics and data visualization of ChIP-seq 
analysis 
ChIP-sequencing data were obtained and analyzed by Ramile Dilshat 
(unpublished data), who performed ChIP-seq experiments using a transfected 
TFEB-GFP construct in 501Mel cells. She then generated WIG files (.wig), text 
files that define the ChIP-seq data tracks. Data tracks were loaded onto the 
IGV genome browser (Robinson et al., 2011) (Thorvaldsdottir et al., 2013) in 
order to analyze the location of binding sites provided by these datasets across 
the genome. Gene Ontology (GO) analyses were performed with the web tool 
DAVID (Huang da et al., 2009a, 2009b) using default parameters. Motif 
discovery and motif enrichment analyses (AME) (McLeay & Bailey, 2010) were 
performed using the MEME suite web tool (Bailey et al., 2009) using default 
parameters. Venn diagrams were generated using JVenn web plug-in (Bardou 
et al., 2014) or manually using Graphpad Prism 7. 
 Statistical analysis 
Results are represented as grouped analysis of the mean from three or more 
independent experiments with standard error of the mean (SEM). Graphpad 
Prism 7 was used for all the statistical analysis. Analysis of qRT-PCR and 
Western blot quantification of the regulatory loop, were performed using 
multiple t-tests, comparing each cell mean to the control cell mean and multiple 
comparison correction by Holm-Sidak method with statistical significance set 
as *P<0.05. All the remaining statistical analysis of qRT-PCR, including 
analysis of autophagy genes and the effects of mTOR inhibition were 
performed using two-way analyses of variance (ANOVA). Statistical analysis 
of the doubling time calculated from the proliferation assay and the luciferase 
reporter assays, were performed using one-way ANOVA. ANOVA analysis 
were performed comparing each cell mean to the control cell mean and 






  MiT-TFE transcription factors are expressed in 
melanoma 
Previous analysis performed in the lab using RNA sequencing data from 368 
metastatic melanoma tumors from The Cancer Genome Atlas (TCGA) 
Research Network: (Cancer Genome Atlas, 2015; 
"http://cancergenome.nih.gov/,") showed that the expression of TFEB, TFE3 
and TFEC was 14-fold, 4-fold and 40-fold lower, respectively, than that of MITF 
(Figure 8A) (Möller et al., submitted). In addition, analysis of TCGA showed 
that MITF, TFEB, TFE3 and TFEC mRNAs are expressed across melanoma 
tumors and are subject to a number of somatic genetic alterations in a subset 
of 363 melanoma specimens. 131 (36%) of all the samples in the dataset 
harbor at least one somatic genetic alteration associated with MITF, TFEB, 
TFE3 or TFEC, including in-frame, missense or truncating mutations, genetic 
fusions, genomic amplifications and mRNA overexpression (Figure 8B). A 
majority of the alterations detected in these tumors that affected MITF are copy 
number amplifications and mRNA upregulations. I could not detect any 
recurrent MITF mutation across the tumors. Most mutations affecting TFEB 
and TFE3 were missense mutations with a single occurrence. Interestingly, 
four samples featured a missense G103E mutation in TFEC. The significance 
of this mutation is unknown and only 1 out of the 4 mutated samples was 
B 
A 
MITF TFEB TFE3 TFEC Fold MITF/TFEB
Fold 
MITF/TFE3
5947 437 1442 144 13.6 4.1Metastatic melanoma
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associated with a change in copy number of TFEC. Furthermore, I investigated 
the gene expression data generated by the TCGA across 363 melanoma 
biopsies for analysis of the correlation in gene expression between MITF, 
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Figure 8. MITF, TFEB, TFE3 and TFEC mutations and expression across 
melanoma tumors and cell lines. (A) Mean expression of MITF, TFEB, TFE3 and 
TFEC in TCGA tumor samples (368 metastatic melanomas). (B) Oncoprint chart 
showing genetic alterations in the MITF, TFE3, TFEB and TFEC genes found in 363 
melanoma biopsies. (C) Co-expression analysis of MITF, TFEB and TFE3 in the same 
subset of melanoma samples. Spearman’s rank correlation coefficient (rho) is -0.49 for 
TFE3 and MITF, 0.30 for TFE3 and TFEB and -0.28 for TFEB and MITF. (D) Cell lines 
were sorted by MITF expression. No correlation was observed in expression between 




0.49), whereas a weak positive correlation in expression between TFE3 and 
TFEB was observed (rho=0.3). TFEB and MITF appeared to have a weak 
negative correlation (rho=-0.28) (Figure 8C). 
Next, we obtained gene expression profiles for 23 melanoma cell lines as 
well as in the normal human epidermal melanocytes (NHEM) generated using 
a microarray platform (Rambow et al., 2015). I analyzed the expression of 
MITF, TFEB, TFE3 and TFEC and found that MITF is highly expressed in most 
of the lines (Figure 8D). Whereas TFEB and TFE3 are detected in most of 
these cell lines, TFEC is either not expressed, or is expressed at very low 
levels in the cells lines. Moreover, the expression of TFEC across metastatic 
tumors is 41-fold lower than that of MITF (Figure 8A). This suggests that TFEC 
is not important in the melanocyte lineage. I therefore focused on MITF, TFEB 
and TFE3 in the remaining analysis. I sorted the melanoma cell lines by MITF 
expression and determined correlation to TFEB and TFE3 expression. No 
correlation was found between the expression of MITF and TFEB (r2=0.07365), 
MITF and TFE3 (r2=0.1223), or TFEB and TFE3 (r2= 0.00047) in these cell 
lines (Figure 8D).  
  Subcellular localization of MITF, TFEB and TFE3 is 
affected by signaling pathways 
Recently, it has been shown that the subcellular localization of TFEB and TFE3 
is regulated by the mTOR pathway (Martina et al., 2012; Martina, Diab, Lishu, 
et al., 2014). In order to determine if this pathway also affects the localization 
of these transcription factors in the melanocyte lineage, I analyzed the 
endogenous expression of these transcription factors in human melanoma cell 
lines by immunostaining and confocal microscopy and determined whether 
their subcellular localization responds to signaling cues. All three transcription 
factors, MITF, TFEB and TFE3, were detected in the human melanoma cell 
line 501Mel using immunocytochemistry. Antibodies specific for each factor 
are listed in Table 5. Whereas TFEB and TFE3 were located mostly in the 
cytoplasm of 501Mel cells but also in the nucleus, MITF showed a predominant 
nuclear presence (Figure 9A). The major isoform of MITF in melanocytes and 
melanoma cells is MITF-M which is primarily located in the nucleus (Fock et 
al., 2018). The cytoplasmic retention of TFEB and TFE3 is mediated by a 
domain of 30 amino acids that is responsible for binding to Rag GTPases at 
the lysosome surface (Roczniak-Ferguson et al., 2012). The Rag-binding 
domain is N-terminal in TFEB, whereas in TFE3 it is located between amino 
acids 110-140 (Martina, Diab, Lishu, et al., 2014). Interestingly, MITF-M lacks 
this N-terminal region resulting in a constitutive nuclear presence of the 
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protein, in contrast with other MITF isoforms such as MITF-A (Martina & 
Puertollano, 2013). Western blot analysis showed that the MITF, TFEB and 
TFE3 proteins are expressed in 501Mel melanoma cells (Figure 9B). The 
western analysis also showed that whereas TFE3 and MITF are both 
expressed in the SKmel28 cells, TFEB is not expressed in those cells (Figure 
A 
B 
Figure 9. MITF, TFEB and TFE3 are expressed in 501 Mel cells. (A) 
Immunofluorescence images showing the expression of endogenous MITF, TFEB and 
TFE3 in 501 Mel melanoma cells. Blue indicates DAPI staining whereas green indicates 
staining of each of the three transcription factors. (B) Western blot analysis of MITF, TFEB 
and TFE3 proteins after MITF, TFEB and TFE3 siRNA knockdown in 501 Mel cells. 
Shown is a representative figure and quantification of three independent experiments, 
bars represent SEM. * indicates significance at p<0.05. 
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10). Short-term knockdown with siRNA against each factor resulted in severe 
reduction or absence of each specific protein, confirming the specificity of the 
antibodies used (Figure 9B, 10).  
Phosphorylation of TFEB at Ser142 by mTORC1 and MAPK promotes its 
cytoplasmic localization (Settembre et al., 2011). Therefore, I investigated if 
inhibiting the mTORC1 and BRAF-MAPK pathways would affect the 
subcellular localization of the MiT-TFE subfamily of transcription factors in 
melanoma cells. Using the mTORC1/2 inhibitor Torin1, and the BRAFV600E 
Figure 10. MITF and TFE3, but not TFEB are expressed in Skmel28 cells. Western 
blot analysis of MITF, TFEB and TFE3 protein levels after MITF, TFEB and TFE3 siRNA 
knockdown in Skmel28 cells, TFEB protein expression was below detection levels. 




selective inhibitor vemurafenib (PLX4032) in human 501Mel cells, resulted in 
an increased nuclear localization of endogenous TFEB and TFE3 proteins, 
suggesting that mTORC and/or BRAF mediate signals that modulate the 
Figure 11. Signaling affects cytoplasmic location of the MITF-TFE family in 
501Mel cells. Immunofluorescence images of human 501Mel cells after treatment with 
vechicle (DMSO), an mTOR inhibitor (Torin1, 1 μM), BRAFV600E selective inhibitor 
(PLX4032, 2 μM) or starved with HBSS minimum medium for three hours, showing 





subcellular localization of TFEB and TFE3 in melanoma cells (Figure 11A, B). 
Furthermore, both inhibitors resulted in reduced cytoplasmic presence of MITF 
(Figure 11C). The same results were observed when constructs containing 
GFP-fusions of the MITF-M, TFEB and TFE3 proteins were overexpressed in 
501Mel cells using a doxycycline-inducible piggybac (pBac) system, and 
subsequent treatment with Torin1 (Figure 12). Torin1 treatment led to nuclear 
localization of all three proteins and a reduction in their presence in the 
cytoplasm. This suggests that overexpression does not affect the 
nucleocytoplasmic distribution of these factors (Figure 12). In Skmel28 
melanoma cells, TFEB is not expressed (Figure 10, 13A). Similar to 501Mel 
cells, TFE3 shows a cytoplasmic distribution and translocation to the nucleus 
upon mTORC and BRAF inhibition (Figure 13B). MITF is mostly nuclear in this 
cell line, with reduced cytoplasmic presence after treatment with the kinase 
inhibitors (Figure 13C). 
Both 501Mel and Skmel28 are human melanoma cell lines that carry the 
mutation BRAFV600E, which makes BRAF constitutively active and a driver in 
tumorigenesis (Davies et al., 2002). Therefore, I analyzed the subcellular 
localization of the MiT-TFE factors and whether it is affected by the mTOR and 
BRAF signaling pathways in a wild type BRAF context, using the Skmel31 
human melanoma cell line. MITF and TFE3, but not TFEB are expressed in 
these cells (Figure 14A). In contrast to my observations in the 501Mel and 
Figure 12. MITF, TFEB and TFE3 subcellular localization in 501Mel cells is 
affected upon mTORC inhibition but not starvation. Human 501Mel cells expressing 
doxycycline-inducible MITF-M, TFEB or TFE3 were treated with an mTORC1 inhibitor 
or HBSS-starved for three hours, then fixed for GFP imaging. 
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Skmel28 cell lines, TFE3 has a substantial nuclear pattern in the Skmel31 cell 
line, and inhibition of mTORC or BRAF does not affect the localization of the 
protein significantly (Figure 14B). Interestingly, a considerable fraction of MITF 
was found to be expressed in the cytoplasm of these cells, and it did not 
respond significantly to mTORC or BRAF inhibition (Figure 13C). 
Figure 13. Signaling affects cytoplasmic location of the MITF-TFE family in 
Skmel28 cells. Immunofluorescence images of human Skmel28 cells after treatment 
with vechicle (DMSO), an mTOR inhibitor (Torin1), BRAF inhibitor (PLX4032) or starved 
with HBSS minimum medium for three hours, showing endogenous TFEB (A), TFE3 





In addition to direct drug-mediated inhibition of mTORC1, amino acid 
deprivation has been shown to inhibit mTORC1 and trigger nuclear localization 
of the MiT/TFE transcription factors in HeLa and HEK293T cells (Martina & 
Puertollano, 2013; Settembre et al., 2012). In order to determine if this was 
also the case in melanoma cells, the cells were treated for three hours with 
Hank’s balanced saline solution (HBSS) medium lacking glucose and amino 
acids. This only partially enriched the nuclear localization of TFEB and TFE3 
Figure 14. Signaling affects cytoplasmic location of the MITF-TFE family in 
Skmel31 cells. Immunofluorescence images of human Skmel31 cells after treatment 
with vechicle (DMSO), an mTOR inhibitor (Torin1, 1 μM), BRAF inhibitor (RAF-265, 5 
μM) or starved with HBSS minimum medium for three hours, showing endogenous 





(Figure 11A, B, 12, 13A, B). The majority of the proteins remained 
cytoplasmic, suggesting that mTORC1 was still active upon starvation in these 
cells (Figure 11, 12, 13, 14). Taken together, these data confirm that the MiT-
TFE subfamily of transcription factors are expressed in a subset of melanoma 
cell lines and their subcellular localization is regulated by the mTORC1 and 
BRAF-MAPK axis but not starvation. It is plausible that mTORC1 might be 
unresponsive to amino acid depletion in melanoma cells and that starvation-
induced autophagy undergoes a different regulation in these cells. 
3.2.1  Phosphorylation of MITF affects its subcellular localization 
I have shown that mTORC inhibition induces the nuclear translocation of TFEB 
and TFE3 but also reduces the cytoplasmic fraction of MITF-M in melanoma 
cells. Interestingly, Ser73 of MITF is located in a conserved domain that 
corresponds to Ser142 of TFEB (Figure 6). In MITF this residue has been 
shown to be phosphorylated by the MAPK pathway in melanoma cells. Thus, 
in order to investigate whether mTOR can phosphorylate Ser73 of MITF, I 
performed immunoblotting in melanoma cells overexpressing either wild type 
MITF-M or a mutated version carrying a Ser73 to alanine (S73A) mutation of 
MITF-M, a non-phosphorylatable version of MITF. The cells were treated with 
Torin1 or vehicle. In accordance with previous studies showing that 
phosphorylation at Ser73 generates a mobility shift observable by Western 
blotting, in which the upper band corresponds to phosphorylated Ser73 
(Hemesath et al., 1998), overexpressed S73A mutant resolved as a single 
band. Pharmacological inhibition of BRAF and mTORC decreased the intensity 
of the upper band of the wild type protein, especially when both treatments 
were performed in combination, suggesting that both signaling pathways can 
phosphorylate Ser73 of MITF-M in melanoma cells (Figure 15). Mutation of 
Ser409 to alanine also triggered a mobility shift of the MITF protein, as 
observed by a lower molecular weight of the MITF doublet in western blot. The 
upper band did not disappear upon mutation of Ser409Ala, suggesting that 
phosphorylation of Ser73 can still take place (Figure 15). 
Next, I analyzed if the phosphorylation status of Ser73 affects the 
nucleocytoplasmic distribution of MITF. For this, I overexpressed the MITF-A 
isoform in 501Mel cells. The reason for choosing this isoform is that since 
MITF-M is primarily located in the nucleus, the fraction that shuttles between 
the cytoplasm and the nucleus is a minor component of the total protein 
(Figure 11). However, MITF-A is mostly cytoplasmic in 501Mel cells and 
therefore this isoform is more appropriate for this analysis. When the mTOR 
pathway was blocked with Torin1, MITF-A translocated to the nucleus (Figure 
16). This same effect was achieved when mutating Ser180 of MITF-A to 
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alanine, the serine residue that corresponds to Ser73 of MITF-M. This mutant 
version of the MITF-A isoform is exclusively nuclear (Figure 16). Taken 
together, these data suggest that mTORC is able to phosphorylate Ser73 of 
MITF-M and Ser180 of MITF-A, promoting the cytoplasmic retention of the 
MITF protein. This is more pronounced in the longer MITF-A isoform, due to 
Figure 15. BRAF and mTORC kinase inhibition affect the phosphorylation of 
Ser73 of MITF. Overexpression of FLAG-tagged wt MITF, S73A MITF and S409A MITF 
in 501 Mel cells. Cells were treated with DMSO (vehicle), BRAF inhibitor (RAF-265, 5 
μM) and mTOR inhibitor (Torin1, 1 μM) for three hours prior to protein extraction. 
Figure 16. MITF-A subcellular localization is dependent upon phosphorylation of 
Ser180 by mTORC. Human 501Mel cells overexpressing wild type (wt) or S180A 
MITF-A were treated with DMSO (vehicle) or an mTORC inhibitor (Torin1, 1 μM) for 
three hours, then fixed for GFP imaging. 
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its more prominent cytoplasmic distribution under normal conditions. These 
data indicate that the phosphorylation of MITF takes place through Ser73 of 
MITF-M and its homologous Ser180 in MITF-A. We cannot exclude the 
possibility that a different site that depends upon phosphorylation of that 
specific residue is also involved.  
The RANKL-dependent signaling pathway has been shown to activate 
TFEB and induce lysosomal biogenesis in osteoclasts through the 
phosphorylation of Ser462/463/467/469 at the C-terminus of TFEB by protein 
kinase C β (PKCβ) (Ferron et al., 2013). This domain is serine-rich and is 
conserved in MITF (Figure 17A). Other serine residues within this domain, 
Ser397/401/405 in MITF-M, have been identified as a phosphodegron domain 
that targets the protein for degradation (Ploper et al., 2015). This serine-rich 
C-terminal domain is conserved in TFEB, TFE3 and TFEC (Figure 17A). I 
analyzed whether GSK3β-mediated phosphorylation of Ser504/508/512 in 
MITF-A, the residues corresponding to Ser397/401/405 in MITF-M, are 
involved in the regulation of the subcellular localization of MITF. For this, I 
overexpressed GFP-tagged wild type or Ser504/508/512Ala versions of MITF-
A in 501Mel cells, and treated the cells with a GSK3β inhibitor or vehicle. MITF-
A is located in both the nucleus and the cytoplasm of these cells. The 
Ser504/508/512Ala MITF-A mutant displayed a more pronounced cytoplasmic 
presence than wild type MITF-A (Figure 17B), indicating that phosphorylation 
of these sites affects the nuclear localization of the protein. Next, the inhibitor 
CHIR99021, a potent selective inhibitor of GSK3β, was employed in order to 
assess changes in the subcellular localization of MITF-A upon inactivation of 
the pathway. The selective GSK3β inhibitor increased the nuclear presence of 
wild type MITF-A (Figure 17B). Interestingly, treating cells overexpressing 
S504/508/512A MITF-A with the GSK3β inhibitor resulted in a predominant 
nuclear localization of the protein (Figure 17B), similar to the effect of the 
inhibitor on wild type MITF-A. This indicates that blockade of the GSK3β 
signaling pathway induces nuclear localization of MITF-A regardless of the 
phosphorylation status of Ser504/508/512, amino acids that were previously 
reported to be phosphorylation targets of GSK3β (Ploper et al., 2015). Mutation 
of this serine-rich domain is not sufficient to prevent nuclear localization of 
MITF upon GSK3β inhibition. 
These data indicate that, similarly to the mTOR pathway, GSK3β can 
promote the cytoplasmic retention of MITF in melanoma cells, possibly through 
the phosphorylation of a region that has yet not been identified, different from 
the one described by Ploper and colleagues. Moreover, mutating the three 
serines Ser504/508/512Ala to non-phosphorylatable alanine at the C-terminal 
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region of MITF, slightly increased the cytoplasmic presence of the protein. This 
suggests that Ser504/508/512Ala are not the residues mediating the GSK3β-
induced cytoplasmic retention of MITF. In summary, GSK3β can phosphorylate 
a number of different residues of MITF and affect its subcellular localization 
and activity.  
Figure 17. MITF-A subcellular localization is dependent upon phosphorylation by 
GSK3β. (A) The MiT-TFE factors feature a serine-rich C-terminal domain. Four serines 
wiithin this domain are putative PKCβ phosphorylation sites, marked in blue and purple 
(Ferron et al., 2013). Putative C-terminal GSK3 phosphorylation sites, marked in red 
and purple (Ploper et al., 2015). (B) Human 501Mel cells overexpressing wild type (wt) 
or S504/508/512A MITF-A were treated with an GSK3β inhibitor (CHIR-99021, 1 μM) 





  MITF, TFEB and TFE3 interact in melanoma cells 
The bHLHZip transcription factors require the formation of homo- or 
heterodimers in order to bind DNA and activate target genes. The different 
members of the bHLHZip family, such as MYC, MAX, MAD and MNT form 
heterodimers that modulate cell growth, proliferation, differentiation, apoptosis 
(Amati & Land, 1994) and oncogenesis (Baudino & Cleveland, 2001; Dang, 
2012). As previously mentioned in the introduction, selection of dimerization 
partners of these factors has an impact on the transcription of their target 
genes. c-Myc/MAX heterodimers promote the transcription of genes involved 
in cell proliferation, whereas MAD/MAX heterodimers bound to the same DNA 
regulatory element are transcriptional repressors (Luscher, 2012). In vitro 
translated MITF has been shown to form stable DNA-binding heterodimers 
with TFEB, TFE3, and TFEC (Hemesath et al., 1994). 
In order to determine if MITF, TFEB and TFE3 are able to interact in 
melanoma cells, 501mel cells expressing piggybac vectors containing 
doxycycline-inducible GFP-tagged TFEB, TFE3, or empty vector, (EV) were 
co-transfected with FLAG-tagged MITF or TFE3. The GFP-tagged protein was 
immunoprecipitated with GFP antibodies. Sodium dodecyl sulfate–
polyacrylamide gel electrophoresis (SDS-PAGE) was performed using whole 
lysate and the immunoprecipitated fraction of each sample. Subsequently, 
immunoblotting was performed using antibodies against GFP, FLAG and actin 
as a loading control. FLAG-tagged MITF was detected when GFP-tagged 
TFEB and TFE3 were pulled down suggesting that MITF can form 
heterodimers with both TFEB and TFE3 (Figure 18A). Likewise, FLAG-tagged 
A B 
Figure 18. MITF, TFEB and TFE3 interact. Western blots showing the results of the 
following co-immunoprecipitation experiments: An MITF FLAG-tagged construct was 
co-transfected with GFP-tagged EV, TFEB or TFE3 (A). A FLAG-HA-tagged TFE3 




TFE3 was detected in the TFEB pull-down fraction (Figure 18B), showing that 
TFE3 and TFEB can interact in melanoma cells. Neither TFE3 nor TFEB were 
detected when the GFP empty vector was immunoprecipitated, showing that 
the interaction is specific (Figure 18A, B). I conclude that MITF, TFEB and 
TFE3 are able to interact in melanoma cells, possibly forming functional 
heterodimers that cooperate at transcribing their target genes. 
3.3.1  The role of a three-residue insertion in the leucine zipper of 
the MiT-TFE transcription factors 
The crystal structure of MITF revealed how the MITF-TFE family of proteins 
form specific hetero- or homodimers and avoid dimerizing with other bHLHzip 
proteins (Pogenberg et al., 2012). This is due to an asymmetric homodimeric 
assembly because of the insertion of a three-residues stammer at the junction 
of the two first heptad repeats of the leucine zipper (Figure 5). This sequence 
is present in all the MiT-TFE transcription factors family members (Pogenberg 
et al., 2012) and the structural feature is probably also conserved. To 
characterize whether the three-residue region within the N-terminal region of 
MITF’s leucine zipper has an impact on its transcription ability and its role in 
determining the interaction partners in a cellular context, an MITF construct 
termed MITF(Δ259-261) lacking this region was generated. HEK293T cells 
transfected with MITF(Δ259-261) showed that, similar to wild type MITF, this 
protein is nuclear (Figure 19A) (Sigvaldadóttir, 2016) (Pogenberg et al., 
manuscript II, in preparation).  
In order to determine if this deletion mutation affects transcription activation 
potential of MITF, I performed transactivation assays in HEK293T cells using 
different variations of the binding elements present in the tyrosinase promoter. 
The wild type tyrosinase promoter has two E-box-like CATGTG regulatory 
elements that have been mutated to the canonical E-box CACGTG and M-box 
TCATGTGA elements (Figure 19B). Luciferase transactivation assays upon 
co-transfection of the cells with wild type or MITF(Δ259-261) versions of MITF, 
together with the E-box or M-box tyrosinase promoter, showed that the 
MITF(Δ259-261) mutant is able to transactivate these DNA regulatory 
elements as efficiently as wild type MITF (Figure 19C) (Sigvaldadóttir, 2016) 
(Pogenberg et al., manuscript II, in preparation). 
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Next, I used co-immunoprecipitation studies to analyze the ability of 
MITF(Δ259-261) to form homo- or heterodimers with wild type MITF, TFEB or 
TFE3. I ectopically co-expressed GFP-tagged wild type or MITF(Δ259-261) 
proteins with a FLAG-tagged wild type MITF construct and immunoprecipitated 
Figure 19. MITF(Δ259-261) maintains its major nuclear localization and 
transcriptional ability. (A) Immunofluorescence images showing the expression of 
overexpressed MITF(Δ259-261) in HEK293T cells. Blue indicates DAPI staining 
whereas red indicates staining of wt MITF or MITF(Δ259-261). (B) Transactivation 
assays in HEK293T cells in which MITF(Δ259-261) or wt MITF were co-transfected with 





the GFP-tagged proteins. Western blot analysis of the immunoprecipitated 
fraction indicated that GFP-tagged MITF(Δ259-261) can form homodimers with 
FLAG-tagged MITF(Δ259-261) but does not interact with FLAG-tagged wild 
type MITF (Figure 20A). When co-expressing GFP-tagged TFEB and TFE3 
with FLAG-tagged wild type MITF or MITF(Δ259-261), wild type MITF was 
detected in the TFEB and TFE3 immunoprecipitated fractions (Figure 20B). 
However, MITF(Δ259-261) was not detected, which suggests that the 
MITF(Δ259-261) fails to dimerize with wild type TFEB or TFE3 (Figure 20B). 
As a negative control, an empty vector expressing GFP was co-expressed with 
either FLAG-tagged wild type MITF or MITF(Δ259-261). The FLAG-tagged 
MITF was detected in the whole lysate but not in the sample fraction containing 
immunoprecipitated GFP alone (Figure 20C). This indicates that the FLAG 





or with the MITF, TFEB and TFE3 proteins and that the protein-protein 
interactions observed are specific. Therefore, these observations allowed us 
to confirm that the three-residue insert results in an asymmetric assembly that 
restricts the ability of MITF to dimerize exclusively with the TFE family of 
transcription factors (Figure 20D).  
C 
D 
Figure 20. Dimerization properties of MITF (Δ259-261). FLAG-tagged wt and MITF 
(Δ259-261) mutants were expressed together with either GFP-tagged wt or MITF 
(Δ259-261) (A), GFP-tagged TFEB or TFE3 (B) or an empty vector expressing GFP 
alone as a negative control (C) in 501mel cells. Protein interactions were analyzed by 
coIP by Western blot detection of either anti-FLAG or anti-GFP antibodies. (D) Removal 
of the 3 amino acid insert in the MITF(Δ259-261) structure leads to a regular 
symmetrical coiled-coil arrangement (upper panel) as opposed to the asymmetry found 
in wild type MITF (lower panel). 
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Next, we hypothesized that removal of the three-residue insertion would 
allow novel interactions with other bHLHZip transcription factors such as MAX, 
a canonical bHLHZip transcription factor that does not present such a break in 
the leucine zipper. I tested this by co-expressing either GFP-tagged versions 
of wild type or MITF(Δ259-261) proteins together with a FLAG-tagged MAX 
construct and immunoprecipitated the GFP-tagged proteins. Interestingly, 
MITF(Δ259-261) was able to interact with MAX whereas wild type MITF was 
not (Figure 21). This indicates that the absence of the three amino acid region 
alters the selection of interaction partners of the MiT-TFE factors and may 
allow the formation of new interactions with other bHLHZip transcription 
factors, such as the c-Myc/MAX/MAD family. 
Modification of the heptad structure within the leucine zipper with the aim 
of modulating the dimerization ability of MITF, might lead to the generation of 
an MITF protein that will only be able to homodimerize. This would potentially 
be a useful tool in order to dissect the unique function of MITF homodimers as 
opposed to the multiple homo- and heterodimeric combinations that occur in 
nature. I have shown that although MITF(Δ259-261) failed to heterodimerize 
with wild type MITF, TFEB or TFE3, it can dimerize with MAX and possibly 
Figure 21. Change in heterodimerization specificity of MITF(Δ259-261). A FLAG-
tagged wt MITF, MITF(Δ259-261) and MAX mutants were expressed together with 
either GFP-tagged wt MITF or MITF(Δ259-261) in 501 Mel cells. Protein interactions 




other bHLHZip transcription factors and may therefore lead to a potential gain 
of function of the resulting novel heterodimers. Therefore, I generated two new 
MITF constructs with the aim of developing an MITF mutant that would only be 
able to form homodimers. First I generated a mutant lacking the three residues 
insert (Δ259-261) in the first heptad of the leucine zipper, although containing 
amino acids 260-262 (EQQ) now placed in the second heptad of MITF 
(MITF(Δ259-261)_N269_R270insEQQ MITF). This mutant was termed 
Figure 22. Change in heterodimerization specificity of MITF stammer-mutants. 
Protein interactions were analyzed by coIP by Western blot detection of either anti-
FLAG or anti-GFP antibodies in 501Mel cells. (A) FLAG-tagged wt MITF, 
dREQ/EQQins and MAX mutants were expressed together with either GFP-tagged 
MITF (Δ259-261) dREQ/EQQins in 501Mel cells. (B) FLAG-tagged H2EQQins and 
MAX mutants were expressed together with either GFP-tagged wt MITF, MITF (Δ259-





dREQ/EQQins. The second mutant carried the N269_R270insEQQ insertion 
in the wild type MITF, termed H2EQQins. We hypothesized that this construct 
would contain two kinks in the leucine zipper. I used co-immunoprecipitation 
studies to analyze the ability of these two MITF mutants to homo- or 
heterodimerize with wild type MITF or with MITF(Δ259-261). FLAG-tagged 
dREQ/EQQins formed homodimers with GFP-tagged dREQ/EQQins (Figure 
22A). It also dimerized with wild type MITF (Figure 22A). However, the 
dimerization ability of dREQ/EQQins with MITF(Δ259-261) was reduced and it 
did not interact with MAX (Figure 22A). Interestingly, H2EQQins was not able 
to homodimerize and its interaction with MITF(Δ259-261) was weak. It did not 
dimerize with MAX but dimerized with wild type MITF (Figure 22B).  
To summarize, we have successfully identified a three-residue insertion 
located at the first heptad of the leucine zipper of the MiT-TFE transcription 
factors that is responsible for the selective dimerization ability of these factors. 
In addition, removal of these three amino acids in MITF resulted in a protein 
that could form functional homodimers with ability to localize to the nucleus 
and transactivate target DNA regulatory elements. This mutant, termed 
MITF(Δ259-261), failed to heterodimerize with wild type MiT-TFE factors but 
gained the ability to form de novo interactions with other bHLHZip transcription 
factors such as MAX, that does not present the three-residue insertion and the 
asymmetric assembly associated to this break in the first leucine zipper 
heptad. My attempts to generate an MITF mutant that is only able to 
homodimerize, by translocating the three-residue insertion to the second 
heptad or by introducing a second three-residues insertion in the second 
heptad, did not succeed. However, I observed that these mutants displayed 
different dimerization properties. We emphasize that modulating the 
dimerization properties of the MiT-TFE transcription factors by means of 
modifying the structure of their leucine zipper region, might prove useful to 
understand how the multiple combinations of dimers in which these factors 
participate affect the regulation of their target genes. 
  MITF, TFEB and TFE3 regulatory loop 
Chromatin immunoprecipitation-sequencing (ChIP-seq) is a technique broadly 
used in molecular biology to identify binding sites of proteins that associate 
with DNA such as transcription factors (Farnham, 2009; Park, 2009). It 
combines immunoprecipitation of the chromatin fragments bound to the protein 
of interest using an antibody against that particular protein and subsequent 
DNA sequencing of the chromatin fragments obtained. ChIP-seq data is 
publicly available for MITF in 501mel cells (Laurette et al., 2015) and in 
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Colo829 human melanoma cells (Webster, 2014). In addition, Ramile Dilshat 
in the Steingrimsson lab has generated ChIP-seq data for TFEB in 501mel 
cells (Ramile Dilshat, unpublished). This data was analyzed in order to 
determine if MITF and TFEB are involved in regulating the expression of each 
other, and of TFE3. This analysis showed that MITF and TFEB bind to a region 
within intron 1 of TFEB (Figure 23A). In addition, they both bind to an intronic 
region downstream of the promoter specific for MITF-A (Figure 23B). In 
contrast, neither MITF nor TFEB were found to bind to the TFE3 promoter or 
any intronic region within the TFE3 gene (Figure 23C). This data suggests that 
Figure 23. MITF and TFEB bind to the MITF and TFEB genes. MITF chIP-seq data 
in 501Mel and Colo829 melanoma cells, and TFEB chIP-seq data in 501Mel cells, show 
that MITF and TFEB bind to the intron 1 of TFEB (A) and that MITF and TFEB bind to 







MITF and TFEB can potentially regulate the transcription of both MITF and 
TFEB through binding to DNA regulatory elements, whereas they cannot 
directly transactivate any putative DNA regulatory elements in TFE3.  
Since MITF and TFEB bind to each other’s regulatory regions, it was 
important to determine if they affect each other’s expression. In order to 
determine whether MITF, TFEB and TFE3 are able to influence each other’s 
expression I assayed the effects of transient doxycycline-inducible 
overexpression and short-term knockdown of each individual factor on the 
expression of the other factors in 501 Mel and Skmel28 human melanoma cell 
lines. I analyzed the mRNA expression by RT-qPCR of human 501mel 
melanoma cell lines overexpressing pBac-MITF, pBac-TFEB, and pBac-TFE3. 
The overexpressed MITF protein is the (-) isoform lacking exon 6a that 
encodes the alternative six amino acids just in front of the basic domain. I used 
primers specific for MITF (+) to measure the expression of the endogenous 
MITF mRNA (Appendix II, Figure 38) and universal MITF (+/-) primers to 
detect expression of total MITF mRNA; TFEB and TFE3 were assayed using 
gene-specific primers (Table 8). Overexpressing MITF (-) significantly 
increased TFEB mRNA expression whereas TFE3 levels remained unchanged 
(Figure 21A). In addition, MITF (-) overexpression significantly reduced the 
expression of endogenous MITF as detected using primers specific to the 
MITF (+) isoform (Figure 24A). Overexpression of TFEB in the 501Mel cell line 
resulted in reduced MITF expression whereas TFE3 mRNA levels were 
unaffected (Figure 24B). Finally, overexpressing TFE3 resulted in decreased 
MITF expression whereas TFEB mRNA levels were not significantly changed 
A B C 
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(Figure 24C). I also analyzed the effects of overexpressing MITF (+) on the 
mRNA levels of its family members and found that the effects were comparable 
to those observed after the overexpression of the (-) isoform, suggesting that 
the presence or absence of those six amino acids does not have additional 
effects (Figure 24D).  
These observations were also detected at the protein level, assayed by 
western blotting. Ectopic expression of MITF increased TFEB protein 
Figure 24. MITF, TFEB and TFE3 regulate each other‘s expression in 501Mel cells. 
The expression of MITF, TFEB and TFE3 as determined by RT-qPCR after 
overexpression of MITF (-) (A), TFEB (B), TFE3 (C) and MITF (+) (D) in 501mel cells 
compared to empty vector. Bars represent SEM. * indicates significance at p<0.05. 
Western blot analysis of MITF, TFEB and TFE3 protein levels after overexpression of 
MITF (E, F), TFEB (E) and TFE3 (F) in 501mel cells. Shown is a representative figure 
for at least three independent experiments and overall quantification (G). Bars 
represent SEM. * indicates significance at p<0.05. 
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expression and decreased levels of endogenous MITF (Figure 24E, F, G). 
Overexpression of TFEB or TFE3 resulted in reduced MITF expression 
whereas overexpression of TFE3 did not significantly affect the expression of 
the MITF protein (Figure 24E, F, G).  
In order to validate the effects of the overexpression, I also used siRNA to 
knock down MITF, TFEB and TFE3 in 501mel melanoma cells and then 
performed qPCR and western blot analysis to determine effects on expression 
of the other factors. MITF knockdown dramatically reduced TFEB mRNA 
(Figure 25A) and protein levels (Figure 9B) to a degree comparable to that 
A 
B 
Figure 25. Knockdown of MITF, TFEB and TFE3 affect each other‘s expression. 
The expression of MITF, TFEB and TFE3 as determined by RT-qPCR after siRNA 
knockdown of each factor compared to control siRNA in 501Mel (A) and Skmel28 (B). 
For the 501Mel knockdown, shown is the average of four independent experiments. 
Bars represent SEM. * indicates significance at p<0.05. 
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observed upon TFEB knockdown. MITF siRNA also resulted in increased 
TFE3 mRNA (Figure 25A) and protein levels (Figure 9B). On the other hand, 
TFEB knockdown increased the mRNA (Figure 25A) and protein levels 
(Figure 9B) of MITF to some extent but did not affect the expression of TFE3. 
Lastly, TFE3 knockdown did not affect the mRNA levels of MITF or TFEB 
(Figure 25A) whereas expression of the MITF protein was increased (Figure 
9B). The replication of the knock-down experiments of each individual factor 
in Skmel28 showed similar effects on the mRNA (Figure 25B) and protein 
expression (Figure 10). Likewise, the overexpression experiments in Skmel28 
cells confirmed the results observed in 501Mel cells (Figure 26).  
In conclusion, these data indicate that MITF, TFEB and TFE3 are able to 
regulate each other’s mRNA expression in melanoma cells, possibly through 
direct binding to genomic regulatory elements and thus direct transcriptional 
regulation. In addition, MITF can repress the expression of TFE3 and, in turn, 
overexpression of TFE3 has an inhibitory effect on the expression of MITF. 
The absence of binding sites for MITF within the TFE3 gene suggests that 
indirect effects that need further elucidation may be involved in the cross-
regulatory relationship between MITF and TFE3.  
Figure 26. MITF, TFEB and TFE3 regulate each other‘s expression in SkMel28 
cells.  RNA expression of MITF, TFEB and TFE3 after overexpression of GFP-tagged 
MITF (+), TFEB and TFE3 in Skmel28 cells compared to control empty vector. Shown 
is the average of at least three independent experiments, bars represent SEM 
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3.4.1  MITF directly regulates the expression of TFEB 
I have shown that MITF affects expression of TFEB and binds to an element 
in intron 1 of TFEB. In addition, ectopic expression of MITF can affect the 
expression of endogenous MITF and it binds to potential DNA regulatory 
elements in the MITF gene. Therefore, I investigated whether the effects of 
MITF on the transcription of TFEB and MITF are due to its direct interaction 
with the respective DNA regulatory elements. Analysis of the MITF ChIP-seq 
data revealed a CAGCTGA element at the binding site located in intron 1 of 
TFEB (Figure 27A) and a CACGTG motif in the binding site located within the 
MITF gene. In order to determine if these regulatory elements mediate a direct 
MITF-dependent regulation, I cloned an 853-base pair sequence of intron 1 of 
TFEB containing the region between bases -29,373 and -28,521 upstream of 
the exon 2 of TFEB. This sequence carries the CAGCTGA binding site in a 
central location. In addition, I mutated the potential MITF-binding motif to 
CCCTTTA. Likewise, the aforementioned DNA sequence located between 
bases -10,366 and -9,697 upstream of the TSS of MITF-M was isolated. This 
sequence contains the potential MITF binding site CACGTG centrally located. 
Another version of this construct was generated where this element was 
mutated to CCCTTTA (Figure 27B). The four constructs were subcloned into 
the pGL3-Promoter luciferase reporter plasmid (Figure 27A, B). The resulting 
reporter constructs were transfected into HEK293T cells, which express the 
MITF and TFE proteins at very low levels, together with a construct expressing 
the wild type MITF-M protein. The tyrosinase (TYR) promoter was used as a 
positive control. The results showed transactivation of the tyrosinase (TYR) 
promoter by MITF, suggesting that the assay worked as intended (Figure 
27C). The expression of the reporter gene downstream of the TFEB intron 1 
element was significantly increased upon expression of FLAG-tagged MITF-
M. This enhanced transactivation was abrogated when the 7-base pair 
sequence was scrambled (Figure 26C). In contrast, overexpression of MITF-
M did not alter the luciferase signal of the putative regulatory region at MITF 
relative to empty pGL3-promoter construct or when the CACGTG element was 
scrambled, indicating that this region is not responsible for the MITF 
transcriptional self-repression observed in the overexpression or siRNA 
studies. Surprisingly, the MITF binding site in intron 1 of TFEB is a CAGCTG 
element and not a canonical CACGTG E-box. MITF has not previously been 
shown to bind to this sequence, therefore, I analyzed whether there are more 
occurrences of the CAGCTG element in the set of sequences reported to be 
bound by MITF in the ChIP-seq data published by Laurette et al. (2015). 





Figure 27. MITF upregulates TFEB through transactivation of a CAGCTGA motif 
at intron 1. (A) ChIP-seq data revealed that MITF binds to a CAGCTGA element with 
an intronic region of TFEB. (B) Putative binding sites of MITF at a regions upstream of 
the TSS of MITF-M. (C) HEK293T cells were transiently co-transfected with a 
p3XFLAG-CMV-14 construct with MITF-M or without (empty vector, EV) and luciferase 
constructs and assayed after 24h for luciferase activity. Luminiscence signal is 
expressed as fold change over an empty luciferase reporter (for tyrosinase) or a 
luciferase reporter containing a minimal SV40 promoter (for TFEB intron 1, TFEB intron 
1 scrambled, MITF enhancer and MITF enhancer scrambled). Error bars represent the 
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seq dataset revealed that the CACGTGA motif was found in 36% of the 
sequences that were reported to be bound by MITF, CACGTG in 41%, 
CAGCTG in 32% and CAGCTGA (the motif found to be bound by MITF in the 
TFEB promoter) in 16%. The CCCTTTA motif used as a scramble control 
occurred in 6.8% of the sequences. Therefore, the canonical E-box is 6-fold 
enriched and the CAGCTG motif is enriched 4.6-fold compared to the scramble 
control (Table 10, upper panel). AME analysis of the TFEB ChIP-seq dataset 
found the CACGTGA motif in 20.48% of the sequences, CAGCTGA in 27.84%, 
CACGTG in 34.17% and CAGCTG in 51.01%. The scrambled CCCTTTA motif 
was found in 11.21% of the sequences. Thus, the canonical E-box motif was 
enriched approximately 1.8-fold in the TFEB ChIP-seq dataset and the 
CAGCTGA motif 2.5-fold (Table 10, bottom panel).  
 
MITF binding sites 
Motif E-value TP %TP FP %FP 
CACGTGA 1.93e-630 2547 36.27 189 2.69 
CAGCTGA 2.95E-165 1107 15.76 195 2.78 
CACGTG 6.53e-561 2876 40.95 429 6.11 
CAGCTG 7.27e-358 2216 31.55 408 5.81 
CCCTTTA 3.63E-20 477 6.79 219 3.12 
      
      
      
TFEB binding sites 
Motif E-value TP %TP FP %FP 
CACGTGA 2.78E-126 1158 20.48 312 5.52 
CAGCTGA 1.18E-242 1574 27.84 298 5.27 
CACGTG 1.59E-129 1932 34.17 821 14.52 
CAGCTG 1.32e-464 2884 51.01 661 11.69 
CCCTTTA 3.81E-28 634 11.21 293 5.18 
Table 10. Analysis of motif enrichment (AME) across MITF and TFEB binding 
sites. E-value: estimate of the expected number of motifs with the given log likelihood 
ratio (or higher), and with the same width and site count, that one would find in a 
similarly sized set of control random sequences TP: number of loci correctly identified 




These results indicate that MITF directly regulates its target genes through 
the direct binding to CANNTG motifs, including the enhancement of the 
transcriptional regulation of TFEB by MITF through a CAGCTG motif located 
in TFEB’s intron 1.  
3.4.2  mTOR and expression of MITF, TFEB and TFE3 
Since inhibiting mTOR signaling results in increased nuclear localization of 
TFEB, TFE3 and MITF in melanoma cells, it is reasonable to assume that this 
will lead to increased transcription activation of their target genes. Moreover, I 
have shown in the previous chapter that MITF, TFEB and TFE3 to a certain 
extent, regulate each other’s expression. Therefore, I investigated whether 
mTOR signaling affects the expression of the MiT-TFE factors at the mRNA or 
protein levels. 501mel cells were treated with the mTORC1/2 inhibitor Torin1 
and subsequently, I analyzed their mRNA expression by RT-qPCR. 
Interestingly, treatment with Torin1 significantly increased the mRNA 
expression of MITF, but did not affect the expression of TFEB or TFE3 (Figure 
28A). I have shown that ectopic overexpression of MITF, TFEB and TFE3 
negatively affects the expression of endogenous MITF in two melanoma cell 
lines (Figure 24, 26). Therefore, I investigated whether blockade of the mTOR 
pathway would enhance these negative regulatory effects, due to an increased 
nuclear localization of these factors upon mTORC inhibition in 501Mel cells 
(Figure 11, 12). RT-qPCR was used to analyze the mRNA expression of 
human 501mel melanoma cell lines expressing pBac-MITF, pBac-TFEB, and 
pBac-TFE3 after treating the cells with Torin1 or vehicle (DMSO) prior to RNA 
extraction. I confirmed that overexpression of the three factors can inhibit the 
mRNA expression of endogenous MITF in melanoma cells (Figure 28B). An 
increase in the endogenous MITF mRNA levels after treatment with Torin1 was 
observed (Figure 28A, B). However, this increase was not seen when MITF 
or TFEB were overexpressed (Figure 28B). Indeed, the reduction in MITF 
mRNA levels upon TFE3 or TFEB overexpression compared to empty vector 
was significantly more pronounced when the cells were treated with Torin1 
compared to vehicle. This indicates that the increase in mRNA expression of 
MITF upon mTORC inhibition does not take place when an increase in TFEB 
or TFE3 expression severely reduce transcription of MITF. 
Subsequently, I analyzed the protein levels of MITF upon mTORC inhibition 
and overexpression of GFP-tagged TFEB, TFE3 or EV as a control. As 
expected, in 501 Mel cells overexpressing TFEB, the expression of MITF 
protein is significantly reduced, indicating a strong suppression mediated by 
TFEB (Figure 28C, D). Overexpression of TFE3 also strongly reduced the 
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MITF protein levels, although the effect was not as pronounced as with TFEB 
overexpression (Figure 28C, D). Phosphorylation at Ser73 generates a 
mobility shift, in which the upper band corresponds to phosphorylated Ser73, 
as observed by Western blotting (Hemesath et al., 1998). Inhibiting the 
mTORC1/2 complex can affect the ratio of the upper band of MITF so that the 
lower band becomes more prominent. This indicates that mTORC can 
phosphorylate MITF, as previously shown in Figure 16 (Figure 28C, E). 
Next, I investigated whether the phosphorylation status of MITF would 
affect the stability of the protein. For this, the cells were treated with 
cycloheximide in order to block de novo protein translation. Interestingly, 
blockade of protein translation upon three hours’ treatment with cycloheximide 
led to an increase in the ratio of MITF’s upper to lower band. This finding might 
suggest that cycloheximide triggers phosphorylation of MITF at Ser73 and that 
the lower band of MITF, corresponding to unphosphorylated Ser73, is readily 
degraded and short-lived if there is no sustained translation of MITF in these 
cells (Figure 28C, E). In the light of this observation, the proteasome inhibitor 
MG132 was used in order to analyze whether the lower band is effectively 
being degraded by the proteasome pathway. Interestingly, the sharp decrease 
of intensity of the lower band of MITF upon cycloheximide treatment was 
abrogated when the proteasome was inhibited (Figure 28F). In addition, the 
overall abundance of MITF protein increased by 50% when compared to 
cycloheximide treatment alone (Figure 28G). In conclusion, these data 
indicate that mTORC signaling increases transcription of MITF. On the other 
hand, mTORC inhibition increases the nuclear localization of TFE3 and its 
activity as a transcriptional repressor of MITF. Interestingly, this increased 
transcription of MITF does not correlate with increased protein expression. I 
hypothesize that inhibition of mTORC triggers dephosphorylation of MITF, 
which induces proteasome-mediated degradation of MITF. This in turn, might 
stimulate a higher turnover rate observed as rapid degradation of 
dephosphorylated MITF coupled with increased transcription through an 
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Figure 28. mTOR inhibition induces the expression of MITF and increases protein 
turnover due to increased dephosphorylation and degradation. (A) The 
expression of MITF, TFEB and TFE3 as determined by RT-qPCR after treatment with 
an mTOR inhibitor for three hours (Torin1, 1 μM) compared to vehicle (DMSO). (B) The 
expression of MITF as determined by RT-qPCR upon overexpression of MITF (-), 
TFEB and TFE3 with or without mTOR inhibition for three hours (Torin1, 1 μM). Error 
bars represent SEM. * indicates significance at p<0.05. (C) MITF protein 
immunoblotting upon overexpression of empty vector (EV), TFEB and TFE3, with or 
without mTOR inhibition (Torin1, 1 μM) or cycloheximide treatment (70 μM)  for three 
hours. Shown is a representative figure for at least two independent experiments and 
quantification of MITF expression relative to actin (D) or the ratio of upper band to lower 
band of MITF (E), represented as fold change relative to EV vehicle control. (F) MITF 
protein immunoblotting upon cycloheximide treatment (70 μM) or cycloheximide and 
MG132 (10 μM) treatment for three hours. (G) Quantification of MITF expression 
normalized to actin represented as fold change relative to vehicle control. Only one 
individual experiments is shown. 
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3.4.3  TFE3 overexpression impairs proliferation of 501Mel cells 
Previous studies have shown that BRAFV600E is beneficial for the proliferation 
of melanoma cells (Hingorani et al., 2003). Moreover, it has been shown that 
MITF is required for the BRAF-mediated stimulation of proliferation, and that 
MITF depletion blocks DNA synthesis in BRAFV600E melanoma cells (Wellbrock 
et al., 2008). BRAF effects on cell growth and proliferation through MITF are 
due to induction of CDK4, CDK2 and p21, which are transcriptional targets of 
MITF that mediate cell cycle progression. CDK2 and p21 were previously 
identified as MITF target genes in melanoma cells (Carreira et al., 2005; Du et 
al., 2003; Wellbrock et al., 2008). 
Using a 501mel cell line expressing a doxycycline-inducible miRNA 
targeting MITF, I investigated whether MITF knockdown would affect the ability 
of these cells to proliferate, and also whether the overexpression of TFEB or 
TFE3 in these cells with or without knockdown of MITF would have any impact 
on their proliferation rate. When MITF was knocked down using the inducible 
miRNA pBac system I observed a decreased proliferation rate in these cells 
(Figure 29A) and an increase in doubling time from 29 hours to approximately 
38 hours (Figure 29B). Overexpressing TFEB had no effect on the proliferation 
rate of the 501 Mel cells expressing a miRNA control (Figure 29B, C). 
However, TFE3 overexpression markedly slowed down the proliferation of 
these cells (Figure 29C) and the doubling time increased to approximately 37 
hours, similar to that of cells with a miRNA targeting MITF (Figure 29B). Next, 
I analyzed the proliferation rate of the 501Mel cells expressing an miRNA to 
knock down MITF or an miRNA control and simultaneously overexpressing 
TFEB or TFE3. The MITF knockdown cells proliferated slower than the control 
cells. However, overexpression of TFEB or TFE3 in the knockdown cells did 
not affect the proliferation rate significantly, compared to the EV control, since 
the variability among the samples was remarkably high (Figure 29D). 
To summarize, TFE3 negatively affects the proliferation of 501Mel cells, 
possibly through the repression of the transcription of MITF, which has been 
shown to be required for survival and cell cycle regulation of human melanoma 
cells. In addition, neither TFEB nor TFE3 can rescue the proliferation of 




  MITF, TFEB and TFE3 activate similar DNA motifs that 
determine a subset of shared target genes 
TFEB is known to directly bind to a 10-base pair palindromic sequence 
GTCACGTGAC, a type of E-box that is enriched in the proximal promoters of 
Figure 29. MITF knockdown reduces the proliferation of 501mel cells. (A) Growth 
curve after measuring confluency of 501mel cells expressing an miRNA against MITF or 
miRNA control. (B) Graph showing doubling time calculated with the formula: Duration 
x log(2)/log(FinalConfluency)-log(InitialConfluency) of 501mel cells expressing miRNA 
against MITF or miRNA control and overexpressing empty vector (EV), TFEB or TFE3. 
Error bars represent SEM. * indicates significance at p<0.05. (C, D) Growth curve after 
measuring confluency of 501 Mel cells expressing a miRNA control (C) or against MITF 




































many lysosomal genes. This sequence has been named Coordinated 
Lysosomal Expression and Regulation (CLEAR) element (Sardiello et al., 
2009). TFE3 is able to regulate genes that are involved in the autophagy 
process and lysosomal biogenesis through the binding to the E-box consensus 
sequence CACGTG, which is contained within the CLEAR regulatory element 
(Aksan & Goding, 1998). Moreover, it has been shown that mutating a series 
of CLEAR elements present in the promoter of the lysosomal gene encoding 
the Ca2+ release channel mucolipin-1 (MCOLN1) abrogated its transcriptional 
activation by TFEB and TFE3 (Martina, Diab, Lishu, et al., 2014). TYR and 
MLANA are two well-known pigmentation genes that are downstream effectors 
of MITF. Both genes contain E/M-box elements known to be bound by MITF 
and required for transcriptional activation (Aksan & Goding, 1998; Verastegui 
et al., 2000). Moreover, oligonucleotides encompassing E-box and M-box 
motifs were used to determine the crystal structure of MITF when bound to 
DNA (Pogenberg et al., 2012). 
Previous studies in the lab suggest that MITF, TFEB and TFE3 are all able 
to activate the transcription of tyrosinase through the two E-box elements 
within its promoter (Arnþórsson, 2016). The transcription factors bind to the 
same DNA element, the E-box (CANNTG), and specifically recognize two 
subsets of the E-box, the CLEAR box (GTCACGTGAC), in the promoter 
regions of lysosomal and autophagy genes, and the M-box (GGTCATGTGCT), 
previously thought to be a pigment-cell-specific regulatory element of 
transcription (Jackson et al., 1991). Analysis of ChIP-seq datasets shows a 
strong binding site for MITF and TFEB in intron 2 of the pigmentation-gene 
MLANA (Figure 30A). In order to assess whether MITF, TFEB and TFE3 can 
all transactivate from this MLANA regulatory element, I performed transcription 
activation assays using a luciferase reporter plasmid containing a 692-base 
pair sequence containing the CACGTGA binding site for MITF and TFEB within 
intron 2 of the MLANA gene. GFP-tagged versions of MITF, TFEB or TFE3 
were overexpressed in HEK293T cells co-transfected with this reporter (Figure 
30A). Overexpression of the three transcription factors increased the luciferase 
signal from the reporter plasmid containing the putative transcriptional 
regulatory element of MLANA 5-fold when compared to the control pGL3-
promoter luciferase reporter plasmid (Figure 30B). Importantly, the expression 
of the TFE3 construct was 6-fold higher than that of MITF, whereas the 
expression of TFEB was 4-fold higher than that of MITF (Figure 30C) in 
HEK293T cells used for this assay. This suggests that the three factors, MITF, 
TFEB and TFE3 are capable of activating common regulatory elements that 
contain sequences related to the canonical palindromic E-box and thus, 
overlap in the regulation of the transcription of target genes, including those 
involved in pigmentation (Verastegui et al., 2000). However, since there is a 
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lot more TFE3 and TFEB proteins expressed in these assays than MITF, we 
cannot exclude the possibility that MITF is a more potent transcriptional 
activator of MLANA than either TFEB or TFE3.  
 
Figure 30. MITF, TFEB and TFE3 transactivate a regulatory element in an intronic 
region of  MLANA. (A) ChIP-seq data revealed that  MITFand TFEB bind to a 
CACGTGA motif within an intronic region of MLANA. (B) HEK293T cells were 
transiently co-transfected with a pEGFP-N1 constructs with MITF-M, TFEB, TFE3 or 
without (empty vector, EV) and luciferase constructs and assayed after 24h for 
luciferase activity. Luminiscence signal is expressed as fold change over an empty 
luciferase reporter. Error bars represent the SEM of three experiments. * indicates 
significance at p<0.05. (C) Western blot analysis and quantification of the protein 
expression of MITF, TFEB and TFE3 proteins after transfection of the respective 
plasmid constructs in HEK293T cells. Shown is a representative figure. 
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3.5.1  MITF and TFEB bind to unique and shared target genes in 
melanoma cells 
Ramile Dilshat, a PhD student in the Steingrimsson laboratory, has recently 
performed ChIP-seq experiments in 501mel cells using a GFP-tagged TFEB 
construct (Ramile Dilshat, unpublished).  Details on this ChIP-seq experiment 
are to be published in her PhD thesis but in order to gain insights into the 
overlapping function of MITF and TFEB, we compared this data to the 
published MITF ChIP-seq data in 501Mel cells of Laurette and colleagues 
(Laurette et al., 2015). We identified the annotated genes corresponding to the 
binding sites detected across the genome in the MITF and TFEB ChIP-seq 
datasets. We found 682 genes that are bound by the two factors and might be 
shared target genes in this human melanoma cell line (Figure 31A). The 
representation factor of the subset of overlapping target genes was 3.3, 
indicating that the number of genes found to be present in both ChIP-seq 
databases is 3-fold higher than the overlap expected purely by chance.  
Subsequently, I performed gene ontology (GO) analysis of the 682 target 
genes in order to look for over-represented classes of genes and to identify 
their relevant biological role. The analysis of “biological processes” terms 
showed significant enrichment of genes involved in intracellular and 
phagosomal pH reduction, transferrin transport, and lysosomal organization 
A 
Representation factor: 3.3  
p < 5.754e-219  
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and regulation of macroautophagy. This confirms previous observations that 
both MITF and TFEB are able to regulate the endosomal pathways (Figure 
31B, Table 11). The analysis of “cellular component” terms displayed a higher 
Figure 31. MITF and TFEB bind to a subset of shared target genes, including 
melanosomal and lysosomal genes. (A) Venn diagram showing the overlapping 
target genes of MITF and TFEB and whether they associate with melanomes or 
lysosomes. (B) GO analysis of the overlapping target genes. Terms from „biological 
process“ and (C) „cellular compartment“. The X-axis represents the fold enrichment 




over-representation of genes located at the melanosomal and endosomal-
lysosomal membranes, together with the vATPase complex. Approximately 
10% of the 682 genes were lysosomal genes and 3% melanosomal genes 
(Figure 31A, C, Table 11). However, 598 genes, a major fraction of the 682 
genes found to be common targets of MITF and TFEB, do not fall under these 
categories and are not over-represented in any specific biological pathway or 
cellular compartment (Figure 31A). 
Biological process # genes Fold e. p-value
Phagosome acidif ication 8 9.91 1.83E-02
Transferrin transport 9 8.36 1.69E-02
Intracellular pH reduction 11 8.17 1.55E-03
Phagosome maduration 9 7.52 3.92E-02
Lysosome organization 12 7.3 1.44E-03
Regulation of cellular pH 14 4.88 1.63E-02
Regulation of macroautophagy 23 4.72 1.64E-05
Organic acid transmembrane transport 15 4.44 2.19E-02
Regulation of autophagy 30 3.36 1.46E-04
Response to insulin 21 3.3 2.64E-02
Vesicle organization 30 3.14 6.26E-04
Response to peptide hormone 29 2.6 4.06E-02
Cellular compartment # genes Fold e. P value
Melanosome membrane 5 13.93 4.88E-02
Proton-transporting VATPase complex 7 9 2.27E-02
Melanosome 19 5.99 1.50E-06
Lysosomal membrane 43 4.12 2.28E-11
Vacuolar membrane 48 4.02 1.57E-12
Late endosome 23 3.32 1.28E-03
Lysosome 65 3.28 2.18E-13
Vacuole 72 3.16 2.99E-14
Endocytic vesicle 24 2.87 8.68E-03
Overlapping gene targets of MITF and TFEB
Table 11. GO analysis of the overlapping target genes of MITF and TFEB. Terms 
from „biological process“ (upper panel) and cellular compartment (lower pannel). Only 
terms with a fold enrichment score over 2.5 are shown. 
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Next, we analyzed the MITF and TFEB ChIP-seq datasets in order to 
identify the specific binding sites across the entire genome in 501Mel cells that 
are bound by MITF and TFEB. We found 553 sites that are bound by both 
transcription factors (Figure 32A).  Next, motif analysis to investigate whether 
any motifs are enriched in the overlapping binding sites was performed. Using 
the MEME Suite (Bailey et al., 2009) a GTCACGTGA motif was found, which 
corresponds to a CLEAR box, to be significantly enriched across the 
overlapping sequences bound by MITF and TFEB, with an E-value of 1.6e-015 
(Figure 32B). The zinc finger protein 263 (ZNF263) binding motif was also 
found (Figure 32C). The E-value is an estimate of the expected number of 
motifs with the given log likelihood ratio (or higher), and with the same width 
and site count, that one would find in a similarly sized set of control random 
sequences (Bailey et al., 2009). This finding further supports the notion that 
MITF and TFEB can both regulate a set of genes involved in endosomal 
biogenesis and autophagy.  
I also analyzed whether MITF and TFEB bind to regions in the vicinity of 
genes corresponding to the gene ontology category for pigmentation 
(GO:0043473) (Appendix III, Table 15) and a published list of 
lysosomal/autophagy genes (Perera et al., 2015) (Appendix III, Table 16). I 
found that out of 96 pigmentation genes, 25 are bound by both MITF and 
TFEB, whereas only 2 are bound by MITF alone and 1 gene by TFEB alone 
(Figure 32D, Table 12). Analysis of the lysosomal and autophagy-related 
genes shows that of the 139 genes, 87 are bound by both factors, 9 are bound 
by MITF alone and 1 gene is bound exclusively by TFEB (Figure 32E, Table 
12). This indicates an extensive overlap in the genes regulated by both MITF 
and TFEB. However, it also suggests that some genes are regulated only by 
one of the factors and not by the other. SPNS2 is the only pigmentation gene 
to be bound by TFEB and not MITF, in addition, it correlates with TFEB in the 
melanoma samples analyzed (Table 12). In contrast, the pigmentation genes 
NF1 and SOX10 are bound by MITF only and SOX10 correlates with MITF in 
expression in the melanoma samples (Table 12). ATP6V1E2 is the only 
lysosomal gene that is exclusively bound by TFEB, whereas ATP6V0D2, 
ATP6V0A2, BECN1, GALC, GLB1L, MAP1LC3B2, SLC17A5, SNCA, ULK2 
are bound by MITF alone (Table 13). Out of the 9 target genes that are bound 
by MITF but not by TFEB; only MAP1LC3B2, ULK2 and SNCA correlate in 
expression with MITF (Table 13). Furthermore, ATP6V1E2 is the only gene 
exclusively bound by TFEB that correlates in expression with TFEB across 




         
Figure 32. MITF and TFEB bind to a subset of ovelapping binding sites.  (A) Venn 
diagram showing the overlapping binding sites across the genome of 501Mel cells. (B, 
C) Motif discovery analysis of the overlapping binding sites of MITF and TFEB, showing 
the CLEAR box (B) and the ZNF263 binding motif (C). (D, E) MITF and TFEB have 







    
 
 
3.5.2  MITF, TFEB and TFE3 differentially regulate the 
transcription of autophagy-related genes  
Previous analyses in the lab (Möller at al., submitted) have shown that in a 
subset of 368 metastatic melanomas categorized in The Cancer Genome Atlas 
(TCGA) Research Network: ("http://cancergenome.nih.gov/,"), a number of 
lysosomal/autophagy-related genes (Appendix III, Table 16) are found among 
the top 2000 genes, whose expression correlates with that of MITF. In addition, 
a different subset of lysosomal genes has been found to correlate in expression 
with TFEB or TFE3 across metastatic melanomas. Of the 139 lysosomal and 
Table 12. List of the pigmentation genes found to be exclusively bound by MITF 
or TFEB in 501Mel cells and whether they correlate in gene expression with MITF 
or TFEB across 363 melanoma samples in TCGA. 
Table 13. List of the lysosomal genes found to be exclusively bound by MITF or 
TFEB in 501Mel cells and whether they correlate in gene expression with MITF or 




autophagy-related genes, 37 correlated with MITF and 30 genes with TFEB 
and/or TFE3, suggesting that each of these factors may differentially regulate 
specific subsets of lysosomal genes (Table 14). MITF, TFEB and TFE3 may 
be modulating different aspects of this complex biological process (Möller at 
al., submitted). The manuscript by Möller et al. describes a correlation between 
MITF and genes required for vesicle trafficking and endosomal transporters, 
consistent with the previously reported role of MITF as a master regulator of 
the v-ATPase complex (Zhang et al., 2015), whereas TFEB and TFE3 
correlate with genes that code for enzymes involved in proteolytic cleavage, 
as determined by gene ontology analysis.  
Therefore, I proceeded to analyze whether in vitro modulation of the 
expression of MITF, TFEB and TFE3 would affect the mRNA expression of 
several autophagy-related genes. A375P human melanoma cells were used, 







































Table 14. Correlation of lysosomal/autophagy genes with MITF, TFEB or TFE3 
in melanoma samples. 
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IV, Table 17), in order to minimize the effects mediated by a predominant 
endogenous factor that might dilute these experimental observations. I 
analyzed the mRNA expression of several target genes upon overexpression 
of MITF, TFEB or TFE3 and siRNA-mediated knockdown of MITF or TFE3. 
The mRNA expression of TFEB in A375P cells was very low (Appendix IV, 
Table 17) and the protein was undetectable by Western blotting, thus no 
siRNA-mediated silencing of TFEB was performed in this experiment. The 
lysosomal genes that were analyzed in this assay included LC3 and LAMP1, 
which are involved in the formation of autophagosomes; the vATPase subunits 
ATP6V0D2 and ATP6V1C1, which participate in the acidification of the 
lysosome; the cathepsin proteases CTSD and CTSZ, and the polysaccharide-
degrading sulfatase GNS. The three last genes encode proteins that are 
important for proteolytic cleavage of substrates in the lysosomes. In the light 
of the ChIP-seq datasets used throughout this study, all seven genes feature 
binding sites for both MITF and TFEB and therefore, are classified as 
overlapping target genes. The results showed that transcription of ATP6V0D2, 
ATP6V1C1 and CTSD was increased upon MITF and TFEB overexpression, 
whereas only the expression of ATP6V0D2 increased upon TFE3 
overexpression (Figure 33A). Interestingly, the TFEB-induced increase in 
ATP6V1C1 expression was abrogated when MITF was knocked down using 
siRNA, suggesting that activation of the transcription of this vATPase subunit 
by TFEB is dependent on MITF (Figure 33B). On the other hand, TFEB-
induced increase in CTSD expression remained unaffected upon silencing 
MITF (Figure 33B). The expression of CTSZ and GNS was slightly reduced 
when TFEB was overexpressed, regardless of whether MITF was knocked 
down or not (Figure 33B). Knockdown of MITF significantly inhibited the 
transcription of ATP6V0D2 (Figure 33C), whereas silencing of TFE3 
significantly increased the mRNA expression of ATP6V1C1 (Figure 33C). 
Knockdown of MITF did not repress the expression of ATP6V1C1, which 
remained at basal values. However, when TFE3 was overexpressed in these 
cells with partially depleted MITF, ATP6V1C1 expression was significantly 
decreased (Figure 33D), indicating that whereas MITF positively regulates 
ATP6V1C1, TFE3 might play a role in the negative regulation of this vATPase 
subunit.  
As shown before, MITF positively regulates ATP6V1C1, whereas TFE3 is 
a negative regulator of this gene. Moreover, TFEB can increase the expression 
of ATP6V1C1 only when MITF is being expressed (Figure 33). In contrast, the 
expression of CTSD increases when either MITF or TFEB are overexpressed. 
Therefore, I tested whether these two genes correlate in expression with MITF, 
TFEB and TFE3 across the 363 melanoma samples in the TCGA. Additionally, 
I included alpha-synuclein (SNCA) in this analysis. SNCA is a lysosome-




Figure 33. MITF, TFEB and TFE3 differentially regulate a selection of autophagy-
related genes.  The expression of a subset of autophagy genes as determined by RT-
qPCR after overexpression of MITF, TFEB and TFE3 (A), siMITF treatment versus 
siCTRL in cells overexpressing TFEB (B), knockdown of  MITF or TFE3 (C) and siMITF 
treatment versus siCTRL in cells overexpressing TFE3 (D). Shown is the average of at 
least three independent experiments. Bars represent SEM. * indicates significance at 
p<0.05. 
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correlate with MITF in the TCGA database of melanoma samples. ATP6V1C1 
correlates positively with MITF (Figure 34A) whereas it negatively correlates 
with TFE3 (Figure 34B), supporting the previous observations that MITF 
activates the expression of this vATPase subunit whereas TFE3 has an 
inhibitory role at the transcriptional level (Figure 33A, C, D). On the other hand, 
CTSD does not correlate with MITF (Figure 34C) but it positively correlates 
with TFEB (Figure 34D), suggesting that although both MITF and TFEB can 
bind to CTSD, their effects on its regulation might differ. I found that the 
expression of SNCA strongly correlates with MITF expression (Figure 34E) 
and moderately anti-correlates with TFE3 (Figure 34F). SNCA is a gene 
believed to have a role in the formation of synaptic vesicles at the presynaptic 
terminals. Following the findings indicating that MITF and TFE3 may 
differentially regulate specific autophagy-related genes such as ATP6V1C1, 
further efforts could be directed at determining whether they play opposite 
roles at the transcriptional regulation of SNCA and other genes involved in the 
endosomal pathways. 
In this study I have shown that MITF and TFEB bind to similar motifs across 
the genome and therefore regulate a subset of common target genes that 
includes both pigmentation and lysosomal genes. I have reported a subtype of 
the E-box motif, namely the CLEAR box, to be enriched within a set of 
overlapping sequences that are bound by both MITF and TFEB. The CLEAR 
motif has been associated with the transcriptional control of a large number of 
genes that are involved in the regulation of endosomal pathways, lysosomal 
function and autophagy (Palmieri et al., 2011), indicating that both factors are 
involved in the transcriptional control of these pathways in melanoma cells. 
Real time quantitative PCR analysis on a selection of autophagy-related genes 
revealed that MITF, TFEB and TFE3 can activate the transcription of a number 
of lysosomal genes. However, some of these genes show an exclusive 
correlation with only one of the factors and appear to be differentially regulated, 
indicating that the roles of MITF, TFEB and TFE3 do not overlap entirely in 





Figure 34. Analysis of the correlation in gene expression between MITF, TFEB or 
TFE3 and selected lysosomal genes across 363 metastatic melanoma samples. 
Correlation between ATP6V1C1 and MITF (A) or TFE3 (B). Correlation between CTSD 




  Summary 
The aim of this thesis was to determine the expression of the MIT-TFE factors 
and their interactions in melanoma tumors and cell lines. These factors 
constitute a subfamily featuring high structural homology, they share a 
conserved bHLHZip domain, which is more similar than in the larger family of 
basic helix-loop-helix leucine zipper family of transcription factors.  
Previous studies have shown that MITF, TFEB, TFE3 and TFEC can form 
DNA-binding heterodimers, but not with other bHLHZip transcription factors 
such as Myc and Max, defining the discrete MiT-TFE subfamily of transcription 
factors within the bHLHZip transcription factors (Hemesath et al., 1994). 
However, the dimerization properties of these factors have not been thoroughly 
described in melanoma cells. Furthermore, the role of TFEB and TFE3 in 
melanoma is poorly understood. Here, I performed co-immunoprecipitation 
studies in 501Mel cells and observed that MITF, TFEB and TFE3 can interact 
with each other. Moreover, I characterized a three-residue insertion 
responsible for selection of dimerization partners by introducing a break within 
the first heptad of the leucine zipper of these factors. 
Using melanoma cell lines available in our lab, I analyzed the subcellular 
localization of these transcription factors and how it is affected by the mTORC 
and the BRAF-MAPK signaling pathways, two signaling cascades that are 
known to trigger phosphorylation of TFEB, TFE3 and some isoforms of MITF 
to modulate their subcellular distribution. Blockade of these signaling pathways 
using drug inhibitors resulted in nuclear translocation of MITF, TFEB and TFE3 
in the melanoma cell lines analyzed, potentially affecting their stability, the 
activity of these proteins as transcription factors and the regulation of 
downstream biological processes. 
Analysis of MITF and TFEB binding sites by ChIP-seq in melanoma cells 
reveals the existence of binding sites for MITF and TFEB in the regulatory 
regions of both MITF and TFEB genes, but not in TFE3. I overexpressed and 
knocked down MITF, TFEB or TFE3 in human melanoma cells and showed 
that the MITF, TFEB and TFE3 proteins affect each other’s expression in 
melanoma cells, thus forming a regulatory loop. Moreover, the alteration in 
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expression of these proteins may induce phenotypic changes, including 
proliferation. 
The ChIP-seq datasets for MITF and TFEB showed a significant overlap of 
binding sites and target genes. This overlap of target genes includes a number 
of lysosomal and autophagy-related genes, indicating that these two factors 
may collaborate in regulating endosomal biogenesis and the autophagy 
process. Subsequently, I characterized the expression of a number of 
autophagy-related genes upon overexpression or knockdown of MITF, TFEB 
and TFE3 and also their co-expression across a publicly available database of 
melanoma specimens. I found that the expression of a subset of autophagy-
related genes is induced by MITF, TFEB and TFE3 indiscriminately. However, 
my analysis also shows that their role in autophagy regulation does not entirely 
overlap and that each factor may be required for a particular stage within the 
autophagy process. 
  MITF, TFEB and TFE3 are expressed in melanoma 
Basic helix–loop–helix leucine zipper (bHLHZip) transcription factors are 
known to participate in development by controlling cell proliferation and 
differentiation. Many of them are also known to be dysregulated in several 
types of cancer. MITF is a bHLHZip factor that was first discovered due to coat 
color mutations in mice (Hodgkinson et al., 1993). In humans, mutations in 
MITF have been linked to the pigmentation disorder Waardenburg Syndrome 
Type 2A (WS2A) (A. E. Hughes et al., 1994) and Tietz’s syndrome (TS) (Smith 
et al., 2000). MITF has been described as a key regulator of melanocyte 
development. TFEB and TFE3 are important in the regulation of lysosomal 
biogenesis and autophagy (Martina, Diab, Lishu, et al., 2014; Sardiello et al., 
2009). MITF, TFEB and TFE3 have been found to be dysregulated in 
pancreatic ductal adenocarcinoma (Kuiper et al., 2003; Perera et al., 2015) 
and renal clear cell carcinoma. In this study, the co-expression of the MiT-TFE 
family was analyzed across several melanoma cell lines and melanoma tumor 
samples. MITF, TFEB and TFE3 are expressed to some extent across a 
majority of these cell lines, whereas TFEC is not. The expression of TFEB and 
TFE3 is roughly 50-fold lower than MITF across cell lines (Figure 8). This is in 
line with previous studies from our lab showing that across 368 metastatic 
melanoma specimens, MITF is 14-fold and 4-fold more highly expressed than 
TFEB and TFE3, respectively (Möller at al., submitted). Although significant 
expression of TFEC was not detected across cell lines or melanoma samples, 
13% of melanoma specimens among the 448 included in The Cancer Genome 
Atlas (TCGA) Research Network: ("http://cancergenome.nih.gov/,") feature 
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genetic alterations in the TFEC locus. A majority of those are mRNA 
upregulation events, hence, this could suggest that TFEC is silenced in the 
melanocyte lineage and that increased mRNA expression of TFEC might have 
role in melanoma development. 
  TFE3, TFEB and MITF show increased nuclear 
localization upon inhibition of mTOR or BRAF 
By immunostaining of cell preparations and confocal imaging I found that TFEB 
and TFE3 are present in both the cytoplasm and the nucleus in melanoma 
cells, whereas MITF is mostly nuclear. This is in accordance with previous 
studies showing that MITF-M is the main isoform expressed in melanocytes 
and melanoma cells. MITF-M lacks an N-terminal domain responsible for the 
interaction with Rag proteins that promote the cytoplasmic retention of TFEB 
and TFE3 (Martina, Diab, Lishu, et al., 2014; Martina & Puertollano, 2013; 
Takebayashi et al., 1996). However, I observed that a fraction of MITF-M 
localizes to the cytoplasm of 501Mel, Skmel28 and Skmel31 human melanoma 
cells (Figure 9A, 11C, 13C, 14C). Ectopically overexpressed GFP-tagged 
MITF-M in 501Mel cells was also partly localized to the cytoplasm (Figure 12), 
therefore ruling out the possibility that other MITF isoforms that contain the N-
terminal Rag-binding domain, such as MITF-A, were responsible for the 
cytoplasmic signal. 
Several studies have shown that a panel of kinases participating in different 
signaling cascades are able to phosphorylate MITF, TFEB and TFE3 
(Hemesath et al., 1998; Hong et al., 2010; Martina et al., 2012; Puertollano et 
al., 2018; Settembre et al., 2011). The mTOR and BRAF-MAPK signaling 
pathways are the two most studied in this regard, showing that they can 
phosphorylate Ser142 and Ser211 of TFEB (Figure 6) (Settembre et al., 
2012). Interestingly, both domains are conserved in the MITF protein and 
correspond to Ser73 and Ser173 of MITF-M and Ser180 and Ser280 of MITF-
A (Figure 6). Phosphorylation of Ser73 of MITF-M by ERK has been shown to 
enhance the activity of MITF by increasing its association with the 
transcriptional coactivator histone acetyl transferase p300/CBP (Price, Ding, 
et al., 1998; S. Sato et al., 1997). Phosphorylation of Ser409 of MITF by p90 
ribosomal s6 kinase (p90RSK) prevents the recruitment of PIAS3, a 
corepressor of MITF (Levy et al., 2003). Phosphorylation of MITF on Ser73 
and Ser409 has been shown to enhance its transcriptional potential and, at the 
same time, trigger ubiquitination and degradation of the MITF protein by the 
proteasome (Price, Ding, et al., 1998; Wu et al., 2000; Xu et al., 2000). 
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mTORC phosphorylates TFEB at the lysosomal membrane. 
Phosphorylated TFEB is recruited by scaffolding 14-3-3 proteins that mask a 
nuclear localization signal (NLS) in the protein, thus promoting cytoplasmic 
retention of TFEB (Martina & Puertollano, 2013; Pena-Llopis et al., 2011; 
Settembre et al., 2012). Therefore, I assessed whether drug inhibition of 
mTORC and BRAF would alter the subcellular distribution of MITF-M observed 
under normal conditions. In this thesis I showed that inhibiting mTORC or 
BRAF promoted nuclear translocation of TFEB and TFE3, and reduced the 
fraction of MITF located in the cytoplasm, when compared to vehicle treatment 
in 501Mel and Skmel28 cells (Figure 11, 12, 13). These two cell lines harbor 
the hyperactivating mutation BRAFV600E, a mutagenesis event that has been 
reported in approximately 50% of melanoma tumors. In order to assess the 
nuclear localization of these factors in wild type BRAF context I utilized the 
Skmel31 cell line that is BRAF wild type. This cell line did not express TFEB at 
detectable levels as determined by immunostaining (Figure 14A). TFE3 
showed a major nuclear presence in this cell line and inhibition of mTOR had 
no effect on its localization, whereas inhibiting BRAF slightly decreased the 
cytoplasmic localization of TFE3 (Figure 14B). More cytoplasmic MITF was 
detected in Skmel31 cells than in the other cell lines analyzed. However, its 
subcellular localization did not respond significantly to inhibition of mTORC or 
BRAF, suggesting that the regulation of the subcellular localization of the MiT-
TFE factors in melanoma cells might be BRAF status-dependent. 
A publication of Martina and colleagues (Martina & Puertollano, 2013) 
shows that a Rag-binding domain is required for mTORC-mediated 
cytoplasmic retention of TFEB. This Rag-binding domain protein is also shared 
by MITF-A but not MITF-M. It consists of 30 N-terminal aminoacids located at 
the exon 1B1b of MITF-A, an exon that is present in all the MITF isoforms 
except for MITF-M due to alternative splicing (Hodgkinson et al., 1993). 
Martina and colleagues showed that a fraction of MITF-M is observable in the 
cytoplasm of the human ARPE-19 retinal epithelium cells used in their study, 
although it did not co-localize with active Rag proteins. This could suggest that 
interaction with Rag proteins may not be the only mechanism behind mTORC-
mediated cytoplasmic retention of MITF-M. Indeed, a nuclear localization 
signal (NLS) that mediates nuclear translocation of MITF-M has been reported 
between amino acids 210 and 221. MITF-M lacking the NLS is retained in the 
cytoplasm (Fock et al., 2018). Thus, I conclude that although MITF-M lacks a 
major signal that mediates the cytoplasmic retention upon mTORC signaling, 
there may be other domains in MITF that play a role in regulating its subcellular 
localization that remain to be elucidated. Furthermore, phosphorylation events 
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mediated by the mTOR and BRAF-MAPK pathways may regulate the 
subcellular localization of MITF-M in a Rag-independent manner. 
Another unexpected observation I made was that starvation of the cell 
cultures with HBSS medium, a minimum cell culture medium that lacks glucose 
and amino acids, did not induce nuclear translocation of MITF, TFEB or TFE3. 
Starvation induces inactivation of mTOR and calcium-dependent 
dephosphorylation of TFEB via the phosphatase calcineurin (Medina et al., 
2015). Dephosphorylation of TFEB and TFE3 triggering an increase in the 
cellular clearance pathways has been reported in several publications 
(Martina, Diab, Li, et al., 2014; Settembre et al., 2013; Settembre et al., 2012). 
The absence of effects on the subcellular localization of any of the three factors 
upon starvation, suggests that nutritional stress in these melanoma cell lines 
is not sufficient to promote nuclear localization of the transcription factors. 
Leucine has been proposed as the key molecular switch in starvation-driven 
mTORC1 inactivation (Fox et al., 1998; Wolfson et al., 2016). Interestingly, in 
melanoma cells with hyperactive MAPK signaling, leucine deprivation failed to 
inactivate the mTORC1 pathway and trigger the autophagy response (Sheen 
et al., 2011). Perera and colleagues have shown that MITF, TFEB and TFE3 
can escape cytoplasmic retention mediated by mTOR regulation under fully-
fed conditions in pancreatic ductal adenocarcinoma (PDA), in contrast to non-
transformed human pancreatic ductal epithelial cells. The constitutive 
localization of the three factors in PDA can induce autophagy activity, thereby 
maintaining a high supply of amino acids, which is advantageous for tumor 
development (Perera et al., 2015). Moreover, a subset of genes involved in 
endolysosomal trafficking and autophagy have been found to be 
overexpressed in melanoma (Alonso-Curbelo et al., 2015).  It is tempting to 
speculate that, in cells of the melanocytic lineage and melanoma, the 
expression of an MITF-M isoform is able to circumvent Rag-dependent 
mechanisms for cytoplasmic retention as an evolutionary advantage of these 
cell types. Melanoma cells express a constitutively active isoform of MITF that 
supports strong proliferation and cell growth and allows a highly-developed 
endosomal network that enhances survival under the stressful conditions of 
the tumor microenvironment. 
  mTOR regulates the distribution of MITF, its protein 
turnover and stability 
4.4.1  mTOR phosphorylates MITF at a site dependent on Ser73 
Previous studies have shown that a number of different kinases take part in 
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the phosphorylation of several serine-residues in MITF, TFEB and TFE3. 
Ser122, Ser142, and Ser211 of TFEB (Martina et al., 2012; Roczniak-
Ferguson et al., 2012; Settembre et al., 2011; Vega-Rubin-de-Celis et al., 
2017) and Ser321 of TFE3 (Martina, Diab, Lishu, et al., 2014) are 
phosphorylated by mTORC1, promoting their cytoplasmic localization (Figure 
6). Consistent with that, mutations of Ser142 or Ser211 of TFEB or mTORC 
inhibition result in nuclear translocation of the TFEB protein. ERK-mediated 
phosphorylation of Ser73 of MITF, homologous to Ser142 of TFEB, has been 
shown to enhance transcriptional activity of MITF (Hemesath et al., 1998). In 
addition, Wu and colleagues showed that a double Ser73/409Ala mutant of 
MITF resulted in increased half-life. They reported that the mutant was 
transcriptionally incompetent and resistant to ubiquitin-mediated proteolysis 
(Wu et al., 2000). However, these two studies have not shown any effects of 
the phosphorylation status of MITF on the subcellular localization of MITF. 
In this thesis, I analyzed the effects of the blockade of mTORC kinase 
activity on the phosphorylation status of MITF and whether this has an impact 
on the subcellular localization of the protein. For this purpose, the use of 
specific antibodies against specific phosphorylated amino acids of the MITF 
protein would have proven useful. Unfortunately, the phospho-specific 
antibodies against Ser73 available at the time the experiments were performed 
did not work successfully. Therefore, I was limited to analyze the mobility shift 
of an MITF doublet as shown by Western blotting in order to infer the 
phosphorylation status of Ser73 upon mTOR inhibition. Importantly, previous 
studies describe that the upper band of the MITF doublet corresponds to 
phosphorylated Ser73 (Hemesath et al., 1998; Wu et al., 2000) and that MAPK-
ERK signaling increases the phosphorylation of Ser73 and therefore the 
intensity of the upper band. As shown in Figure 15, the Ser73Ala mutant of 
MITF-M resolves as a single band in Western blot. This corresponds to the 
lower band of the MITF doublet. The addition of a phosphate group would 
theoretically add roughly ∿90 Da to the molecular weight of the protein 
whereas the mobility shift I observe is around 5 KDa, suggesting that additional 
post-translational modifications are primed by the phosphorylation of Ser73 of 
MITF. Another possibility is that phosphorylation of Ser73 of MITF induces a 
conformational change that affects its mobility through the SDS-PAGE gel. A 
three-hour inhibition of both mTORC and BRAF using specific inhibitors 
resulted in reduced intensity of the upper band of wild type MITF and 
Ser409Ala MITF after three hours, although the upper band did not disappear 
completely (Figure 15). No alterations in protein levels of the single band 
observed for the Ser73Ala MITF were observed. This indicates that, in addition 
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to the BRAF signaling pathway, mTOR can phosphorylate MITF in a site that 
is either Ser73 itself or dependent on Ser73 phosphorylation, and that other 
kinases may be involved in this phosphorylation event. 
4.4.2  Dephosphorylation of Ser73 promotes nuclear localization 
and degradation of MITF 
The MITF-A isoform shows a predominantly cytoplasmic distribution in 
melanoma cells as opposed to MITF-M which is primarily nuclear. Thus, the 
effects of a drug-mediated increase in nuclear localization of the MITF protein 
would be easier to observe on MITF-A than on MITF-M. Inhibition of mTOR 
triggered nuclear translocation of MITF-A (Figure 16), suggesting that MITF-A 
shares the mechanism of regulation of its subcellular localization with TFEB 
and TFE3 (Figure 11A, B, 12, 13B, 14B). Following the observation that 
mTOR inhibition reduces the intensity of the upper band of MITF-M to a certain 
degree, which is dependent on Ser73 phosphorylation, I transfected these cells 
with a version of MITF-A where Ser180, the serine residue that corresponds to 
Ser73 of MITF-M is mutated to alanine. Ser180Ala MITF-A was almost 
exclusively nuclear, suggesting that the phosphorylation event at Ser180 of 
MITF-A is crucial for cytoplasmic localization of the protein (Figure 16).  
In order to determine if mTOR inhibition affected the expression of the MiT-
TFE factors I analyzed their mRNA expression by RT-qPCR. In Figure 28, real 
time qPCR analysis of MITF showed increased mRNA levels in 501Mel cells 
upon three-hour treatment with mTOR inhibitor (Figure 28A). Thus, with the 
purpose of analyzing whether the mTOR-mediated increase in MITF 
transcription would translate to the protein level, I analyzed the endogenous 
levels of MITF by Western blot upon mTORC inhibition. I did not observe an 
increase in protein levels (Figure 28C, D). Thus, I analyzed any potential 
effects of mTOR on protein stability and degradation of MITF. To this end, the 
cells were treated with cycloheximide, a potent inhibitor of protein translation. 
Unexpectedly, cycloheximide treatment increased the upper to lower band 
ratio of MITF, coupled with a markedly reduced presence of the lower band 
(Figure 28C, E). mTOR inhibition significantly decreased the upper to lower 
band ratio, suggesting dephosphorylation of MITF, as previously discussed 
(Figure 15). However, treatment with the mTOR inhibitor and cycloheximide 
severely reduced the presence of the lower band, similar to treatment of 
cycloheximide alone (Figure 28C, E). These results suggest that 
dephosphorylation of Ser73 or a different site primed by dephosphorylation of 
Ser73 triggers degradation of the MITF protein. Subsequently, the proteasome 
inhibitor MG132 was used with the aim of assessing whether the degradation 
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of dephosphorylated MITF is mediated by the proteasome complex. As shown 
in Figure 28F, inhibition of the proteasome increased the intensity of the lower 
band despite blockade of protein translation with cycloheximide treatment. In 
addition, total protein levels of MITF increased when compared to 
cycloheximide treatment or vehicle control (Figure 28F, G). This suggests that 
degradation of MITF is through the proteasome pathway. Another interesting 
observation from this experiment was that, as seen by Western blotting 
(Figure 28C, F), there is not only an increased ratio of MITF’s upper band to 
lower band upon cycloheximide treatment compared to vehicle control, but the 
presence of the upper band is increased in absolute terms, with or without 
Torin1 treatment, compared to vehicle control. It is possible that this is due to 
cycloheximide-mediated blockade of protein translation, which may prevent de 
novo synthesis of proteins that are required for dephosphorylation of MITF. It 
has been shown that protein and mRNA levels of protein phosphatase 1 alpha 
(PP1α) decline over time after cycloheximide treatment, suggesting that this 
treatment also affects transcription (Price, Horstmann, et al., 1998). 
Cycloheximide-induced blockade of protein translation can reduce the 
expression of transcription factors and ribosomal proteins and thus, affect 
downstream transcriptional machinery (Gokal et al., 1986). Moreover, the cells 
undergoing mTORC inhibition in this assay still have an active BRAF-MAPK 
pathway, which I have shown to trigger phosphorylation of MITF at the same 
site/s (Figure 15). Cycloheximide treatment has been reported to inhibit MAPK 
phosphatase-1, which in turn induces phosphorylation of ERK (W. W. Lin & 
Hsu, 2000). This effect of cycloheximide could explain the observed increase 
in phosphorylation of MITF. 
Wu and colleagues showed 18 years ago that MAPK-ERK signaling 
phosphorylates MITF at Ser73 and Ser409, targeting MITF simultaneously for 
increased activity and degradation (Wu et al., 2000). However, this study is 
considerably different to the statements discussed in this thesis. Wu et al. used 
Steel factor (Sl) to stimulate the MAPK-ERK pathway and showed a sharp 
decrease in MITF protein levels after blockade of protein translation. 
Interestingly, in the work by Wu and colleagues, they show that the Ser73Ala 
MITF mutant underwent degradation similar to the wild type protein upon 
MAPK-ERK stimulation, suggesting that the phosphorylation of other sites 
different to Ser73 are involved in this MAPK-mediated degradation of MITF. In 
addition, they reported that a double mutant Ser73/409Ala is more stable when 
compared to wild type or Ser73Ala MITF. It is important to notice that the 
Ser73/409Ala mutant reported by Wu et al. ran at a significantly lower 
molecular weight to what was expected (see Figure 6A in Wu et al.). This has 
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not been observed in our lab (data not shown) suggesting that the particular 
construct used might not be full-length MITF. 
In this thesis, I have shown that mTORC can phosphorylate MITF on a 
residue or combination of residues dependent on the phosphorylation of 
Ser73. A recent publication showed that inhibition of the BRAF-MAPK pathway 
with vemurafenib did not affect the stability of wild type MITF upon 
cycloheximide treatment. Furthermore, Ser73Ala MITF was not found to have 
a shorter half-life than the wild type protein (Fock et al., 2018). This study also 
shows an increase in phosphorylation of ERK upon cycloheximide treatment, 
which could result in increased phosphorylation of MITF. Therefore, in the light 
of these results, I cannot conclude whether the observed relative increase of 
the upper band of MITF upon blockade of de novo protein translation with 
cycloheximide treatment is a result of increased degradation of the fraction of 
MITF that is unphosphorylated or a mobility shift due to an increase of 
phosphorylated MITF at Ser73. Nevertheless, in Figure 28C, D, I show that 
the levels of total MITF protein decrease upon cycloheximide treatment and 
that inhibition of proteasomal activity abrogates the degradation triggered by 
cycloheximide treatment (Figure 28F, G). The lower band of MITF rapidly 
disappears when protein translation is inhibited, which may suggest that MITF 
is continuously expressed and that phosphorylation is important in order to 
stabilize MITF. The fact that I observed an increase in mRNA levels of MITF 
upon mTOR inhibition could point to a downstream effect of the increased 
degradation of MITF that triggers an increase in MITF transcription. In this line, 
I observed that transient siRNA-mediated knockdown of MITF resulted in 
increased transcription of the MITF gene (Figure 25). This clearly indicates 
that MITF suppresses its own expression and is involved in its own regulation. 
I will discuss this further in the section 5.7 describing the regulatory loop 
between MITF, TFEB and TFE3. These data imply an mTORC-dependent 
effect on MITF turnover: MITF is degraded faster when mTORC is inactive and 
there is increased de novo expression aimed to compensate for the loss of 
MITF protein (Figure 35). Finally, I conclude that the mechanisms behind 
transcriptional and post-transcriptional regulation of MITF by the mTORC 
pathway are complex and require further elucidation.  
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  GSK3β signaling pathway affects the subcellular 
localization of MITF 
Ploper and colleagues have characterized a C-terminal domain of MITF which 
contains several serine residues (Figure 17A). They linked three of these 
residues, corresponding to Ser504/508/512 in MITF-A, to GSK3β-mediated 
phosphorylation and proteasomal degradation. Active Wnt signaling induced 
endosomal sequestration and inactivation of the GSK3β complex which led to 
increased stability of the protein and enhanced endosomal biogenesis in a 
positive feedback loop (Ploper et al., 2015). In their work they do not report 
whether the mutation of these three C-terminal serines of MITF-M affects its 
subcellular localization. When I overexpressed the Ser504/508/512Ala MITF-
A mutant, the protein was significantly more cytoplasmic than wild type MITF 
in 501Mel cells (Figure 17B). Blockade of the GSK3β pathway with the 
Figure 35. Proposed model for the effects of mTOR inhibition on MITF. 
Pharmacological or stress-induced inactivation of mTOR promotes dephosphorylation 
of MITF at Ser73 and additional Ser73-dependent residue/s, which triggers 




selective inhibitor CHIR99021, induced nuclear localization of MITF-A, as 
opposed to the more ubiquitous presence of the protein observed in the vehicle 
control (Figure 17B). This is similar to the increase in nuclear localization of 
MITF observed upon inhibition of mTOR discussed in the previous chapter. 
Interestingly, the Ser504/508/512Ala mutant of MITF-A localized to the nucleus 
upon GSK3β inhibition (Figure 17B). This suggests that the GSK3β pathway 
regulates the subcellular localization of MITF-A in a manner independent of 
the three C-terminally located serines characterized by Ploper et al. (2015). 
Another study highlighted GSK3β as a negative modulator of the autophagy 
response showing that this kinase can phosphorylate TFEB and promote 
cytoplasmic retention of the protein. The use of the GSK3β inhibitor 
CHIR99021 affected the electrophoretic mobility of TFEB, suggesting a 
dephosphorylation event, coupled with an increase in its nuclear localization. 
Moreover, GSK3β inhibition elicited the autophagy response in human 
pancreatic cancer cells through TFEB (Marchand et al., 2015).  
I conclude that, in addition to inducing phosphorylation of the C-terminus of 
MITF leading to proteasome-mediated degradation of the MITF protein, 
GSK3β affects the subcellular localization of MITF, possibly through the 
phosphorylation of alternative sites in MITF. Elucidating which residues are 
targets of phosphorylation by GSK3β in MITF and whether they are conserved 
in TFEB, would prove useful to understand how this signaling pathway affects 
the subcellular localization and activity of transcription factors, such as MITF 
and TFEB, that are crucial for the regulation of autophagy in cancer cells, 
including melanoma. 
  Dimerization of MITF, TFEB and TFE3 in melanoma 
cells 
In this thesis, I show that the three factors, MITF, TFEB and TFE3, interact in 
501Mel cells (Figure 18), possibly forming functional heterodimers. This is in 
line with previous studies showing that these factors are capable of forming 
stable DNA-binding heterodimers when translated in vitro in a cell-free system 
(Hemesath et al., 1994) and that TFE3 can heterodimerize with MITF in 
osteoclasts (Weilbaecher et al., 1998). Moreover, TFE3 has been suggested 
to preferentially heterodimerize, as opposed to MITF’s preference to form 
homodimers (Hemesath et al., 1994). This is in contrast with a study that claims 
that TFE3 does not form heterodimers with MITF in mouse B16 melanoma 
cells, and that TFE3 homodimers cannot bind M-box elements (Verastegui et 
al., 2000). Previous studies in the lab have shown that TFE3 was able to 
transactivate a luciferase reporter construct containing the wild type tyrosinase 
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promoter. The tyrosinase promoter features two DNA regulatory motifs, which 
are a variation of an M-box with a 5’ flanking thymine in only one of the DNA 
strands. The presence of 5’ flanking thymines in both strands is sometimes 
considered as part of the M-box motif (Aksan & Goding, 1998). Thus, these 
two motifs were mutated to the canonical M-box in order to test whether TFE3 
could activate the M-box element. TFE3 was able to activate the modified 
tyrosinase promoter with two M-boxes (Arnþórsson, 2016). This was 
performed in HEK293T cells that do not express any of the MiT-TFE 
transcription factors, suggesting that TFE3 alone can bind to M-box elements 
and activate gene transcription, in contrast to the study by Verastegui and 
colleagues. 
Verastegui et al. (2000) immunoprecipitated nuclear extracts of B16 mouse 
melanoma cells, which endogenously express MITF and TFE3, and reported 
that virtually no TFE3 was pulled down by the anti-MITF antibody. In this thesis, 
I have used whole 501Mel cell lysates in order to co-immunoprecipitate 
overexpressed MITF and TFE3. One possible explanation for this discrepancy 
is that MITF is expressed at a much higher level in B16 cells than TFE3, 
therefore favoring the detection of MITF homodimers over MITF-TFE3 
heterodimers. Another possible explanation is that perhaps only the 
cytoplasmic fraction of MITF interacts with TFE3, which is present in both the 
cytoplasm and nuclei of these cells. However, I show that immunoprecipitation 
of TFE3, pulled down abundant MITF (Figure 18), suggesting that these 
interactions take place in the nucleus as well. In addition, overexpression of 
MITF or TFE3 did not result in a different subcellular localization of the protein, 
when compared to their endogenous localization in 501Mel cells (Figure 11, 
12). Perhaps overexpression of TFE3 enables MITF-TFE3 heterodimers to 
take place. Further investigations on this matter should include cell 
fractionation preparations in order to determine in which subcellular 
compartment these interactions occur. 
4.6.1  A three-residue insert mediates the selection of 
dimerization partners of the MiT-TFE factors 
In this thesis I successfully characterized a three-residue domain, the 
stammer, which disrupts the continuity of the coiled-coil leucine zipper domain 
of the MiT-TFE transcription factors, as responsible for their dimerization 
properties. I have generated an MITF mutant where the motif has been 
excised, MITF (Δ259-261), and demonstrated that the lack of the stammer 
motif does not affect the mutant’s subcellular localization or functionality as a 
transcription factor (Pogenberg, Ballesteros Alvarez et al., Manuscript II, in 
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preparation). Generation of a crystal structure of MITF(Δ259-261) showed that 
the dimeric arrangement is unperturbed whereas the stability of the protein is 
enhanced. The presence of the stammer in the MiT-TFE transcription factors 
interrupts the leucine zipper heptad pattern present in other bHLHZip factors 
such as c-Myc, MAD and MAX. This restricts the ability of MITF, TFEB, TFE3 
and TFEC to selectively dimerize with each other and avoid the other family 
members. Removal of the stammer, as shown by co-immunoprecipitation 
studies using the MITF(Δ259-261) mutant alters the selection of homotypic 
interactions in which the mutant can participate. MITF(Δ259-261) severely 
reduces its ability to interact with TFEB and TFE3, although its ability to 
homodimerize remains intact (Figure 20). Interestingly, as observed in the co-
immunoprecipitation studies, MITF(Δ259-261) gains interaction abilities with 
MAX (Figure 21), indicating that the removal of the stammer allows for de novo 
homotypic interactions with other bHLHZip factors that do not have the three-
residue insertion in the leucine zipper. These data have implications for future 
perspectives in research aiming to manipulate the specificity of the interactions 
and dimerization ability of transcription factors containing a leucine zipper.  
We were interested in taking this further by developing an MITF mutant that 
would only homodimerize and not dimerize with any other MiT-TFE 
transcription factor, in order to study the specific role of MITF homodimers in 
melanoma. The MITF(Δ259-261) mutant was able to interact with MAX and 
possibly other bHLHZip transcription factors and, therefore, may act in a 
dominant negative fashion. Therefore, I cannot rule out newly acquired 
functions of the heterodimers containing this mutation that do not occur in vivo. 
I therefore generated two new MITF mutants: one in which the stammer was 
moved from the junction between heptads 0-I to the one between heptads I 
and II (Figure 5B), and a second mutant containing the wild type stammer and 
a second stammer introduced at the junction between heptads I-II. Co-
immunoprecipitation studies showed that both mutants were able to dimerize 
with wild type MITF and displayed a severely reduced interaction ability with 
MITF(Δ259-261) (Figure 22). Interestingly, the mutant containing two stammer 
insertions failed to homodimerize (Figure 22B). These results indicate that the 
presence of the three-residue insert is critical for the interaction with the other 
MiT-TFE family members. When the insertion was placed at the junction 
between heptads I-II of the leucine zipper in the dREQ/EQQins mutant 
(MITF(Δ259-261)_N269_R270insEQQ), the protein displayed the same 
dimerization properties as the wild type MITF protein, suggesting that this 
change in localization of the insertion did not have an impact on the 
dimerization properties of the protein. 
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The selection of dimerization partners has been shown to be a mechanism 
that modulates transcription factor activity (Amoutzias et al., 2008). A good 
example of this concept in bHLHZip transcription factors is the c-
Myc/MAX/MAD network, with c-Myc and MAX forming dimers that promote cell 
differentiation in contrast with MAX/MAD heterodimers that have a repressive 
function (Amati & Land, 1994; Luscher, 2012). This highlights that the fine-
tuned balance of the relative concentrations of these factors can profoundly 
impact cell biology and cell fate. The development of a hypothetical novel 
mutation in MITF that would only allow the protein to form heterodimers, 
coupled with genetic editing techniques like CRISPR could prove valuable to 
investigate the function of MiT-TFE homodimers versus heterodimers and to 
gain insights into the underlying mechanisms of target gene selection. 
 MITF, TFEB and TFE3 regulatory loop in melanoma 
Another major finding of this thesis was that the MiT-TFE transcription factors 
affect each other’s expression and form a regulatory loop that involves both 
direct and indirect effects. This constitutes yet another layer of regulation of 
the expression and function of the factors. In this study, I demonstrate that 
MITF, TFEB and TFE3 are expressed to some extent across a majority of 
melanoma samples and cell lines and they display a complex cross-regulatory 
relationship, affecting each other’s expression through a combination of direct 
transcriptional activity and indirect effects that need further investigation 
(Figure 36). Ectopic overexpression of MITF reduced the endogenous 
transcription of MITF in a self-limiting regulatory loop. MITF and TFE3 
participate in a negative regulatory loop in melanoma and I found that TFE3-
mediated reduction in MITF expression affects the proliferation of a human 
melanoma cell line. I suggest that an indirect regulatory mechanism is involved 
in the effects of MITF on TFE3 since there are no binding sites for MITF located 
in the TFE3 gene. This finding is further strengthened by the observation that 
the expression levels of MITF and TFE3 anti-correlate across a well-
established database of melanoma specimens accessible at TCGA 
("http://cancergenome.nih.gov/,") (Figure 8C). 
On the other hand, I show that MITF can induce the expression of TFEB 
through direct binding and transcriptional activation. In turn, TFEB inhibits the 
expression of MITF. A limitation of this study was the fact that I only had access 
to MITF and TFEB ChIP-seq data in melanoma cells. Therefore, I cannot 
conclude whether the TFE3-mediated reduction in MITF expression involves 
direct repression of transcription. More efforts are needed to reveal the 
mechanism underneath the homeostatic self-regulation of MITF expression 
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and whether the inhibitory effects of TFEB and TFE3 on MITF are direct 
transcriptional effects or indirect effects. 
TFEB has been shown to control cellular lipid metabolism through a 
starvation-induced auto-regulatory loop that involves nuclear translocation of 
TFEB and increased transcription of TFEB (Settembre et al., 2013). In this 
study, I have not assessed whether TFEB overexpression or depletion affects 
expression of the endogenous mRNA or protein levels of TFEB. Since intron 1 
of TFEB features a binding site for both MITF and TFEB, as shown by ChIP-
seq data (Figure 23A), further investigations on whether TFEB stimulates its 
own expression through this particular motif would prove useful.  
4.7.1  MITF, TFEB and TFE3 inhibit the expression of MITF 
It is known that the transcriptional regulation of MITF throughout development, 
during proliferation and differentiation of the melanocytic lineage and 
melanoma progression is complex and involves several different mechanisms. 
Figure 36. Model of the cross-regulatory relationship between MITF, TFEB and 
TFE3 in melanoma. 
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Transcription factors, such as PAX3, SOX10 and LEF-1 have been shown to 
positively regulate MITF-M expression, leading to differentiation of 
melanocytes during neural crest development (Potterf et al., 2000; Stolt et al., 
2008; Takeda, Yasumoto, et al., 2000; Tassabehji et al., 1992). In this study I 
show that ectopic overexpression of MITF-M represses the endogenous 
expression of MITF in melanoma cells at both the mRNA and protein levels in 
two different melanoma cell lines (Figure 24, 26). In addition, the transient 
siRNA-mediated knockdown of MITF resulted in increased transcription of the 
MITF gene (Figure 25). This clearly indicates that MITF suppresses its own 
expression and is involved in its own regulation. Publicly available ChIP-seq 
data show that there are MITF-peaks upstream of the first common exon 2 (in 
the first intron of the M-isoform) containing potential binding sites with 
CACGTG motifs (Figure 23B). Luciferase reporter assays were employed in 
order to analyze whether a particular E-box motif in this region was responsible 
for the self-repression of MITF. I therefore generated a reporter construct 
containing a 670 bp sequence within the first intron of MITF-M with the 
CACGTG element that is a binding site for MITF (Figure 27B). I also generated 
another construct where this element was mutated to CCCTTTA as a 
scrambled control (Figure 27B). Overexpression of MITF did not repress 
transactivation of any of these two reporter constructs when compared to the 
empty reporter construct (Figure 27C). We therefore plan to further 
characterize how MITF inhibits its own expression by analyzing whether MITF 
transrepresses a reporter gene under an alternative DNA regulatory element 
that is located upstream in the MITF gene, which presumably is a binding site 
for MITF (Figure 23B).  
The observations that MITF can repress its own expression in a self-
regulatory loop contradict previous studies showing that MITF itself induces 
the transactivation of its own promoter. MITF-M was reported to activate its 
own expression when it was co-expressed with lymphoid-enhancing factor 1 
(LEF-1). However, expression under the MITF-M promoter was enhanced by 
the expression of MITF only when the domain in LEF-1 that mediates binding 
and formation of transcriptional complexes with β-catenin was intact (Saito et 
al., 2003; Yasumoto et al., 2002). Previous studies have shown that β-catenin 
alone, a transcription factor downstream of the Wnt signaling pathway, 
activates the transcription of MITF and melanocyte differentiation (Larue et al., 
2003). In this case MITF-M may merely act as a co-factor that enhances the 
activity of β-catenin, without having any affinity to that particular regulatory 
region within the MITF-M promoter. In another study, Northern blot analysis 
showed that α-MSH treatment resulted in increased mRNA expression of 
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MITF, peaking at two hours and entering a declining phase beyond this time 
point, indicating a homeostatic regulatory mechanism that was coupled with a 
decrease in protein expression beginning at 4 hours (Price, Horstmann, et al., 
1998). Interestingly, when protein translation was inhibited with cycloheximide, 
there was no decline observed in MITF mRNA expression, suggesting that 
increased MITF protein is required for the observed reduction of MITF’s 
transcription. I hypothesize that an increase in MITF protein expression may 
inhibit the transcription of MITF in a self-repressing regulatory loop through 
direct binding to regulatory elements within the MITF gene. 
TFEB and TFE3 overexpression can repress the expression of both MITF 
mRNA and protein (Figure 24, 26). In turn, knockdown of TFEB increases the 
expression of MITF whereas knockdown of TFE3 does not (Figure 25). I 
assessed by RT-qPCR the mRNA expression of MITF upon TFEB or TFE3 
overexpression on MITF mRNA expression in the presence of an mTORC 
inhibitor. mTORC inhibition increases nuclear localization of TFEB and TFE3 
and might hypothetically enhance the inhibitory effect of TFEB and TFE3 on 
MITF expression. Inhibition of mTORC further enhanced the decrease in MITF 
transcripts upon TFEB and TFE3 overexpression; the TFE3-mediated 
reduction in MITF’s mRNA expression was more profound when mTORC was 
inhibited (Figure 28B). In contrast, mTORC inhibition did not further enhance 
the reduction of MITF protein levels (Figure 28C, D) (Figure 35). 
4.7.1.1  MITF knockdown reduces the proliferation rate of a 
MITFhigh melanoma cell line 
In this thesis, I have shown that a 501Mel cell line expressing doxycycline-
inducible miRNA against MITF shows a reduced proliferation rate and 
extended doubling time when compared to control cells (Figure 29A, B). 
Overexpression of TFE3 in cells expressing control miRNA recapitulated the 
lower proliferation rate of the miR-MITF cells, suggesting that TFE3-mediated 
modulation of the expression of MITF may have an impact in the proliferation 
ability of certain melanoma cell lines and tumors (Figure 29B, C). I hypothesize 
that TFE3 can negatively affect the proliferation rate of 501Mel cells through 
the transcriptional repression of MITF, as discussed in the previous chapter.  
Slow-proliferating miR-MITF cells did not increase their doubling time upon 
TFE3 overexpression (Figure 29B, D), which suggests that the effects of TFE3 
on the proliferation of 501Mel cells are MITF-dependent. Surprisingly, TFEB 
overexpression did not affect the proliferation of the cells expressing a control 
miRNA (Figure 29) despite the severe effects on MITF transcription upon 
TFEB overexpression observed in other experiments performed in this cell line 
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(Figure 24, 28). I have observed that transient transfection of TFEB in these 
cells induced high mortality. I did not observe an increase in cell mortality with 
the transfection of empty vector or TFE3. I transfected the cells with either 
TFEB, TFE3 or empty vector (EV) control at the same time as the miRNA 
expression was induced, and after 24 hours, cells were trypsinized and 
transferred to a new plate for analysis of confluency. Therefore, a high mortality 
due to transfection with TFEB could have led to the selection of non-
transfected cells which would virtually be the same as those overexpressing 
empty vector. One way to get past this problem would be to use stable cell 
lines expressing both the doxycycline-inducible miR-MITF construct and TFEB 
or TFE3 constructs, together with their respective controls. This way I would 
likely avoid the high cell mortality rates sometimes observed upon 
lipofectamine transfections. 
It is not surprising to observe that MITF is required to maintain the 
proliferation rate of some melanoma cell lines. Previous studies in the lab have 
shown that transient or stable knockdown of MITF impairs proliferation of 
Skmel28 cells. Skmel28 cells carrying a CRISPR Cas9-mediated knockout of 
MITF also show significantly reduced growth and migration ability (Ramile 
Dilshat, manuscript in preparation). Hence, I hypothesize that in melanoma cell 
lines expressing MITF, a higher expression of TFE3 can significantly reduce 
the transcription and protein expression of MITF (Figure 24, 28), which in turn 
impairs the proliferation ability of these cells (Figure 29B, C). 
MITF has a very well established role in maintaining melanocyte lineage 
identity and in conferring anti-apoptotic effects in melanoma (Garraway et al., 
2005). However, to this date there is not a broad consensus on whether MITF 
is crucial for sustaining proliferation and growth in melanoma. A study has 
shown that the effects of doxycycline-inducible titration of MITF with an shRNA	 
against MITF in melanoma cells were not as profound as expected, and that 
single-cell heterogeneity was a major factor in the variability of the response to 
MITF depletion, even within a fairly homogeneous cell line (Vlckova et al., 
2018). Using the microRNA  miR-101 to reduce MITF expression in melanoma 
cell lines established from 29 patients with stage IV metastatic melanomas, 
resulted in suppressed cell proliferation, invasion and migration (Luo et al., 
2013). 
MITF regulates genes involved in DNA replication and repair and depletion 
of MITF triggers the DNA damage response and entry into a senescence state 
(Strub et al., 2011). It was proposed that cells depleted of MITF do not survive 
or become undifferentiated non-melanoma tumor cells (Vachtenheim & 
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Ondrusova, 2015), raising doubts of whether we can consider MITF-negative 
cell lines to be melanomas. Different levels of MITF expression in melanoma 
modulate the cellular function. In response to environmental triggers, 
melanoma cells can shuttle between an invasive low-proliferating phenotype 
characterized by low expression of MITF and a more differentiated, 
proliferative and less invasive phenotype with higher expression of MITF (Hoek 
& Goding, 2010). Relapsed melanoma tumors following adoptive cell transfer 
therapy targeting premelanosome protein (PMEL) showed reduced expression 
of pigmentation genes and inflammation-dirven dedifferentiation (Landsberg et 
al., 2012). Inflammatory cues inhibit the translation initiation factor eIF2B and 
induce the expression of activating transcription factor 4 (ATF4) which, in turn, 
represses MITF and activates tyrosine-protein kinase receptor UFO (AXL) 
(Falletta et al., 2017). MITF expression levels have been found to anticorrelate 
with AXL and a low MITF/AXL ratio is a marker of resistance to several targeted 
therapies in melanoma tumors, including BRAF inhibition (Muller et al., 2014).  
Interestingly, ectopic expression of MITF in a well-established MITF-
negative cell line, RPMI-7951, did not result in activation of lineage-specific 
differentiation markers nor downstream targets of MITF (Vachtenheim et al., 
2001). This is in line with another study showing that MITF activation of 
melanocyte-specific promoters is dependent on the activation of chromatin 
remodelers BRG1 and SMARCA2 (de la Serna et al., 2006). However, the 
transcription of genes involved in cell-cycle arrest and induction of the 
differentiation did not require the expression of the chromatin remodelers 
mentioned above, highlighting the role of MITF in regulating melanoma survival 
and identity. Thus, it is important to take into consideration that the cellular 
context associated to different MITF expression levels across tumors and cell 
lines may be caused by profound changes of the chromatin architecture and 
transcriptional landscape and therefore may not be possible to recapitulate 
through transient modulation of MITF expression.  
4.7.2  MITF directly induces the expression of TFEB through an E-
box-like motif 
I show that MITF increases the expression of TFEB mRNA and protein (Figure 
24, 26). Analysis of MITF ChIP-seq data revealed a binding site in intron 1 of 
TFEB (Figure 23). Using luciferase reporter gene assays on HEK293T cells I 
demonstrate that the increase in TFEB expression mediated by MITF is 
through direct binding to a CAGCTGA motif located at the binding site reported 
by the ChIP-seq data (Figure 27). Therefore, I analyzed whether the 
CAGCTG(A) sequence, where the two central bases are swapped with respect 
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to the canonical E-box CACGTG motif, represents a common motif in the MITF 
ChIP-seq dataset published by Laurette and colleagues and the TFEB ChIP-
seq dataset from our lab (Ramile Dilshat, unpublished). Analysis of motif 
enrichment (AME) of the MITF binding sites across the ChIP-seq dataset from 
501Mel cells (Laurette et al., 2015) showed that the CAGCTGA motif is present 
in 16% of the MITF-bound sequences, compared to 36% of the sequences 
presenting a CACGTGA element and 7% that contain a CCCTTTA motif, used 
as scramble control in the transactivation assay (Table 10). These data 
suggest that MITF can bind to CAGCTGA motifs and activate the transcription 
of downstream genes. Analysis of the MITF structure bound to the CACGTG 
and CATGTG sequences showed that Arg217 of MITF forms specific bonds 
with the two central bases of the E-box (CACGTG) motif, whereas it does not 
form base-specific bonds with the two central bases of the CATGTG M-box 
motif (Pogenberg et al., 2013). Instead, specific bonds are formed with the two 
bases flanking the 6 bp motif, -4 and +4, and with -3, -2 and +3, counting from 
the center of the motif (Figure 37). These bases are all conserved in the 
GCAGCTGA motif at the MITF binding site in TFEB used in this experiment.  
Figure 37. MITF/DNA interactions with the E-box (left) and M-box (right). Base-
specific interactions are highlighted in bold. Hydrogen bonds are represented in regular 
characters and dashed lines.. Adaptation from (Pogenberg et al., 2012) 
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4.7.3  MITF negatively affects the transcription of TFE3 
Verastegui et al. (2000) reported that stimulation of cAMP signaling with 
forskolin induced the expression of MITF protein while it decreases the 
expression of TFE3 (Verastegui et al., 2000). In this thesis, I have shown that 
transient MITF overexpression resulted in reduced expression of TFE3 in 
Skmel28 cells and in 501Mel cells. However, no reduction in mRNA or protein 
expression of TFE3 was detected in the doxycycline-inducible pBac-MITF 
501Mel cell line (Figure 24, 26). It is important to point out that both Skmel28 
and 501Mel cell lines exhibit high endogenous levels of MITF whereas the 
expression of TFE3 is much lower. Therefore, overexpressing MITF might 
have weak repercussions on TFE3’s overall expression. Knocking down MITF, 
on the other hand, led to increased transcription of TFE3 in both cell lines 
(Figure 25), although at the protein level the effect was not significant due to 
high variability (Figure 9B). Verastegui and colleagues have explained their 
observations such that TFE3 and MITF are differentially regulated by cAMP 
signaling. I have shown that MITF inhibits the expression of TFE3. Therefore, 
an increase in MITF expression upon stimulation of cAMP signaling with 
forskolin inhibits TFE3 expression. I did not find any binding sites for MITF or 
TFEB in the TFE3 gene upon analysis of both ChIP-seq datasets (Figure 23C). 
It is likely that the regulation of TFE3 does not involve direct transcriptional 
regulation by MITF or TFEB. Other mechanisms are likely to be involved and 
need further characterization. 
 MITF and TFEB display a common repertoire of target 
genes 
Many efforts have been directed at elucidating how MITF, TFEB and TFE3 
direct the selection of transcriptional targets while they bind to similar DNA 
regulatory elements. These factors are able to regulate a similar repertoire of 
target genes but each one seems to regulate a specific set of genes. Previous 
results in the lab and by other researchers, have shown that MITF, TFEB and 
TFE3 overlap in their ability to activate E-box motifs present in the vicinity of 
their target genes (Aksan & Goding, 1998). Here, I report that an E-box located 
in intron 2 of MLANA, a gene involved in the pigment process and established 
as a marker of melanocytic differentiation and melanoma diagnosis, is bound 
by both MITF and TFEB. Moreover, MITF, TFEB and TFE3 are able to 
transactivate a MLANA regulatory element, as shown using a luciferase 
reporter assay (Figure 30). Interestingly, previous studies in the lab using a 
CRISPR MITF knock-out Skmel28 cell line showed that the expression of 
MLANA transcripts was severely affected by the lack of MITF and that TFEB 
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or TFE3 overexpression in this knockout cell line was not able to drive the 
expression of this gene (Katrín Möller, unpublished data). The mechanism by 
which MITF, and not TFEB nor TFE3, is required for the transcription of 
MLANA in these cells is unknown but may be dependent on the context of 
chromatin architecture. 
Analysis of MITF and TFEB ChIP-seq datasets in 501Mel human 
melanoma cells has shown that 682 genes, approximately 30% of the genes 
in each of the datasets, are bound by both MITF and TFEB. Interestingly, over 
85% of the overlapping genes are not melanosomal or lysosomal genes, but 
no other GO terms were found to be significantly enriched in this analysis. 
Analysis of the overall specific binding sites of MITF and TFEB showed that 
25% (553) of the binding sites reported for MITF are shared with TFEB (Figure 
32A) and motif discovery analysis on these 553 overlapping binding sites 
revealed the CLEAR box as the most frequent DNA regulatory element among 
these genes (Figure 32B), together with the zinc finger protein 263 (ZNF263) 
binding motif. A limitation of this study is that for the analysis of MITF binding 
sites, we overlapped the ChIP-seq dataset in 501Mel cells with a dataset 
obtained in Colo829 cells (Webster et al., 2014). It is possible that 
superimposing these two datasets has filtered out a large number of genes 
that are bound by MITF in 501Mel cells, considering the broad heterogeneity 
in genetic and epigenetic profile between cell lines. We confirmed that many 
lysosomal and pigmentation genes are bound by both MITF and TFEB, thus 
likely representing shared targets (Figure 32C, D); a striking majority of a well-
established list of lysosomal and autophagy-related genes, which can be found 
in Appendix III, Table 16; featured binding sites for both transcription factors. 
These finding are in agreement with other studies demonstrating that MITF, 
in addition to its role in controlling the transcription of a great number of 
pigmentation and melanosomal genes, correlates with the expression of a 
large number of lysosomal genes in melanoma cell lines. Ectopic 
overexpression of MITF has been reported to enhance the biogenesis of 
endosomal vesicles and expression of associated markers (Ploper et al., 
2015). TFEB, has been depicted as the master regulator of autophagy and 
lysosomogenesis, through the direct binding and transcriptional modulation of 
CLEAR regulatory elements, located in the vicinity of promoters that regulate 
the trancription of several lysosome and autophagy-related genes (Palmieri et 
al., 2011). Moreover, our lab in collaboration with Vivian Pogenberg at the 
EMBL in Hamburg has succesfully generated a crystal structure of MITF bound 
to the CLEAR box, indicating that the regulation of lysosomal and autophagy-
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related genes by MITF is through direct binding to these particular motifs 
(Möller et al, submitted).   
  The complex regulation of autophagy 
Previous analysis performed in the lab (Möller, 2016) have shown that the 
regulation of a significant fraction of lysosomal and autophagy-related genes 
is mediated by the MiT/TFE transcription factors. In their work, gene ontology 
analysis showed that MITF mainly correlates with a subset of genes required 
for phagosome acidification and transmembrane transport, whereas the subset 
of genes correlated with TFEB/TFE3 is involved in proteolysis and degradation 
of the autophagy cargo. These data indicate that the three factors are important 
for the control of two distinct aspects within the complex autophagy process. 
Indeed, work performed by Ploper and colleagues (2015), showed that 
overexpression of MITF in C32 melanoma cells induced the expression of 
several lysosomal genes and increased the presence of intracellular vesicles 
that were positive for LAMP1 and Rab7, indicating an expansion of the late 
endosomal network. Interestingly, MITF overexpression did not increase 
autophagy function. Considering that a number of autophagy genes remained 
unaffected upon MITF overexpression, they concluded that MITF can elicit an 
increase in endosomal biogenesis but other transcriptional events are required 
in order to obtain fully functional lysosomes (Ploper et al., 2015). 
We have thoroughly analyzed the ChIP-seq data of MITF and TFEB 
(Figure 32, 34E), the correlation of lysosomal genes with MITF, TFEB and 
TFE3 in melanoma samples (Appendix III, Table 16; Figure 34) and 
performed qPCR measurements of the expression of lysosomal genes in a 
melanoma cell line (Figure 33). The data compiled in this thesis indicate that 
MITF, TFEB and TFE3 are able to increase the mRNA expression of 
autophagy-related genes. However, some autophagy-related genes are 
exclusive targets of one of these factors, whereas other genes involved in the 
process, such as ATP6V0D2, are shared targets of MITF, TFEB and TFE3. In 
more detail, MITF and TFEB can increase the expression of ATP6V0D2, 
ATP6V1C1 and CTSD, genes involved in autophagy vesicle acidification and 
substrate proteolysis (Figure 33A). However, MITF is important for the 
regulation of ATP6V1C1 but is not required for the transcription of CTSD, which 
is also upregulated by TFEB. TFEB correlates in expression with CTSD in 
melanoma tumors and is important for the regulation of CTSD in the melanoma 
cell line analyzed. TFEB can induce the transcription of the ATPase subunit 
ATP6V1C1, but is not essential, as it cannot induce the transcription of 
ATP6V1C1 when MITF is silenced (Figure 33B). In addition, I found that TFE3 
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is a negative modulator of ATP6V1C1, it is not required for the transcription of 
CTSD and might be required for the expression of CTSZ and GNS (Figure 
33C, D). 
Taken together, these data indicate that MITF, TFEB and TFE3 bind to a 
repertoire of target genes that are involved in lysosomal biogenesis and 
autophagy. However, the regulation of their autophagy-related transcriptional 
targets does not entirely overlap and seems to have different outcomes. This 
suggests that each factor may regulate a specific subset of target genes and 
that the regulation of autophagy requires the interplay of the three factors. 
Alternatively, heterodimers involving different combinations of the three factors 
may be important for some of the genes. 
 Final remarks and future directions 
Genetic and genomic alterations that affect the levels of expression and/or 
functionality of bHLHZip transcription factors have been long known to play a 
role in human disease. The MYC oncogene has been found to be dysregulated 
in >50% of human cancers making this factor and its network partners forefront 
targets for the development of novel therapies. However, targeting 
transcription factors is notoriously difficult due to the lack of active sites for 
small molecules and their natural nuclear localization (Dang, 2012), which 
leads to the search for indirect approaches.  
MITF displays a prominent role in melanoma survival and progression, with 
the mutant MITFE318K linked to familial and sporadic melanoma (Yokoyama 
et al., 2011), but also renal clear cell carcinoma (Bertolotto et al., 2011). 
Increased MITF expression, associated with chromosome 3p amplification, 
has been found in a subset of malignant melanomas (Garraway et al., 2005). 
Interestingly, the related TFEB protein is expressed at high levels in pediatric 
renal cell carcinomas (Kuiper et al., 2003) and TFE3 has also been reported 
to be translocated in up to 30–50% of renal cancer cases (Ramphal et al., 
2006). In healthy human kidney, the four MiT-TFE subfamily members are 
expressed at comparable levels. In contrast, a subset of renal cell carcinoma 
tumors displayed a fusion of TFEB, located in chromosome 6, with the Alpha 
gene in chromosome 11. AlphaTFEB fusion gene links TFEB with the 
regulatory regions upstream of the Alpha gene, leading to promoter 
substitution and a 60-fold increase in expression (Kuiper et al., 2003). TFE3 
depletion in TFE3-translocated renal cell carcinoma inhibited tumor 
proliferation, and ectopic overexpression of MITF rescued proliferation (Davis 
et al., 2006). Likewise, TFE3 restored cell proliferation of an MITF-driven renal 
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clear carcinoma when MITF was knocked down (Davis et al., 2006), indicating 
that MITF and TFE3 may have redundant roles at regulating proliferation and 
survival of specific tissues. 
Dimerization is an important layer of regulation of transcription factors and 
it is crucial for bHLHZip factors to be functional in their role at transcribing 
downstream target genes. In this thesis, we have described the structural 
feature within the leucine zipper of the MiT-TFE transcription factors that 
restricts their dimerization ability within the subfamily and demonstrated that 
they can form heterodimers in melanoma cells. Dysregulation in the expression 
of MITF, TFEB and TFE3 could most likely affect the proportion of dimers 
formed and alter the regulation of target genes. Another network of bHLHZip 
transcription factors that has been widely studied is the Myc-Max-Mad network. 
Max is a ubiquitous protein that by forming heterodimers with Myc, can recruit 
nucleosome remodelers such as histone acetyl transferases (HATs) that would 
expose binding sites in target promoters and allow transcription by the relevant 
factors. Mad-Max heterodimers silence their target genes by recruiting histone 
deacetylases (HDACs), which have the opposite effect to the recruitment of 
HATs (Amoutzias et al., 2008). Chromatin remodelers such as BRG1 and 
HDAC7 have been reported to modify the configuration of chromatin at 
genomic loci that are bound by MITF for activation of the transcription of target 
genes in melanoma and osteoclasts, respectively (Laurette et al., 2015; Stemig 
et al., 2015). Interestingly, it has been shown that HDAC7 features an MITF-
interacting domain, and that its ability to repress transcription was largely 
independent on its catalytic domain, suggesting that recruitment of MITF is a 
mechanism of transcriptional repression independent of the deacetylase 
activity of HDAC7 (Pham et al., 2011), which is reminiscing of the role of Mad-
Max heterodimers at silencing downstream promoters. 
I have shown that phosphorylation events downstream of signaling 
pathways such as BRAF-MAPK and mTORC are crucial at regulating the 
subcellular localization and activity of MITF, TFEB and TFE3. Moreover, 
blockade of the mTORC pathway triggers a partial dephosphorylation event on 
MITF that has an impact on protein stability, inducing proteasome-mediated 
degradation of MITF and an increase in transcription through a mechanism 
that remains to be elucidated. 
The effects of mTORC on MITF expression further link the master regulator 
of melanocytes and melanoma to the endosomal pathways and autophagy, a 
new role of MITF that is receiving increasing attention. Here, I have shown that, 
in addition to TFEB and TFE3, MITF regulates the expression of genes 
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involved in lysosomogenesis and autophagy. This finding points to a certain 
degree of redundancy or cooperation between these factors at regulating their 
target genes. However, it is also apparent that they activate different subsets 
of genes that do not overlap entirely, and that the expression of one factor 
alone is not sufficient to drive lysosomogenesis and the autophagy process. I 
have also observed that MITF and TFE3 have antagonistic roles in regulating 
a subset of lysosomal genes. One of them, alpha-synuclein (SNCA) has been 
shown to be a direct target of MITF in the melanocytic lineage (Hoek et al., 
2008). Alpha-synuclein is a protein involved in vesicle trafficking that is 
expressed predominantly in the brain. Interestingly it is also expressed in 
melanoma lesions, and it has been proposed as a marker in melanoma and 
an important player in a reported association between Parkinson’s disease 
diagnosis and first-degree family history of melanoma (Gao et al., 2009; 
Welinder et al., 2014). MITF is expressed in the central nervous system. 
Specifically, in the mouse brain, MITF is detected in the cortex, hippocampus, 
cerebellum and olfactory bulb. Several isoforms have been detected across 
the different brain tissues but, interestingly, MITF-M is predominant in the 
olfactory bulb where it has been associated to the maintenance of homeostatic 
neuroplasticity (Atacho et al., submitted). Taken together, these studies 
indicate that the multi-layered interactions existing within the network of MiT-
TFE transcription factors may have implications that go beyond melanoma 
biology. 
BRAF inhibition, and specifically the vemurafenib agent that I used in this 
study for the inhibition of mutant BRAFV600E in 501Mel and Skmel28 cells, 
has been the most promising therapeutic approach for the treatment of 
metastatic melanoma in recent years (Bollag et al., 2010). Several upstream 
regulators and downstream targets of the mTOR pathway have been found to 
be dysregulated in several types of cancer. Two well characterized mTOR 
downstream effectors, p70S6K and 4EBP1 have been reported to contribute 
to the process of tumorigenesis (Law, 2005). It is important to take into 
consideration that pharmacological modulation of BRAF and/or mTOR activity 
can exert direct effects on a wide array of cellular processes, including cell 
cycle regulation, cell metabolism and autophagy, but also indirect effects 
through the regulation of the subcellular localization of MITF, TFEB and TFE3, 
their activity and stability. Unwanted effects that could lead to an upregulation 
of the autophagy response have been linked to increased vesicle trafficking 
and chemoresistance in melanoma (Huang et al., 2012) 
In light of the evidence indicating that the roles of MiT-TFE factors do not 
overlap completely despite being able to activate similar DNA regulatory 
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elements, more efforts are needed to clarify how the selection of their particular 
target genes is mediated. Perhaps these factors require the interaction with 
different cofactors that attract them to secondary motifs or that modify nuclear 
architecture.  My findings demonstrate that the MiT-TFE transcription factors 
are able to regulate each other’s expression, and that MITF is the predominant 
family member across several melanoma cell lines and tumors, leading to a 
higher presence of MITF homodimers compared to other possible 
combinations of dimers. Considering the crucial role of the MiT-TFE 
transcription factors in several types of cancer and disease, understanding the 
imbalance in expression of these factors and how this may impact the 
phenotype and biology in diseased versus normal tissue, could prove valuable 
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Figure 38. MITF (+) primers aligned to the cDNA sequence of human MITF (+) or 
(-). Primers are listed in Table 8. The sequence aligned by the forward primer is 
marked in red, whereas the (+) isoform-specific sequence aligned by the reverse 






Table 15. List of pigmentation genes (GO:0043473) 
Gene Protein product 
ADAMTS20 ADAM metallopeptidase with thrombospondin type 1 motif 20 
ADAMTS9 ADAM metallopeptidase with thrombospondin type 1 motif 9 
AP1G1 adaptor related protein complex 1 gamma 1 subunit 
AP1M1 adaptor related protein complex 1 mu 1 subunit 
AP3B1 adaptor related protein complex 3 beta 1 subunit 
AP3D1 adaptor related protein complex 3 delta 1 subunit 
ARCN1 archain 1 
ARL6 ADP ribosylation factor like GTPase 6 
ASIP agouti signaling protein 
ATP6AP2 ATPase H+ transporting accessory protein 2 
ATP7A ATPase copper transporting alpha 
ATRN attractin 
BAX BCL2 associated X, apoptosis regulator 
BBS2 Bardet-Biedl syndrome 2 
BBS4 Bardet-Biedl syndrome 4 
BBS5 Bardet-Biedl syndrome 5 
BBS7 Bardet-Biedl syndrome 7 
BCL2 BCL2, apoptosis regulator 
BCL2L11 BCL2 like 11 
BLOC1S1 biogenesis of lysosomal organelles complex 1 subunit 1 
BLOC1S3 biogenesis of lysosomal organelles complex 1 subunit 3 
BLOC1S4 biogenesis of lysosomal organelles complex 1 subunit 4 
BLOC1S5 biogenesis of lysosomal organelles complex 1 subunit 5 
BLOC1S6 biogenesis of lysosomal organelles complex 1 subunit 6 
C10orf11 chromosome 10 open reading frame 11 
C12orf10 chromosome 12 open reading frame 10 
CD63 CD63 molecule 
CDH3 cadherin 3 
CITED1 
Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 
1 
DCT dopachrome tautomerase 
DCTN1 dynactin subunit 1 
DCTN2 dynactin subunit 2 
DOCK7 dedicator of cytokinesis 7 
DRD2 dopamine receptor D2 
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DTNBP1 dystrobrevin binding protein 1 
EDA ectodysplasin A 
EDAR ectodysplasin A receptor 
EDN3 endothelin 3 
EDNRB endothelin receptor type B 
EN1 engrailed homeobox 1 
FIG4 FIG4 phosphoinositide 5-phosphatase 
GLI3 GLI family zinc finger 3 
GNA11 G protein subunit alpha 11 
GNAQ G protein subunit alpha q 
GPR143 G protein-coupled receptor 143 
HPS1 HPS1, biogenesis of lysosomal organelles complex 3 subunit 1 
HPS3 HPS3, biogenesis of lysosomal organelles complex 2 subunit 1 
HPS4 HPS4, biogenesis of lysosomal organelles complex 3 subunit 2 
HPS5 HPS5, biogenesis of lysosomal organelles complex 2 subunit 2 
HPS6 HPS6, biogenesis of lysosomal organelles complex 2 subunit 3 
IHH indian hedgehog 
KIF13A kinesin family member 13A 
KIT KIT proto-oncogene receptor tyrosine kinase 
KITLG KIT ligand 
LEF1 lymphoid enhancer binding factor 1 
LYST lysosomal trafficking regulator 
MAP2K1 mitogen-activated protein kinase kinase 1 
MC1R melanocortin 1 receptor 
MEF2C myocyte enhancer factor 2C 
MITF melanogenesis associated transcription factor 
MKKS McKusick-Kaufman syndrome 
MLPH melanophilin 
MREG melanoregulin 
MYO5A myosin VA 
MYO7A myosin VIIA 
NF1 neurofibromin 1 
OCA2 OCA2 melanosomal transmembrane protein 
PAX3 paired box 3 
PMEL premelanosome protein 
POMC proopiomelanocortin 
RAB11A RAB11A, member RAS oncogene family 
RAB11B RAB11B, member RAS oncogene family 
RAB17 RAB17, member RAS oncogene family 
RAB1A RAB1A, member RAS oncogene family 
RAB25 RAB25, member RAS oncogene family 
RAB27A RAB27A, member RAS oncogene family 
RAB27B RAB27B, member RAS oncogene family 
RAB29 RAB29, member RAS oncogene family 
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RAB32 RAB32, member RAS oncogene family 
RAB38 RAB38, member RAS oncogene family 
SHROOM2 shroom family member 2 
SHROOM3 shroom family member 3 
SNAI2 snail family transcriptional repressor 2 
SNAPIN SNAP associated protein 
SOD2 superoxide dismutase 2, mitochondrial 
SOX10 SRY-box 10 
SPNS2 sphingolipid transporter 2 
SZT2 seizure threshold 2 homolog (mouse) 
TH tyrosine hydroxylase 
TYR tyrosinase 
TYRP1 tyrosinase related protein 1 
USP13 ubiquitin specific peptidase 13 (isopeptidase T-3) 
VPS33A VPS33A, CORVET/HOPS core subunit 
VPS33B VPS33B, late endosome and lysosome associated 
ZEB2 zinc finger E-box binding homeobox 2 
ZIC2 zic family member 2  
 
Table 16. List of lysosomal and autophagy-related genes 
Gene Protein product 
ACD shelterin complex subunit and telomerase recruitment factor 
AGA aspartylglucosaminidase 
ANPEP alanyl (membrane) aminopeptidase 
ARL8B ADP-ribosylation factor-like 8B 
ARSA arylsulfatase-peptidase A 
ARSB arylsulfatase-peptidase B 
ASAH1 N-acylsphingosine amidohydrolase (acid cermidase) 1 
ASNA1 arsenite-stimulated ATPase component of the arsenite transporter 
ATG10 autophagy related 10 homolog 
ATG12 autophagy related 12 homolog 
ATG13 autophagy related 13 homolog 
ATG14 autophagy related 14 homolog 
ATG16L1 autophagy related 16-like 1 
ATG16L2 autophagy related 16-like 2 
ATG2A autophagy related 2 homolog A 
ATG2B autophagy related 2 homolog B 
ATG3 autophagy related 3 homolog 
ATG4A autophagy related 4 homolog A 
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ATG4B autophagy related 4 homolog B 
ATG4C autophagy related 4 homolog C 
ATG4D autophagy related 4 homolog D 
ATG5 autophagy related 5 homolog 
ATG7 autophagy related 7 homolog 
ATG9A autophagy related 9 homolog A 
ATG9B autophagy related 9 homolog B 
ATP13A2 ATPase type 13A2 
ATP6V0D2 ATPase, H+ transporting, lysosomal 38 kDa V0 subunit d2 
ATP6V1B1 ATPase, H+ transporting, lysosomal 56/58 kDa V0 subunit  B1 
ATP6V1G3 ATPase, H+ transporting, lysosomal 13 kDa V0 subunit G3 
ATP6V0A1 ATPase, H+ transporting, lysosomal V0 subunit a1 
ATP6V0A2 ATPase, H+ transporting, lysosomal V0 subunit a2 
ATP6V0A4 ATPase, H+ transporting, lysosomal V0 subunit a4 
ATP6V0B ATPase, H+ transporting, lysosomal 21 kDa V0 subunit b 
ATP6V0C ATPase, H+ transporting, lysosomal 16 kDa, V0 subunit c 
ATP6V0D1 ATPase, H+ transporting, lysosomal 38 kDa V0 subunit d1 
ATP6V0E1 ATPase, H+ transporting, lysosomal V0 subunit E1 
ATP6V0E2 ATPase, H+ transporting, lysosomal V0 subunit E2 
ATP6V1A ATPase, H+ transporting, lysosomal 70 kDa, V1 subunit A 
ATP6V1B2 ATPase, H+ transporting, lysosomal 56/58kDa, V1 subunit B2 
ATP6V1C1 ATPase, H+ transporting, lysosomal 42 kDa, V1 subunit C1 
ATP6V1C2 ATPase, H+ transporting, lysosomal 42 kDa, V1 subunit C2 
ATP6V1D ATPase, H+ transporting, lysosomal 34 kDa, V1 subunit D 
ATP6V1E1 ATPase, H+ transporting, lysosomal 31 kDa, V1 subunit E1 
ATP6V1E2 ATPase, H+ transporting, lysosomal V1 subunit E2 
ATP6V1F ATPase, H+ transporting, lysosomal 14 kDa, V1 subunit F 
ATP6V1G1 ATPase, H+ transporting, lysosomal 13 kDa, V1 subunit G1 
ATP6V1H ATPase, H+ transporting, lysosomal 50/57 kDa, V1 subunit H 
BECN1 beclin 1 (coiled-coil, myosin-like BCL2 interacting protein) 
CD63 CD63 molecule (also known as LIMP1 or tetraspanin) 
CLCN5 chloride channel 5 (nephrolithiasis 2, X-linked, Dent disease) 
CLCN6 chloride channel 6 
CLCN7 chloride channel 7 
CLN3 ceroid-lipofuscinosis, neuronal 2, juvenille 
CREG1 cellular repressor of E1A-stimulated genes 1 
CTNS cystinosis, nephropathic 
CTSA cathepsin A 
CTSB cathepsin B 
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CTSC catheptin C 
CTSD cathepsin D 
CTSF cathepsin F 
CTSH cathepsin H 
CTSK cathepsin K 
CTSL cathepsin L/L1 
CTSV cathepsin V/L2 
CTSO cathepsin O 
CTSS cathepsin S 
CTSZ cathepsin Z 
CTSE cathepsin E 
CTSG cathepsin G 
CTSW cathepsin W 
DNASE2 deoxyribonuclease II, lysosomal 
DPP4 dipeptydyl-peptidase 4 
DPP7 dipeptydyl-peptidase 7 
FUCA1 fucosidase, alpha-L 1, tissue 
GAA glucosidase, alpha 
GABARAP GABA(A) receptor-associated protein 2 
GABARAPL1 GABA(A) receptor-associated protein like 1 
GABARAPL2 GABA(A) receptor-associated protein like 2 
GABARAPL3 GABA(A) receptor-associated protein like 3 
GALC galactosylceramidase 
GBA Glucosidase beta (Gaucher disease) 
GLB1L galactosidase, beta 1-like 
GM2A GM2 ganglioside activator 
GNS glucosamine (N-acetyl)-6-sulfatase (Sanfilippo disease IIID) 
HEXA hexosaminidase A (alpha polypeptide) 
HEXB hexosaminidase B (beta polypeptide) 
HGSNAT heparan-alpha-glucosaminide N-acetyltransferase 
HPS1 Hermansky-Pudiak syndrome 1 
HPS4 Hermansky-Pudiak syndrome 4 
IDS iduronate 2-sulfatase (Hunter syndrome) 
LAMP1 lysosomal-associated membrane protein 1 
LAMP2 lysosomal-associated membrane protein 2 
LAMTOR1 late endosome/lysosomal adaptor, MAPK and MTOR activator 1  
LAMTOR2 late endosome/lysosomal adaptor, MAPK and MTOR activator 2 
LAPTM4B lysosomal associated protein transmembrane 4 
LIPA lipase A, lysosomal acid, cholesterol estarase 
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MANBA mannosidase, beta A, lysosomal 
MAP1LC3A microtubule-associated protein 1 light chain 3 alpha 
MAP1LC3B microtubule-associated protein 1 light chain 3 beta 
MAP1LC3B2 microtubule-associated protein 1 light chain 3 beta 2 
MCOLN1 mucolipin 1 (mucolipidosis type IV) 
MTCH1 mitochondrial carrier 1 
NAGA N-acetylgalactosaminidase, alpha 
NAGLU N-acetylglucosaminidase, alpha 
NPC1 Neimann-Pick disease, type C1 
NPC2 Neimann-Pick disease, type C2 
PIK3C3 phosphoinositide-3-kinase, class 3 
PIK3CG phosphoinositide-3-kinase,catalytic, gamma polypeptide 
PPT1 palmytoyl-protein thioesterase 1 
PSAP prosaposin 
SCARB2 scavenger receptor class B, member 2 
SFTPA1 surfactant protein A1 
SFTPA2 surfactant protein A2 
SGSH N-sulfoglucosamine sufohydrolase 
SLC11A2 solute carrier family 11, member 2 
SLC12A4 solute carrier family 12, member 4 
SLC17A5 solute carrier family 17, member 5 
SLC26A11 solute carrier family 26, member 11 
SLC29A3 solute carrier family 29, member 3 
SLC2A8 solute carrier family 2, member 8 
SLC36A1 solute carrier family 36, member 1 
SLC44A2 solute carrier family 44, member 2 
SMPD1 sphingomyelin phosphodiesterase 1 
SNCA synuclein, alpha 
SQSTM1 sequestosome 1 
TMEM175 transmembrane protein 175 
TMEM55A transmembrane protein 55A 
TMEM63A transmembrane protein 63A 
TPP1 tripeptidyl peptidase I 
TTPA alpha tocopherol transfer protein 
ULK1 unc-51-like kinase 1 
ULK2 unc-51-like kinase 2 
UVRAG UV radiation resistance associated gene 
VAMP1 vesicle-associated membrane protein 1 
VPS8 vacuolar protein sorting 8 homolog  
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VPS11 vacuolar protein sorting 11 homolog  
VPS18 vacuolar protein sorting 18 homolog  
VPS33A vacuolar protein sorting 33 homolog A 











Table 17. RT-qPCR analysis of the expression of MITF, TFEB and TFE3 
in 501Mel and A375P cell lines. 
 
Table 18. RT-qPCR analysis of the expression of MITF, TFEB and TFE3 
in 501Mel and A375P cell lines. 
